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Abstract 
Background 
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive and life-limiting condition of unknown cause with 
no curative treatment. The impact of IPF on a patient’s quality of life is devastating, yet relatively little attention 
has been devoted to understanding the disease from a combined physiological and psychological perspective. 
There are large gaps in our knowledge of the impact of IPF on the quality of life of patients and, importantly, on 
the effectiveness of palliative care such as pulmonary rehabilitation (PR) programmes. 
Methods 
We initiated this set of investigations by speaking to ten IPF patients recruited from an IPF support group in 
Swansea, Wales. The aim of this stage of the study was to understand how patients coped with their initial 
diagnosis, how they live with the disease day-to-day, their experiences and opinions about the support they 
receive, and their views on any rehabilitation programmes that they were offered. Semi-structured interviews 
were conducted and an inductive thematic approach was used to analyse the data, allowing us to identify 
common themes in the patients’ experiences. In addition, we sought to identify recommendations for practice 
that could be applied more globally, to add much needed information that might help to enhance the quality 
of life for IPF patients in the future.  
Secondly, we quantified the effects of an eight-week PR programme for IPF patients, conducted at Morriston 
Hospital, Swansea. Fifteen individuals (13 with IPF and two with pulmonary fibrosis associated with rheumatoid 
disease) underwent physical and physiological assessments during a three-day testing protocol: a) On Day 1, 
physical function (six-minute walk test) and ventilatory function (spirometry) were measured; b) On Day 2, 
patients’ cardio-respiratory responses to slowly-increasing, wide-ranging metabolic challenge (using a protocol 
consisting of periods of rest, incremental bicycle exercise to maximal effort, and post-exercise recovery) were 
assessed via respiratory gas analysis and ECG recording; c) On Day 3, patients’ cardio-respiratory responses to 
rapid-onset, high-workload metabolic challenge were assessed (using a protocol including a rapid-onset, 
constant workload bicycle exercise) by modelling dynamic respiratory oxygen and heart rate responses. Cardiac 
(RR) interval data were derived from the ECG and used to quantify heart rate variability (HRV) and the cardiac 
acceleration (AC) and deceleration (DC) capacities (via phase rectified signal averaging, PRSA). Respiratory gas 
analysis was used to measure the rate of oxygen uptake (V̇O2) and oxygen uptake efficiency slopes (OUES). All 
assessments were performed before and after participants completed the PR programme. 
Results 
Inductive analysis of interviews identified seven second-order themes and eleven first-order themes, 
represented by two General Dimensions: ‘Patient experience with the condition’ and ‘Patient-led 
recommendations for practice’. The key message on ‘coping’ in these patients was that acceptance of their 
condition led to a sense of optimism. Participants reported using appraisal-focused coping strategies to change 
their perspectives (thinking positively) and emotion-focused strategies to overcome depression (the main 
opportunity for emotional expression being an IPF support group). The support group also facilitated problem-
focused coping: individuals exchanged knowledge and experience and gave one another tips on how live with 
their condition. 
Following the rehabilitation programme, heart rate was elevated by 11-18% during exercise and recovery 
states. HRV was not statistically influenced by rehabilitation during any stage of the assessment protocol; 
however, qualitative changes were apparent with HRV increasing by 68-75% during all stages of the protocol. 
Statistically, AC and DC were similar pre- and post-rehabilitation (AC = -2.7 and -3.2 ms; DC = 2.3 and 3.2 ms, 
respectively) but again we observed qualitative improvements in these indices of 19% and 38%, respectively. 
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Post-rehabilitation V̇O2 was significantly increased (p=0.01-0.03) during the first two minutes of heavy-intensity 
exercise, whilst HR was reduced (p=0.04) during this period. OUES and standard measures of respiratory 
performance (minute ventilation, peak V̇O2) were unchanged following rehabilitation, whilst peak HR and work 
rates were significantly reduced during incremental exercise only. 
Conclusion 
Health professionals should provide patients with information that focuses on living with IPF, encouraging them 
to make lifestyle changes and adaptations to improve quality of life. Family members should receive education 
about IPF so that they can support such changes. Patients should be encouraged to join a support group and to 
participate in physical activity (again preferably group-based). This study offers novel findings that will help 
inform much-needed changes in the practice of supporting IPF patients to cope with their diagnosis and disease 
progression.  
These studies also provided initial indications that PR programmes might improve heart rate dynamic responses 
in IPF patients via modulation of the autonomic control of heart rate, even when traditionally-reported 
respiratory and physical functions are unchanged or diminished. PR also improved the rate of oxygen uptake 
during heavy-intensity exercise, despite substantially lower heart rates. This suggests that the rehabilitation 
programme increased systemic arterial-tissue oxygen exchange and/or influenced cardiovascular function to 
improve systemic oxygen delivery. We might therefore expect that individuals with IPF would find it easier to 
perform the activities of daily life, including those requiring substantial metabolic demands, following 
rehabilitation. 
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Physiological Definitions 
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to red blood cells.  
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Chapter 1 
Introduction 
Chronic lung disease 
There are two primary categories of chronic lung pathology, referred to as ‘obstructive’ and ‘restrictive’ lung 
diseases which impair the function of the human respiratory system. ‘Obstructive diseases such as Chronic 
Obstructive Pulmonary Disease (COPD) and restrictive diseases such as Interstitial Lung Disease (ILD) both 
reduce an individual’s ability to ‘breathe’ (that is, to uptake and use oxygen) but their mechanisms of action 
differ significantly. Obstructive disease causes physical airway (bronchial) restriction (lumen narrowing) whilst 
restrictive disease impedes alveolar stretching [1, 2].  
 
Idiopathic Pulmonary Fibrosis (IPF) is the commonest of the interstitial lung diseases (ILD) [3]; it causes 
progressive fibrosis of the alveolar walls and severe impairment of lung function [3]. The median survival for 
patients diagnosed with IPF is 2.5 to 3.5 years but the range is wide, with some individuals following a slowly 
declining trajectory over many years and others experiencing rapid disease progression [4]. Histologically, it is 
characterised by deposition of excess extracellular matrix within the alveolar interstitium and fibroblastic foci.  
These changes, described as usual interstitial pneumonia (UIP), have a typically peripheral, basal distribution 
which can be observed on CT scanning of the thorax [3]. Interestingly, similar pathological changes are 
sometimes observed in patients with collagen vascular disease such as rheumatoid arthritis. Patients with UIP 
usually present with symptoms of increasing breathlessness and fatigue which results in difficulty conducting 
day-to-day activities and a reduced quality of life  [5]. COPD is an umbrella term used to describe progressive 
lung diseases including emphysema, chronic bronchitis, and refractory (non-reversible) asthma. COPD is a 
progressive disease characterized by increasing breathlessness and, whilst it remains incurable, there are 
several treatments that can relieve their symptoms [6]. These include oxygen therapy and bronchodilator 
medication (both of which give rapid and effective but temporary relief) and longer-term therapies such as 
pulmonary rehabilitation (PR). PR can be very effective in managing the symptoms of COPD [7], allowing 
individuals with COPD to have a relatively normal day-to-day life [7].  Unfortunately, unlike in COPD, the physical 
changes that define restrictive lung diseases (UIP characteristics) are not reversible, although new anti-fibrotic 
therapies that slow the decline in lung function in these diseases are now available [3]. National guidelines also 
recommend that PR is offered to help improve functional performance in patients with restrictive lung disease 
[8]. 
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Exercise-based PR 
The primary goal of physical exercise-based PR  is to “restore patients to the highest possible functional state” 
[9]. Whilst PR can improve exercise performance and lung function in other forms of chronic lung disease (such 
as COPD)  [8], evidence of its influence on IPF patients is limited [10] but growing  [11, 12]. Two reports have 
noted improved six-minute walk distance (6MWD), health-related quality of life (HRQoL) and reduced symptom 
severity in individuals with ILD following eight weeks of PR [13]. However some authors have suggested that PR 
might not be effective for IPF patients when compared with COPD [10]14, 15]. This is because any 
improvements obtained from PR cannot be sustained over time in IPF patients (typically being reversed within 
months after completion of the programme), and because of the progressive nature of the disease [10, 14, 15]. 
Nevertheless, the physiological mechanisms by which the initial improvements are achieved are important, 
but little understood. Hence is it important to look into this to better understand both the IPF patient’s 
response to exercise at a physiological level and the degree of improvement of these variables following a 
sustained period of rehabilitation.  
 
A fundamental confounder in evaluating the effectiveness of PR as a therapy for restrictive lung disease is 
that, despite the different pathophysiological characteristics of obstructive and restrictive lung pathology, 
patients with either of these diseases are typically (almost always) offered identical PR programmes. PR 
typically includes an educational component and a physical exercise component, which is typically one hour 
long, during which 10 minutes are spend warming up and cooling down and the rest spent on bouts of toning 
exercises (weights) and cardiovascular exercises (treadmill / bicycle ergometer). One might argue that this 
approach is not optimal, or even that it is not appropriate for IPF patients: why would we expect that physical 
exercise could reverse the influences of fibrotic changes in the lung? However, the value of PR should not be 
interpreted solely in terms of measurable physiological improvements or anatomical changes; arguably the 
most relevant potential benefit of PR in patients with restrictive disease is an improvement in their day-to-day 
quality of life. We might speculate that PR would contribute to this via factors such as improved social 
interaction (such as attending group PR sessions), increased confidence in undertaking physical activity 
(reinforced by performance in a supervised PR session) and improved perceptions of stamina related to the 
above. 
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Outcome measures to assess the efficacy of PR 
Mindfulness of a patient’s Quality of Life (QoL) is an important factor that should underpin the holistic care of 
people with IPF, of which PR is just one part. From a healthcare perspective it is important to try to understand 
the psychological impact of an IPF diagnosis: patients are told that they have a life-limiting disease (that is little-
recognised and poorly-understood by the general public) and that there are no curative options [1]. From a 
patient’s perspective a diagnosis of IPF is therefore often completely unexpected and confusing, provoking a 
range of psychological responses and causing much anxiety. Healthcare professionals have an important role in 
helping to improve or preserve QoL, taking into account the impact of physical, psychological and social 
wellbeing [4, 5]. A recent review [6] highlighted studies that have attempted to measure or improve QoL in IPF 
(using patient-reported outcome measures and interventions) and those that have identified unmet patient 
needs (such as emotional support and information resources). A few studies have assessed the individual 
psychological impact of an IPF diagnosis and patients’ experiences of living with the disease [7-11]. 
 
The single best measure of an individual’s aerobic fitness (capacity for oxygen utilisation) is considered to be 
their peak or maximal oxygen uptake (V̇O2max). However, in practice the measurement of V̇O2max can be 
difficult - for example in older people with impaired mobility or in people with cardiorespiratory disease and 
limited functional capacity. Previous research by colleagues in Swansea University has reported that values for 
the peak rate of oxygen uptake in people with IPF are half those of similarly aged healthy individuals, whilst 
their peak heart rates (HR) are 20% lower [16]. These results imply that there is reduced tissue oxygen utilization 
following the onset of exercise, which in large part results from impeded central (cardiovascular) oxygen 
delivery. However, it is not known whether PR can improve systemic oxygen delivery and utilisation in people 
with IPF and other causes of UIP. 
 
Alternatives to measuring V̇O2max have been developed to help overcome the difficulties often encountered 
in its measurement in patients. One of these, the ‘oxygen uptake efficiency slope’ (OUES), quantifies the body’s 
oxygen uptake and extraction efficiency as the rate of increase of oxygen uptake (V̇O2) in response to increases 
in minute ventilation (VE) during incremental exercise. OUES has several advantages over other measures of 
aerobic exercise performance: it can be determined accurately from submaximal exercise protocols (below 60-
75% functional reserve) yet is strongly correlated with V̇O2 max; it is completely objective (tester-independent) 
and it has better inter-protocol agreement [17]19]. However, whilst OUES has been quantified in various 
populations including children, adults with heart disease and elite athletes [19]22] it has not been used to 
study patients with chronic lung disease. An alternative to OUES is the analysis of so-called ‘pulmonary oxygen 
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uptake kinetics’, which involves mathematical modelling of the rate of change of oxygen utilisation in response 
to a sudden change in exercise workload. This provides insight into an individual’s ability to absorb and utilize 
oxygen to fuel a change in metabolic activity [23]. Several studies have explored the influence of PR on oxygen 
uptake kinetics in COPD [10]. Puente-Maestu et al. [24] examined the effects of supervised and unsupervised 
eight-week PR programmes on a mono-exponential oxygen uptake model and observed an increase in the mean 
endurance time at a work rate equivalent to 70% of V̇O2max in both groups, whilst CO2 output, minute 
ventilation and heart rate were also observed to have increased post training. Few studies have applied this 
technique to patients with ILD. McNarry et al. [16] compared the oxygen uptake response in patients with 
emphysema and IPF and found that both displayed V̇O2 kinetics that were similarly slow in comparison to 
controls. A study of 11 patients with IPF also observed improvement in treadmill exercise time and maintained 
oxygen consumption following a three-month PR programme, whereas controls suffered a decline in V̇O2 
kinetics [25]. Other reports have noted improvements in exercise tolerance, dyspnoea and quality of life in 
people with IPF who undergo PR [3, 14, 25], but the physiological mechanisms by which such improvements 
occur are not understood. 
 
Heart rate dynamics are thought to provide a good proxy for the response of cardiac output and muscle blood 
flow to increased metabolic demand [26, 27], albeit they do not account for the contribution of stroke volume 
in meeting this demand [27]. One way to determine HR responsiveness is to measure the variation in beat-to-
beat duration of the cardiac cycle or heart rate variability (HRV)  [28]. This technique has been widely used to 
estimate the influences of the autonomic nervous system (ANS) on heart rate in various populations. However, 
caution must be applied when HRV is used to determine an individual’s capacity to increase or decrease heart 
rate. Firstly, because HRV must be determined during steady-state conditions and extended assessment 
periods. Hence, it cannot provide an overall measure of steady-state conditions and extended assessment 
periods or of the range of cardiac dynamics that occur across multiple states or that are transient in nature. 
Secondly, the use of HRV as an independent measure of sympathetic and parasympathetic control is not 
straightforward  [28]. An alternative measure of cardiac dynamics that avoids these restrictions is the use of 
phase rectified signal averaging (PRSA) [29]. This method yields averaged RR time series that separately 
characterize all heart rate modulations that result in accelerations and decelerations. It is known that individuals 
with COPD have a degree of cardiac autonomic dysfunction, reflected by altered HRV during rest and exercise 
[30] but with a normal diurnal variation [31]. They also have a tendency towards reduced PRSA-derived cardiac 
dynamic capacities that are ameliorated with oxygen therapy [31]. However, neither HRV nor cardiac 
acceleration/deceleration capacities have been evaluated in individuals with UIP. A comparison of these 
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variables before and after physical rehabilitation might indicate whether these patients would benefit from PR 
interventions in terms of improved cardiac responsiveness to everyday activities. 
 
Aims of the thesis 
Although several qualitative studies have been conducted on patients’ experiences with IPF most of these have 
focused on the impact of specific aspects (breathlessness, fatigue, dyspnoea) of the disease on quality of life, 
but not the overall psychological and the sociological impact of IPF on the individual patient. Hence chapter 4 
of this thesis describes a qualitative investigation that sought to extend our knowledge by synthesising an 
‘overall impact’ of the disease - that is, integrating its individual impacts on physical, psychological and social 
wellbeing in daily life. The aim of this study was to explore the idiographic1 experiences of patients with IPF 
within our local health board in South West Wales, and thus to improve our understanding of the psychosocial 
impact of the disease in this region. In so doing, we hoped to gain insight into how to best support the 
psychological needs of individuals diagnosed with IPF. The study offers novel findings that will help to inform 
much-needed local changes in the practice of supporting IPF patients to cope with their diagnosis and disease 
progression. 
 
The focus of Chapter 5 is the comparison of HRV and heart rate responsiveness in ILD patients before and 
after an exercise-based PR programme. HRV analysis was chosen as a tool to estimate cardiac autonomic 
nervous system function during steady-state conditions, whilst cardiac acceleration and deceleration capacities 
(derived using the PRSA method) provided estimates of overall heart rate responsiveness across multiple 
physiological conditions. This is the first study to report these descriptors of heart rate dynamics in individuals 
with restrictive lung disease. In this context, the aim of this study was to determine the influence of an eight-
week, exercise-based PR programme on measures of cardiac autonomic control in patients with UIP. 
Specifically, we sought to quantify HRV and indices of cardiac acceleration and deceleration capacity for these 
individuals during periods of rest and exercise. 
 
The drivers for the investigations described in Chapter 6 of this thesis were, i) a desire to investigate the 
influence of PR on patients’ capacities to respond to extreme (high-intensity, rapid onset) metabolic challenge, 
as encountered, for example, during some physical activities of daily living, and ii) a recognition that any 
meaningful assessment of the physiological efficacy of PR in restrictive lung disease requires the quantification 
                                                          
1 In psychology, the term idiographic describes the study of the individual, who is seen as a unique agent with a unique 
life history, with properties setting him/her apart from other individuals. 
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of multiple physiological biomarkers. In particular, it was speculated that any such influence would involve not 
only respiratory function but also cardiac function, taking account of the inter-dependent nature of the 
ventilation-perfusion and arterial-tissue oxygen exchange mechanisms. Thus, in an attempt to estimate their 
capacities to cope with extreme metabolic challenge, the aim of the investigations reported in this chapter 
was to quantify patients’ dynamic cardiorespiratory responses (oxygen uptake kinetics and heart rate 
kinetics) to a sudden and substantial metabolic challenge, before and after PR. 
 
Summary 
Studies conducted on the outcomes of PR for IPF patients are limited, and most have quantified the outcomes 
of PR using functional measures such as the six-minute walk distance, the dyspnoea scale and maximum oxygen 
uptake. Although some studies have indicated improvements in these parameters, they have been of limited 
value in providing evidence for the efficacy of PR. In particular they did not adequately consider the 
physiological impact of PR, giving rise to a gap in the knowledge of the physiological adaptability of IPF patients 
in response to physical rehabilitation. This thesis will address this gap, as well as extending the concept of the 
‘efficacy’ of PR by investigating patients’ perceptions of its psychological and sociological impact.  
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Chapter 2 
Idiopathic pulmonary fibrosis and the efficacy of pulmonary rehabilitation: 
Literature review 
 
2.1 Background  
Interstitial lung disease (ILD) is an umbrella term given to diseases including IPF , amyotrophic lateral sclerosis 
(ALS) and sarcoidosis, each of which is a  restrictive pulmonary pathology  [13]. According to the American and 
European respiratory societies ILD can be categorised under five main groups [32]:  
1. Exposure-related ILDs (occupational, environmental, avocational and due to medication) 
2. Connective tissue related ILDs (scleroderma, rheumatoid disease and Sjogren’s syndrome) 
3. ILDs caused by granulomas (sarcoidosis) 
4. ILDs caused by various other known disorders (pneumonia, vasculitis)  
5. ILDs of unknown cause (idiopathic interstitial pneumonia).   
 
The American Thoracic Society and the European Respiratory Society further classify idiopathic interstitial 
pneumonia into two groups: ‘Major’ idiopathic interstitial pneumonia (which includes IPF) and ‘Rare’ idiopathic 
interstitial pneumonia [3].  
IPF is a chronic, progressive and life-threatening condition of unknown cause and the commonest of the 
Idiopathic Interstitial Pneumonias. In the UK there are 32,500 people affected by IPF with 6000 fresh cases of 
IPF reporting every year, with a prevalence of 50 per 100,000 people [33].  The histological pattern of IPF is 
characterised by the deposition of excess collagen and other molecules of the extracellular matrix within the 
alveolar interstitium, together with a modest inflammatory cell infiltrate [36]. This pathological process results 
in a gradual loss of functioning alveolar units and a decline in pulmonary function. Consequently, people with 
IPF develop progressive breathlessness and eventually die from respiratory failure. Whilst new therapies which 
slow the decline in lung function have recently become available, there is still no cure for IPF which has a median 
survival of three years although the range is wide; some patients follow a slowly declining trajectory over many 
years whilst others may have a rapidly progressive course [37]. The majority of patients will therefore require 
supportive care at some point in the course of their disease and national guidelines recommend that oxygen 
therapy, PR and palliative care should be offered when appropriate (NICE 2013) [10]. 
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PR  programmes are of proven value in the management of patients with COPD in whom they improve 
exercise performance and quality of life [8]. However, the benefit of such programmes in terms of improving 
exercise performance in people with IPF is less clear  [8]. With this in mind, the aims of this chapter are to 
provide an overview of IPF, to explore previous research on the effectiveness of PR for IPF patients, and to 
consider the potential benefits (physiological and psychological) of PR and how best to measure these. In 
this way the present chapter will help to explain the rationale for the studies reported in this thesis (Chapters 
4-6) as well as supporting the methods employed (Chapter 3).  
 
2.2 Idiopathic pulmonary fibrosis  
2.2.1 Classification 
IPF  is a chronic, progressive, irreversible and life threatening condition of unknown cause and the commonest 
of the Idiopathic Interstitial Pneumonias [38]. IPF may also be referred to as ‘usual interstitial pneumonia’ (UIP). 
It is characterised by progressive fibrosis without substantial inflammation [39] and is common in the middle-
aged and elderly populations. IPF patients have a median age of 66 years [38].  
 
2.2.2 Aetiology of IPF 
IPF is believed to result from a range of diseases such as scleroderma, sarcoidosis, and inflammation due to 
infection, and also from environmental factors such as exposure to silica, metal, wood and asbestos dusts [39].  
Other major causes of IPF are, cigarette smoking [40], medication such as antidepressants [40], infectious agents 
[41] and chronic aspiration [42],[43] and viral infections [44]. These infections include hepatitis C, Epstein-bar 
virus, and adenovirus [44]. Although familial IPF is rare, genetic factors are also considered a cause of IPF [45].  
  
2.2.3 Epidemiology of IPF  
According to Raghu et al. [46], the prevalence of IPF is higher in men than women (in the ratio 1.5:1.7) and this 
increases with age. A study conducted in New Mexico among almost half a million people for a duration of two 
years found the incidence ratio of the disease to be 11:7 (men: women) and the prevalence ratio to be 20:13 
(men: women) [47]. Another study conducted in Japan found that the highest prevalence of IPF (28 per 100,000 
population) is in the age group 60-69 years and was lowest (5 per 100,000 population) in the age group 20-49 
years [48]. A statistically definitive epidemiological study conducted by the British Lung Foundation through 
their ‘respiratory health of a nation’ project [33] looked in to the prevalence and incidence rates of IPF through 
the Health Intelligence network which represents 5% of the population. They calculated the mortality figures 
through official government statistics and their results showed that an estimated 32,500 people in the UK are 
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suffering from IPF, with 6000 new cases reported every year where the incidence is increased with age (85% of 
diagnoses are among people who are over 70 years old). The prevalence was highest in Northern Ireland, North-
West England, Scotland and Wales. Furthermore the study also revealed that there are 9000 hospital admission 
every year with IPF with an annual mortality of 5,300 [33]. The study further finds that IPF is 50% more common 
among males and it had killed 60% more men compared to women between the years of 2008 – 2012. The 
study claims that IPF is common than previously recognised leading to a small but significant burden on the 
NHS. Another study conducted in the UK by Gribbin et al [34].  analysed a primary care database of roughly four 
million patients and found that there were 962 cases of IPF reported between the years 1991 and 2003. The 
data showed a crude incidence rate of 4.6 per 100,000 and a rise of 11% in the incidence of IPF during that 
period. However, this notably large increase in incidence likely reflects an improvement in diagnostic methods 
over this period (with high resolution tomography introduced in the early 1990’s) and more patients being 
diagnosed specifically with IPF, rather than a true increase in the incidence rate of IPF. 
 
2.2.4 Disease Progression  
Following diagnosis with IPF the life expectancy of a patient is a median of three years [49]. Before diagnosis 
every patient has an asymptomatic period which will vary from months to years, during which he/she is exposed 
to micro injuries to the lung tissue until the onset of symptoms [38]. Once diagnosed there are three different 
heterogeneous clinical courses (clinical phenotypes) that a patient could take during the remainder of their lives 
(three distinct paths of health decline) [38]: 1) Rapid progressive type, 2) Acute exacerbation type, and 3) Stable 
or slow progressive type . The worst prognoses are for older individuals (˃ 70 years), those of low body mass 
index (BMI), those with a history of smoking, and those with severe physiological impairment and pulmonary 
hypertension [4].  
1. Rapid progressive: This subgroup of patients are usually male smokers with a high BMI. Also known as 
accelerated IPF, this is a relatively uncommon course. Death occurs within 2 – 3 years despite the fact 
that it has similar lung function, chest imaging and histological findings as those with the slow 
progressive form [38]. 
 
2. Acute exacerbation: This subgroup is defined by the rapid deterioration of the patient’s condition in the 
absence of known triggers such as infections, pulmonary embolism, or heart failure [50] [51]. This 
accounts for 5-20% of IPF cases [52, 53]. These patients have a mortality of more than 60% during 
hospital admission following exacerbation, and for those who survive the mortality is more than 90% 
within six months [53].  
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3. Stable or slow progressive: Most of the patients diagnosed with IPF fall under this category of the 
disease, and they require medical care for months or years after diagnosis [38]. Symptoms in these 
patients include cough and dyspnoea, and reduced lung volumes and capacities lead to hypoxaemia 
that increases with exercise [38].  
 
2.2.5 Pathogenesis  
The histological pattern of IPF is characterised by the deposition of extracellular matrix in the alveolar 
interstitium. The exact cause of IPF is still unknown, but the “inflammatory/alveolitis” hypothesis was widely 
accepted for decades [45]. In this hypothesis it was assumed that IPF is a chronic inflammatory disease due to 
unknown stimulus and when left untreated it would lead to progressive lung disease and ultimately cause 
fibrosis [54], [55]. However this theory was discarded when evidence showed that IPF responded poorly to long-
term anti-inflammatory therapy [56][58].  
The current hypothesis, known as the “epithelial/mesenchymal” hypothesis, describes IPF as a disease which 
arises due to epithelial cell activation from unknown exogenous and endogenous (micro injury) stimuli [59]. 
These injuries could result from smoking, viruses, wood and metal dust, oxidants and ageing, which in turn 
cause disruption of the alveolar epithelium [60]. This results in the constant migration, activation and 
proliferation of mesenchymal cells and the subsequent formation of fibroblastic foci in the alveoli. This leads to 
the accumulation and deposition of extracellular matrix, causing abnormal wound repair [59] and leading to 
deposition of excess collagen and other molecules of the extracellular matrix within the alveolar interstitium 
[36].  This pathological process results in a gradual loss of functioning alveolar units and a decline in pulmonary 
function. 
 
2.2.6 Diagnosis  
Diagnosis of the disease is complex and is key to developing an appropriate management plan [45]. The 
diagnostic criteria shown in Table 2.1 are those presented in the American Thoracic Society guidelines [9]. 
  
23 
 
 
M
aj
o
r 
cr
it
er
ia
 (
al
l 4
 f
ea
tu
re
s 
m
u
st
 b
e 
p
re
se
n
t)
 
Exclusion of other known causes of interstitial lung disease, such as 
drug toxicities, environmental exposures and collagen vascular 
disease 
Abnormal pulmonary function studies that include evidence of 
restriction with or without impaired gas exchange 
Bibasal reticular abnormalities with minimal ground glass opacities on 
high resolution computed tomographic scan 
Transbronchial lung biopsy or bronchoalveolar lavage showing no 
features to support an alternative diagnosis  
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More than fifty years of age 
Insidious onset of otherwise unexplained dyspnoea on exertion  
Duration of illness greater than three months 
Bibasal inspiratory crackles (dry or ‘Velcro”-type in quality) 
 
Table 2.1: Diagnostic criteria for IPF without a lung biopsy [9] 
 
2.2.7 Clinical and Physiological features  
The clinical features of IPF include progressive exertional dyspnoea which can be misdiagnosed as pulmonary 
oedema or respiratory tract infections, cough and breathlessness [45]. The physiological features of IPF are 
mainly associated with lung function and can be assessed using spirometry [61]. Spirometry in IPF patients 
shows an increase in the ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) 
(FEV1/FVC) [62], reduced total lung capacity (TLC) and a reduction in FVC/carbon monoxide transfer factor (DLCO) 
after 1 year [63], [64].  
 
2.2.8 Influence on Pulmonary function 
Lung volumes: The results obtained for pulmonary function testing in IPF resembles restrictive impairment 
of the lung [9]. Residual volume, functional residual capacity (FRC) are reduced in all the patients diagnosed 
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with IPF [9]. However, lung volumes in smokers are very high compared with the IPF patients who had never 
smoked before [65]. 
 
Pressure-volume curve: Studies show that the pressure-volume curve is shifted down and right indicating a 
noncompliant stiff lung [9]. As the disease progresses the lung compliance is further decreased reducing the 
lung volume further [66]. 
 
Airways mechanics: Patients diagnosed with IPF show rapid shallow breaths (referred as tachypneic), hence 
the work of breathing is high [9, 67, 68]. This is thought to be a mechanical response to a higher elastic load 
since no chemical basis for hyperventilation is identified [9, 69, 70].  
 
Gas exchange: Carbon monoxide transfer factor (DLCO) is reduced due to contraction of the pulmonary 
capillary volume coupled with ventilation/perfusion abnormalities [9]. A resting arterial blood gas analysis 
(ABG) of IPF patients shows respiratory alkalosis due to mild hypoxemia caused by ventilation/perfusion 
mismatch but not by impaired oxygen diffusion or anatomical shunts [9]. During exercise the arterial-alveolar 
gradient (AaPO2) increase by 20 to 30% and the arterial oxygen saturation (SaO2) and arterial oxygen pressure 
(PaO2) falls [9].  Furthermore IPF patients increase their minute ventilation due to an increase in breathing 
frequency compared to healthy people who increases it by increasing tidal volume (VT) [9].  
 
Pulmonary haemodynamics:  Pulmonary hypertension is not common during the early onset of the disease 
[9] but does occur during exercise, even at the early stages of the disease. However when the vital capacity 
of the lung is below 50% of predicted values, or the carbon monoxide saturation is below 45% of predicted, 
pulmonary hypertension could be expected even during rest [9].  
 
2.2.9 Management of the disease  
Currently there are limited treatment options for IPF [71]. Various research studies have been conducted in 
an attempt to eliminate or supress the inflammatory response which was believed to lead to IPF, but with 
little success [9]. Some of the treatment options includes administering corticosteroids [72,73], cytotoxic and 
immunosuppressive agents (azathioprine, Cyclophosphamide) [72, 74, 75] and antifibrotic agents such as 
colchicine or D-penicillamine [76,77]. Whilst new therapies are tested regularly there is no permanent 
solution in sight other than lung transplant [9].The majority of patients will therefore require supportive care 
at some point in the course of their disease and national guidelines recommend that oxygen therapy, PR and 
palliative care should be offered when appropriate [10].  
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2.3 Pulmonary rehabilitation  
PR programmes are a cornerstone of respiratory patient treatment strategies, providing a programme of 
exercise, education and support to teach patients how to deal with their condition and maximise their 
functional capacity. These programmes typically last for a few weeks following the initial diagnosis but the 
scientific basis underpinning the type, intensity and duration of the exercise component of these programmes 
remains under-researched [2]. The British Thoracic Society (BTS) published recommendations on creating PR 
programmes in the UK, based on NICE (National Institute for Health and Care Excellence) guidelines. According 
to the BTS, PR  is an interdisciplinary programme that is tailored to optimise the performance of physical activity 
and is a key management strategy in people with COPD [10]. The American Thoracic Society states that the 
primary goal of PR is to “restore patients to the highest possible functional state” [47]. According to the BTS, 
the following are improved in COPD patients as a result of undertaking PR in adults: exercise capacity, dyspnoea 
severity, physical activity levels, muscle strength, psychological status, self-efficacy. No such guidelines exist for 
ILD or IPF patients.  
 
2.3.1 Constituents of a PR programme 
PR programmes include patient assessment, physical exercise programmes, educational materials, and the 
promotion of behavioural change, and are designed to improve quality of life [8]. Education is a major 
component of any rehabilitation programme hence same is said to PR. [BTS guidelines recommends that these 
sessions should be conducted discreetly and should be aimed to support the lifestyle and behavioural changes 
to improve self-efficacy. The purpose of education in PR is to support behavioural and lifestyle change and to 
assist patients in self-management to promote decision making and self-efficacy [10]. These educational 
sessions are usually  based on information about human anatomy/physiology, oxygen therapy, smoking 
cessation, chest clearance techniques, nutritional advise, goal-setting, confidence-building and self-
management [10]. Sewell et al. [78]  compared the effectiveness of individualized rehabilitation programmes 
(personal goal-setting) against general exercise programmes and found no significant difference in the 
outcomes. The BTS recommends simple generalized training programmes over individualized programmes, and 
supervised training programmes rather than non-supervised (home based) programmes as part of the 
rehabilitation process.  
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2.3.2 Duration of a PR programme 
The optimal duration of a PR programme is debatable; although various programmes have been used, lasting 
for between 4 and 12 weeks, most outpatient PR programmes in the UK last between 6 and 12 weeks [10]. The 
BTS recommends a 6-12 week programme including a minimum of 12 supervised exercise sessions [10]. Various 
studies have been conducted to compare the effectiveness of shorter and longer programmes. A study 
conducted by Green et al. [79] concluded that for patients recruited from the same centre, those undertaking 
a seven week training programme had better health outcomes than a group who undertook a 4 week 
programme. Solanes et al. [80] claimed that a minimum of 8 weeks of rehabilitation (with three sessions per 
week) is necessary for improvements in health outcomes to be observed. 
 
2.3.3 Physical activity components of PR 
The BTS recommends that a combination of progressive muscle resistance and aerobic training should be 
included in PR programmes to improve strength and endurance in COPD patients.  Aerobic training should focus 
on improving lower limb endurance such as through walking or cycling [10]. Swallow et al. [81] suggested that 
because lower limb weakness is common in COPD patients it would be advisable for rehabilitation training to 
focus on improving leg strength, thereby improving quality of life. Studying a group of 45 COPD patients, 
Bernard et al. [82] found that those who undertook a combination of strength and aerobic exercise had 
improved muscle strength but no additional improvement in exercise capacity compared to those who did only 
aerobic exercise. Mador et al. [83] compared the effects of endurance training alone and combined endurance 
and strength training in 24 COPD patients. Those who undertook combined training had significant 
improvements in muscle strength (quadriceps, hamstrings, pectoralis major and latissimus dorsi) but no 
significant improvement in quality of life compared with the group who did endurance exercise alone. In 
contrast, Vonbank’s study of 36 COPD patients found that those who took undertook progressive strength 
training alone showed improved muscle strength, exercise capacity and quality of life compared with those who 
undertook either endurance training alone or a combination of strength and endurance training [84].  
 
2.3.4 Compliance with a PR programme: barriers and facilitators 
Particular attention should be given to minimise the dropout rate in PR programmes.  There are four main 
reasons why people drop out from these programmes [85]: (1) the intensity of the programme being perceived 
as too high, (2) transportation difficulties, (3) failure to perceive health  improvements, and (4) unsupportive 
families or friends. Bjoernshave et al. [86] suggested that other reasons include not feeling comfortable in taking 
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part in group activities, not feeling safe with health professionals who are conducting rehabilitation 
programmes, and personal beliefs or experiences about their illness. These authors stated that good support 
from family and peers would enhance patient adherence to PR. 
 
It is important to talk to patients before enrolling them in a PR programme [10], to consider their individual 
perceptions, needs and experiences [87]. This is perhaps especially pertinent for IPF patients who, according to 
Duck et al. [87], perceive three main difficulties: issues with diagnosis, reduction in quality of life and issues 
concerned with living with the condition. Commenting on the experiences of IPF patients in the UK, Bajwah et 
al. [88] indicated that  a typically difficult and protracted diagnosis is usually followed by a further stressful 
period for these patients. This is mainly due to the lack of information they receive about IPF and about their 
prognosis, which is likely one of the main confounders to attempts to improve the quality of life of these 
patients [88]. Bajwah et al. [88] also identified that early referral to palliative care (PR) and support groups, as 
well as providing patients with psychological support, would improve the quality of life in IPF patients. 
 
2.3.5 Pulmonary rehabilitation in ILD and IPF 
Although PR is a well-established method to treat patients with COPD to improve their exercise performance 
[8], the same cannot be said for ILD patients. There are very little physiological data reported from well-defined 
studies of the effectiveness of PR in managing patients with IPF [9]. The ATS recommend that a PR programme 
for ILD patients should consist of a combination of exercise training, education, and psychological support in 
order to improve exercise tolerance, reduce the symptoms of breathlessness, and ultimately to improve quality 
of life [9, 91].  
 
A study conducted by Swell et al. [78] randomised 180 patients between a control group which followed an 
individualized training programme and the study group who followed a group exercise session. The 
individualized training programme had individualized exercises identified through the Canadian Occupational 
Performance Measure (COPM) while the test group followed a set of 10 general exercises. The study showed 
that groups had improved their fitness similarly (no significant difference). 
 
Studies conducted by Kozu et al.  compared the responses of IPF and COPD patients to PR. 45 IPF and 45 COPD 
patients were assessed, and the study showed that the improvement achieved in IPF patients (for all outcome 
measures) were less than in COPD patients. The existing literature on this subject area is unclear about the 
outcome of PR programmes on ILDs [13]. Nishiyama et al. [94] evaluated the effects of PR in 13 IPF patients, 
finding no statistically significant influences on measures of pulmonary function, arterial blood gas analysis or 
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dyspnoea ratings. However, six-minute walk test distances and health-related quality of life scores (St George’s 
quality of life questionnaire) showed marked improvements [94]. Another study conducted by Jeffrey at al. 
claimed that PR improves functional capacity and fatigue levels in IPF patients [95]. Holland et al. [96] found 
improvements in six-minute walk test distance, forced vital capacity and dyspnoea in 25 ILD patients following 
8 weeks of PR. Similar results were obtained by Ozalevil et al. [97] in which a home-based PR programme 
reduced perceived dyspnoea and leg fatigue and improved the six-minute walk test distance.  
 
Although PR appears to have some positive effects on IPF patients, this improvement could be dependent on 
the severity of the disease. Kozu et al. [92] assessed the influence of PR in 65 IPF patients, concluding that IPF 
patients with a lower dyspnoea score responded better to PR than those with a higher dyspnoea score. 
Furthermore the biggest issue with PR for IPF patients is that any initial improvements are not sustainable over 
a long period of time [98]. This was confirmed by  Spiruit et al. [8] who stated that PR has little effect on IPF 
compared to COPD and improvement is not sustained for a period longer than six months. Holland et al [15]. 
observed 34 IPF patients who underwent PR for eight weeks, again finding that initial improvements in the six-
minute walk test distance, dyspnoea scale and level of fatigue were not sustained at six months following 
intervention. 
 
Therefore, whilst there is some evidence of benefit from PR in IPF, relatively little is understood about its 
influence on either oxygen uptake, delivery or utilisation capacity or its efficiency in these individuals.   
 
2.4 Evaluating the physiological impact of Pulmonary Rehabilitation 
2.4.1 Heart rate variability and heart rate dynamics 
Heart rate dynamics are thought to provide a good proxy for the response of cardiac output and muscle blood 
flow to increased metabolic demand [27], albeit they do not account for the contribution of stroke volume in 
meeting this demand. One way to determine HR responsiveness is to measure the variation in beat-to-beat 
duration of the cardiac cycle, known as HRV [99]. This technique has been widely used to estimate the influences 
of the autonomic nervous system (ANS) on heart rate in various populations. Physiological factors including 
blood pressure and respiratory rate have a profound effect on the autonomic modulation of heart rate in 
healthy people. HRV analysis provides a non-invasive method for estimating the magnitude and temporal 
variation of these influences. Unusual magnitudes or patterns of variation of HRV can indicate possible 
autonomic dysfunction. 
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Two main categories of statistical indices have been used to quantify HRV: i) the time domain measures and ii) 
the frequency domain measures.  Time domain analysis is conducted using descriptive statistical methods, and 
two indices are commonly used: i) ‘SDNN’ is the standard deviations of all ‘normal-to-normal’ RR intervals; it 
provides an overall estimation of HRV (including the influences of both sympathetic and parasympathetic 
nervous systems) [28]; ii) ‘RMSSDNN’ is the square root of the mean squared difference of successive RR 
intervals; it quantifies the high frequency components of the RR time series and so reflects the activity of the 
parasympathetic nervous system [28].  
 
Frequency domain analysis involves splitting the heart rate signals into different frequency components, 
allowing analysis of the relative power of the constituent frequency ‘bands’ [100]. By analysing these 
components, it is possible to understand the relative influences of the sympathetic and parasympathetic 
components of the ANS on heart rate (or, more correctly, on cardiac interval). One common method of 
calculating the power distribution of a signal is through power spectral density (PSD) analysis. PSD quantifies 
the power of a signal within a very narrow frequency range; in HRV analysis the PSD is integrated across 
specified frequency bandwidths [100] to quantify the sympathetic and parasympathetic components of the HRV 
data. A graphical representation of the power distribution of cardiac interval (RR) data is shown in Figure 2.1. 
The plots indicate that three different frequency ranges contribute to the RR data: 1) High frequency 
components (HF) in the range 0.15-0.40 Hz, 2) Low frequency components (LF) in the range 0.04-0.15 Hz, and 
3) Very low frequency components (VLF) in the range ≤ 0.04 Hz) [100]. VLF is  associated with thermoregulation 
and vasomotor tone, LF activity is associated with the baroreceptor (blood pressure regulatory) reflex, and HF 
activity is associated with respiration [100], [101]. Figure 2.2 illustrates the averaged power distribution during 
periods of rest, exercise and recovery for the same individual.        
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Figure 2.1: (top) RR interval of a healthy 21-year-old male during rest (0-24 min), exercise (24-48 min) and 
recovery (48-63 min). (bottom):  time-frequency plot for the same individual as above. High power is 
represented by red, medium power by orange/yellow, and low power by blue [100].  
31 
 
 
Figure 2.2: Power spectrum for periods of rest, exercise and  recovery for the same individual as in Figure 2.1 
[100]. 
 
HRV can be used across a range of pathologies since it is a non-invasive and relatively easy way to measure the 
activity of the ANS on the heart. Despite its advantages, caution must be applied when HRV is used to determine 
an individual’s capacity to increase or decrease heart rate. In particular, HRV must be determined during steady-
state conditions and for extended periods, so it cannot provide an overall measure of the range of cardiac 
dynamics that occur across multiple states or that are transient in nature. An alternative measure of cardiac 
dynamics that avoids these restrictions uses the technique of PRSA  [29]. This method separately characterizes 
all heart rate modulations that result in either accelerations or decelerations within an RR data set. The PRSA 
procedure involves aligning sections of the RR data series relative to selected ‘anchor points’, which correspond 
to either points of increase in the signal (deceleration) or of decrease in the signal (acceleration) [29]. Signal 
averaging of the two phase rectified data sets then enables quantification of the ‘acceleration capacity’ (AC) 
and ‘deceleration capacity’ (DC) for the individual [102]. PRSA is a good indicator of the vagal activity of the 
heart [102] (AC and DC reflect the magnitude of reduced (vagolytic) or enhanced (vagotonic) parasympathetic 
(vagal) modulation of cardiac interval, respectively). Bauer et al. [103] concluded that DC is a good indicator of 
32 
 
mortality after myocardial infarction (MI) and that it is more accurate than left ventricular ejection fraction 
(LVEF) and HRV, whilst Kantelhardt et al. [104] found that survivors of myocardial infarction showed a linear 
decrease in DC with age. 
 
It is known that individuals with COPD have a degree of cardiac autonomic dysfunction, reflected by altered 
HRV during rest and exercise [30] but with a normal diurnal variation [31]. They also have a tendency towards 
reduced PRSA-derived cardiac dynamic capacities that are ameliorated with oxygen therapy [105]. However, as 
far as we are aware, neither HRV nor cardiac acceleration/deceleration capacities have been evaluated in 
individuals with IPF. A comparison of these variables before and after physical rehabilitation might indicate 
whether they would benefit from such interventions in terms of improved cardiac responsiveness to everyday 
activities. 
 
2.4.2 Oxygen uptake kinetics and oxygen uptake efficiency slope  
Maximal oxygen uptake is considered to be the single best measure of aerobic fitness (capacity for oxygen 
utilisation) but in practice its measurement can be difficult (for example in older people or those with 
cardiorespiratory disease state, who have limited functional capacity). Other traditional measures of aerobic 
exercise tolerance such as V̇O2 at the ventilatory anaerobic threshold (VAT) can be similarly problematic in 
older/patient populations. Alternative techniques have been developed that offer advantages in terms of 
exercise tolerance. Two methods are of particular note: 1) ‘Pulmonary oxygen uptake kinetics’ analysis, and 2) 
‘oxygen uptake efficiency slope’ analysis. 
Pulmonary oxygen uptake kinetics analysis involves mathematical modelling of the rate of change of oxygen 
utilisation in response to a sudden change in exercise workload. This provides insight into an individual’s ability 
to absorb and utilize oxygen to fuel metabolic activity [23]. The procedure involves fitting either a mono-
exponential or bi-exponential model to the empirical temporal data, with the time-constant of the best-fit 
model reflecting an individual’s oxygen utilisation response rate. Several studies have explored the influence of 
physical PR on oxygen uptake kinetics in COPD [8]. Puente-Maestu et al [106] examined the effects of supervised 
and unsupervised eight-week PR on a mono-exponential oxygen uptake model, observing a post-PR increase in 
mean endurance time (493 ± 281 seconds in the supervised group and 254 ± 283 seconds in the unsupervised 
group) when participants exercised at a work rate equivalent to 70% of V̇O2max. Furthermore, these authors 
also observed that mean Tau (τ) V̇O2 decreased from 83 ± 17 to 67± 11 seconds (supervised group) and from 84 
± 12 to 79±16 seconds (unsupervised) for the two groups. Mean τ for CO2 output, minute ventilation and heart 
rate were also observed to have increased post-training.  Similar studies in IPF patients have been limited. 
McNarry et al. [107] observed that the peak rate of oxygen uptake (V̇O2) in IPF patients is half that of similarly 
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aged healthy individuals, whilst their peak heart rates are 20% lower and their kinetic HR responses to heavy 
intensity exercise are 2.5 times slower. These results provide evidence of reduced tissue oxygen utilization 
following the onset of exercise in people with IPF, which in large part results from impeded central 
(cardiovascular) oxygen delivery. However, the study included only three IPF patients. Jackson et al. [108] 
observed that a three-month PR improved treadmill exercise time and maintained oxygen consumption (V̇O2) 
in 11 IPF patients following rehabilitation, whereas a control group suffered significant reduction in V̇O2 over 
the same period. 
 
 
 
Baba et al. [17] introduced the ‘OUES’, which quantifies the body’s rate of increase of oxygen uptake (V̇O2) in 
response to increases in minute ventilation (VE) during incremental exercise. OUES is calculated using the linear 
relationship between V̇O2 and the logarithm of VE during incremental exercise:  
 
V̇O2 = a × log 10 VE + b 
 
where “a” (the slope or the OUES) represents the rate of increase of VO2 in relation to VE and “b” is the intercept 
[18, 19]. V̇O2 is graphically presented on the y-axis and the logarithm of VE on the x-axis, with a greater slope 
reflecting greater efficiency [19]. Furthermore, use of the logarithm of VE linearizes the otherwise curvilinear 
V̇O2/VE slope, leading to a patient effort-independent result [19].  This is especially useful when using the 
method with individuals who have cardio-respiratory dysfunction (as in chronic lung disease), who have limited 
capacity to conduct strenuous exercise.  The relationship between VE and V̇O2 is determined by the pulmonary 
dead-space/tidal volume ratio (Vd/Vt), the arterial partial pressure of carbon dioxide (pCO2), and the respiratory 
exchange ratio (RER). Consequently, OUES facilitates a mechanistic assessment of two fundamental 
cardiovascular processes during exercise: 1) blood perfusion to the lungs (related to Vd/Vt) and 2) blood 
perfusion to working muscles (related to pCO2 and RER), in response to underlying metabolic demand. OUES 
appears to have several advantages compared with other measures of aerobic exercise performance: it can be 
measured accurately from submaximal exercise protocols (below 60-75% functional reserve) ] [2, 8, 14, 16, 25, 
109] yet is strongly correlated with V̇O2max [2]; it is completely objective (tester-independent)  [2, 8, 109]; it 
has better inter-protocol agreement [10]. OUES has been quantified in various populations (children and adults 
with heart disease, elite athletes [4, 109]) but not in patients with chronic lung disease.  
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2.5 Evaluating Psychological, sociological and physical impact of the disease on quality of life  
2.5.1 Interpretive frameworks 
There are two theories used when it comes to evaluation of psychological impact of a disease on an individual. 
They are 1) Deci and Ryan’s [111] self-determination theory and 2) Lazarus and Folkman’s [113] transactional 
theory of stress and coping. In brief, self-determination theory (SDT) is a theory of human motivation and 
personality in the social context; it is further explained by six mini-theories, one of which considers the role of 
basic psychological needs in determining our well-being and positive functioning. These include the need to feel 
competent, related, and autonomous [111]. When need-satisfaction is thwarted our well-being and functioning 
are adversely affected [111]. Competence refers to the need of an individual to be effective and capable in their 
social environment [114]. Relatedness describes the need of an individual to relate to, interact with, and 
experience the care of, others, and autonomy refers to the need to be independent and able to control oneself 
and one’s life. These three psychological needs are universal and their fulfilment leads to psychological well-
being, which is reflected in physical well-being and vice versa [111] [112]. The usefulness of these theories to 
explore chronic health conditions has been demonstrated previously. For instance, Rahman et al. [115] used 
SDT to analyse motivation and need satisfaction as predictors of psychological and behavioural outcomes in 
patients presenting with a range of health conditions who engaged in an exercise referral scheme. A further 
study by these authors involving cardiac rehabilitation patients reinforced the value of SDT for understanding 
the experiences of patients who are suffering from chronic conditions [116]. 
 
Lazarus and Folkman propose that stress is not simply an emotion but also the outcome of an ongoing 
relationship between the individual and their environment [112] [113]. More specifically, when an individual 
encounters a stressor (such as an IPF diagnosis) they will evaluate the impact of the stressor in relation to 
personal objectives in their life. This process is termed appraisal, of which there are four possible evaluations: 
Harm/Loss (referring to damage already caused, e.g. being diagnosed with a terminal disease), Threat (referring 
to potential harm, e.g. an upcoming medical test), Challenge (the event offers opportunity for personal 
growth/achievement) and Benign (the event is not stressful and no action is taken) [112]. These appraisals are 
not mutually independent and could occur simultaneously at any given time when faced with a stressor. Lazarus 
states that coping is a cognitive and behavioural effort employed by a person to tackle demands that are created 
by the stressors [117] [113]. He further theorises that different stressors will lead to the use of different coping 
mechanisms (problem-focused and emotion-focused). Problem-focused coping mainly aims to resolve the 
practical problems associated with the stressor on a daily basis. These include changing lifestyle through seeking 
information on the stressor, or planning and prioritizing [117]. Emotion-focused coping revolves around 
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managing unpleasant feelings that are caused by a stressor - for example isolation, distancing, managing hostile 
feelings and wishful thinking [117] [118].  
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Chapter 3 
Methods 
The studies reported in this thesis consist of qualitative and quantitative investigations focussing on patients 
with IPF. The first is a qualitative assessment of patients’ experiences of coping with this disease and, based 
on this experience, their recommendations for its clinical management. The second is a set of assessments 
of the physiological impact of a PR programme in IPF patients. This chapter describes the methods used in 
the design and execution of each study.    
 
3.1 Study 1: Patients’ experiences of coping with Idiopathic Pulmonary Fibrosis and their 
recommendations for its clinical management 
  
3.1.1 Study design and setting 
The aim of this first study was to understand how patients coped with their initial diagnosis, how they live with 
the disease day-to-day, their experiences and opinions of the professional support they received, and their 
views on any rehabilitation support that they were offered. A patient-centred approach was therefore used to 
explore the social, psychological and physical impact of IPF. Semi-structured interviews were conducted by an 
experienced academic. Interview questions were written by the researchers but guided by informal 
conversations with patients. An inductive thematic approach was used to analyse the data, allowing us to 
identify common themes in the patients’ experiences. Ethical approval to conduct the study was obtained from 
the College of Engineering Research Ethics Committee (Appendix A), and the study was performed in 
accordance with the Declaration of Helsinki. 
 
3.1.2 Participants 
We recruited participants from a monthly support group for patients with IPF in Swansea. We first contacted 
the chairman of the support group to gain his approval to approach group members. Members of the research 
team then attended a group meeting to provide an overview of the study; patients had an opportunity to ask 
questions and were then invited to participate in the study. Those interested in participating were then 
provided with patient information sheets and contacted via email or telephone to arrange individual interviews 
at convenient locations. This was followed by a second round of participant recruitment (via invitation letters 
posted to members of the group), and similar arrangements were made regarding interviews. Our sampling 
criteria required that participants must have been diagnosed with IPF, be aged 18 years or older and be able to 
write and converse in English (to facilitate data collection). 
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3.1.3 Qualitative data collection methods 
All interviews were conducted by two individuals: i) a senior member of the research team who had extensive 
experience of conducting qualitative research, but who had little knowledge of IPF prior to conducting the 
interviews, and ii) the primary researcher (SS). The senior researcher helped to reduce bias in the interview 
process, and as she was an experienced participant interviewer it ensured that patients were put at their ease 
(from their detailed and in-depth responses, participants appeared to be very comfortable discussing the 
personal aspects of their disease). The primary researcher was knowledgeable about IPF and about PR, so took 
the lead on asking participants specific questions about the rehabilitation programme and its role in disease 
management. 
  
At the outset of each interview, participants were reminded of the purpose of the study, that participation was 
entirely voluntary and that they were free to stop the interviews at any point and to decline to answer any 
question if they wished. Once any queries were addressed, they were asked to provide their written informed 
consent to participate. The interviews were semi-structured, following the steps outlined by Rubin and Rubin 
[123]. The interviews started with introductory questions, followed by transition questions, then the main 
questions and summary questions. An exact list of questions asked in this study cannot be provided as the 
specific questions posed were led by the participants’ responses; however, an overview and indication of the 
purpose of the intended questions which guided the interviews is given in Table 3.1. The questions were devised 
by the two interviewers based on the primary researcher’s knowledge of IPF and prior interactions with patients 
in the support group and with the clinical staff treating them. Interviews lasted for approximately 45-60 minutes 
and were audio recorded to assist with transcription at a later date. The interviews were transcribed verbatim. 
To maintain anonymity, pseudonyms were given to individual participants when reporting their responses, and 
all names and locations were redacted from the transcripts. (After the first interview was transcribed, the 
interviewers reflected on the interview experience and the responses yielded. This resulted in minor changes 
to the wording of the opening questions to ensure optimal focus on the main topic of subsequent interviews.)  
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Table 3.1: Example of the Overview and the purpose of questions asked during patient interviews.  
Question type Example question Purpose of the question 
Introduction 
Can you tell me about the onset of 
your condition and a little bit about 
it? 
This question aimed to engage the patient with the 
topic and to allow them to express their personal 
understanding of their condition. 
Transition 
How does IPF make you feel on a 
day-to-day basis? 
This question was used to gain an overall 
impression of the psychological impact of the 
disease from the patient’s perspective, and to link 
the introductory and main questions. 
Transition How do you make the most of it? 
These questions helped to facilitate the flow 
between topics of interest during the interview. 
These types of question were followed by a main 
question, depending on the patient’s response. 
Main 
If you think back to your life before 
being diagnosed with your medical 
condition, what are the things that 
you did before but are prevented 
from doing now? 
This type of question was asked to get an indication 
of the patient’s lifestyle before diagnosis of the 
disease and how IPF had affected the patient’s daily 
life. This is the key information in which the 
interviewers were interested. 
Summary 
 
Is there any other way that it 
affects you? 
 
These questions were intended to sum up the main 
topics of the interview, allowing the patient to 
summarise their overall experiences and personal 
perspectives of living with the disease. 
 
3.1.4 Data analysis 
As this is an under-explored area, an inductive thematic approach [124] was used to analyse the data, allowing 
identification of common themes representing the patients’ experiences and also helping us to relate their 
personal stories. Using this approach, notes and initial impressions (raw data themes) were recorded during the 
interviews and these ideas were tracked and continually revised throughout the transcription process. This 
analysis followed strategies outlined by Miles and Huberman [125] where quotes (representing raw data) were 
highlighted and labelled with an initial raw data theme that reflected the idea or meaning conveyed in the 
quote. This process continued until all quotes relevant to the research aim were highlighted and either allocated 
to an existing raw data theme or, if they did not fit into an existing theme, given a new raw data theme label. 
To ensure that the original meaning of the raw data was retained, following this initial process, the primary 
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researcher reassessed the transcripts to verify the allocations of labels to the raw data. The raw data generated 
by interview quotes were coded using patient identification codes to allow us to assess how representative 
each theme was of overall participants’ experiences. After the data were coded and categorized into raw data 
themes, they were reviewed systematically to identify common meaning across different raw data themes. 
Those that had shared common meaning were grouped together to form a ‘first-order theme’, which was given 
an appropriate label to represent the shared common meaning of its composite raw data themes. This process 
was repeated with the resulting first-order themes to produce ‘second-order themes’, and finally with the 
second-order themes to produce ‘general dimensions. 
 
An extended process of peer-debriefing was used to establish the trustworthiness of the data analysis: the 
senior interviewer acted as a critical friend to challenge and check the credibility of the data analysis and 
interpretation (performed by SS). The critical friend independently reviewed each transcript and highlighted 
salient quotes to produce raw data. Based on the classifications by SS, she then determined whether she was 
in agreement with their allocation to raw data themes and noted where her allocations differed. She also noted 
where she identified additional raw data and to which themes, she would allocate these. The two analysts 
discussed this first stage of analysis and agreed on some changes to the allocations of raw data to raw data 
themes, and on the addition of new raw data to some themes. The analysts then discussed the initial 
identification of first and second-order themes. SS independently reviewed the modifications discussed during 
peer-debriefing and incorporated those he felt were appropriate into the next interpretation of the data. 
‘Member checking’ was also used, although only to a limited extent as only two participants engaged with this 
process. This involved forwarding interview transcripts to participants for review prior to data analysis. Those 
who responded verified the transcript content and none replied asking to withdraw their comments or 
objecting to their interview content. 
 
3.2 Study 2: Physiological impact of pulmonary rehabilitation for IPF patients 
3.2.1 Study setting  
This part of the study was also conducted in accordance with the Declaration of Helsinki. Ethical approval to 
conduct the study was obtained from Wales Research Ethics Committee 6 (Ref. 16/WA/0272; Appendix A), 
part of the UK Health Departments’ Research Ethics Service. Approval and permission to execute the study 
was obtained from the local health board (Abertawe Bro Morgannwg University Health Board) (Ref. 206031; 
Appendix A). Swansea University was the Sponsor for the study, as required by the Research Governance 
Framework for Health and Social Care and/or Medicines for Human Use (Clinical Trials) Regulations 2004. 
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3.2.2 Participants 
Participant recruitment was led by a consultant chest physician, who informed eligible patients about the 
study (including its purpose, protocol, expected commitment and the possible risks of involvement). Patients 
attending the Interstitial Lung Disease Clinic at Moriston Hospital, Swansea, who had been diagnosed with 
IPF by a Multi-Disciplinary Team, according to the American Thoracic Society (ATS) and European Respiratory 
Society (ERS) guidelines [2] were potentially eligible to participate in the study. An additional clinical 
assessment was performed on all potential participants; they were not eligible to participate if they had any 
of the following exclusion criteria: 
 
o Respiratory infection within the previous two months 
o Known coronary or valvular heart disease 
o Any other serious co-morbid condition (e.g. emphysema, uncontrolled diabetes, renal disease)  
o Significant hypoxia (oxygen saturation below 85%) when breathing air and undergoing conventional 
screening for a PR programme  
o Musculoskeletal problems that would make it impossible to exercise 
o Current smokers.  
 
All recruited participants provided their written informed consent to participate in the study. They were then 
enrolled in the PR programme (Section 3.2.4) at Morriston Hospital, Swansea.  
 
3.2.3 Physiological data collection methods: Pre- and post-rehabilitation testing 
3.2.3.1 Day 1  
Participants were first asked to complete the Quality of Life  questionnaires (European Quality of Life – 5 
Dimensions (EQ5D) questionnaire developed by the EuroQol Group [126], Hospital Anxiety and Depression 
Score (HADS) [127], MRC breathless scale [128] and Kings ILD questionnaire [129]).  This was followed by the 
six-minute walk test (6MWT). The 6MWT evaluates the integrated response of all the systems involved during 
exercise, especially the pulmonary and cardiovascular system [130]. The tests were performed according to the 
American Thoracic Society’s guidelines [131]. Two cones were placed on either end of a 30 meters corridor to 
mark the test ‘course’. Participants were then asked to walk between the cones as fast as they could for six 
minutes, and the distance covered was recorded. Each of the above assessments was carried out at Morriston 
Hospital, Swansea. The results of this study are reported in Chapter 4. 
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3.2.3.2 Day 2  
Participants were asked to visit the lung function laboratory at Morriston Hospital, Swansea, for baseline 
physiological assessment. They were asked to not consume alcohol for 24 hours before the test day and to not 
consume caffeine for six hours prior to the scheduled tests, but otherwise to have eaten and consumed fluids 
as normal. To test the cardiovascular and the respiratory systems, participants were asked to complete an 
incremental exercise test on a stationary bicycle (ergometer) (VIAsprint™ 150P Ergometer, Vyaire Medical, 
Mettawa, IL, USA) in accordance with methods described by Arena et al. [132]. They first completed three 
minutes of baseline cycling with no workload, after which the work rate was increased at a rate of 10-15 W∙min-
1 depending on the individual predicted maximum workload, until the limit of exercise tolerance was reached. 
Participants were asked to maintain a cadence of 55–60 rpm. The test was stopped by the researchers if a 
patient desaturated to an oxygen level below 85%. Throughout the test, which included six-minute periods of 
rest before and after exercise, a continuous Holter ECG was recorded (Reynolds Lifecard Digital CF system; 
Spacelabs Healthcare Ltd., Hertford, UK), providing ECG data with a 1024 Hz sampling frequency, 12-bit 
resolution and a sample accuracy of 2.5 µV. The ECG leads were positioned in the ‘modified V5, CC5, modified 
V5R’ electrode configuration. Patients were also asked to breathe through a facemask which allowed us to 
sample the air that they inspire/expire using an online respiratory gas analyser (MGC Ultima CardiO2; MGC 
Diagnostics, St Paul, MN, USA) and blood oxygen saturation was continuously monitored (Nonin Model 7500, 
Plymouth, MN, USA). The rates of oxygen uptake (V̇O2) and carbon dioxide production (V̇CO2) and minute 
ventilation (VE) were measured from the breath-by-breath respiratory gas data using the Breeze computer 
software (Breeze Software 6.4.1, Medical Graphics, MN, USA). The V̇O2maxwas determined by averaging the 
V̇O2 values from the final 10 seconds before the limit of exercise was reached. Aerobic threshold (AT) was 
identified by two physiologists using a combination of the two methods used by Castro et al. [133]: (1) using 
the point of upward inflection of the V̇CO2 vs V̇O2 curve and (2) using the onset of a consistent increase in 
ventilatory equivalent for oxygen (VE/V̇O2) with no increase in the ventilatory equivalent for carbon dioxide 
(VE/V̇CO2). Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured using 
the spirometry test function of the online respiratory gas analyser. All tests were initiated at the same time of 
day (± 1 hour). The results of this study are reported in Chapter 5. 
 
3.2.3.3 Day 3 
Participants returned to the lung function laboratory at Morriston Hospital, Swansea, having again refrained 
from consuming alcohol for 24 hours from consuming caffeine for six hours, but to have eaten and consumed 
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fluids as normal. Participants were asked to perform a second bicycle exercise test (VIAsprint™ 150P Ergometer, 
Vyaire Medical, Mettawa, IL, USA) consisting of a six-minute warmup with no external resistance, followed by 
an immediate transition to a fixed uniform workload. The uniform workload was calculated as 40% of the 
difference between the AT and the V̇O2Max (Δ40%) [16] which was calculated from the incremental test 
performed on day 2. This workload was maintained for six minutes or until the participant reached their limit 
of tolerance, after which there was an immediate transition back to cycling with no external resistance for a 
further three minutes. Participants were asked to maintain a pedalling cadence of 55-60 rpm throughout each 
stage of the test. Patients breathed through a facemask connected to an online respiratory gas analyser (MGC 
Ultima CardiO2; MGC Diagnostics, St Paul, MN, USA) and a Holter ECG recorder (Reynolds Lifecard Digital CF 
system; Spacelabs Healthcare Ltd., Hertford, UK) recorded an ECG throughout the test. All tests were initiated 
at the same time of day (± 1 hour). The results of this study are reported in Chapter 6. 
 
3.2.4 The Pulmonary Rehabilitation programme  
Following baseline measurements participants began an eight-week PR programme (two sessions per week, 
two hours per session) under the direction of the physiotherapist staff at Moriston Hospital, Swansea. This 
programme consisted of ten minutes of ‘warming up’ (20 sets of ‘marching on the spot’, ‘heal digs’, ‘knee lifts’, 
‘shoulder rolls’, ‘knee bends’ and ‘high knees’) followed by a range of strength training exercises (‘bicep curls’, 
‘triceps extension’, ‘dumbbell press’, ‘dumbbell fly’, ‘leg extension’ and ‘dumbbell squats’) and cardiovascular 
exercises (choice of treadmill, bicycle ergometer or cross-trainer exercise). Each patient was asked to choose a 
weight that they could safely handle at the beginning of the rehabilitation for use in each exercise, and they 
were encouraged to increase their weights on each day of rehabilitation as the programme progressed. For the 
cardiovascular exercise patients were asked to select a mode of exercise with which they were comfortable, 
which was maintained throughout the programme but with increasing workload (resistance) as rehabilitation 
progressed. The strength exercises lasted five minutes each and the cardiovascular exercise lasted ten minutes, 
followed by a ten-minute cool-down period (which included sets of ‘hip flexor stretch’, ‘thigh stretch’, ‘calf 
stretch’ and ‘lower back stretch’). Upon completion of the rehabilitation programme patients were asked to 
return to the hospital for repeat physiological and functional assessments. 
 
3.2.5 Cardiac and respiratory data analysis  
3.2.5.1 HRV analysis 
ECG recordings were assessed for quality by human observation using the Spacelabs Pathfinder system 
(Spacelabs Healthcare Ltd., Hertford, UK), primarily to verify the absence of excessive noise or artefact. Beat-
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to-beat cardiac intervals (RR) were then measured automatically by the Pathfinder system (using a proprietary 
algorithm) and any spurious data points (artefacts) were removed manually prior to subsequent analysis. The 
RR data were then analysed using the Kubios HRV software package (version 3.1; [134]) in three separate but 
contiguous sections covering the Pre-exercise (rest), Exercise and Recovery (post-exercise) stages. The RR data 
within each of these sections was first detrended using the ‘Smooth priors’ function (Lambda = 500). Heart rate 
(HR) and HRV variables were next quantified according to the European Society of Cardiology Task Force 
guidelines [135]: (1) RMSSD (the square root of the mean squared differences of successive RR intervals), (2) 
SDRR (the standard deviation of RR intervals), (3) Total Power (the total amount of ‘power’ (variance) in the 
bandwidth ~0 to 0.4 Hz), (4) VLF (the very low frequency power, in the bandwidth 0.003-0.1 Hz), (5) LF (the low-
frequency power, in the bandwidth 0.04-0.15 Hz), (6) HF (the high-frequency power, in the bandwidth 0.15-0.4 
Hz), (7) LFn (the normalised low frequency power): LFn=LF/(Total Power – VLF), (8) HFn (the normalised high-
frequency power): HFn=HF/(Total Power – VLF)] and (9) the ratio LF/HF. 
 
3.2.5.2 PRSA analysis 
The PRSA procedure [29] was used  to quantify the acceleration capacity (AC) and deceleration capacity (DC): 
(1) multiple DC and AC ‘anchor points’ were identified, respectively, as those RR intervals longer than or shorter 
than the preceding RR interval; (2) a truncated RR time series was defined around each of the anchor points (a 
61-point series, including 30 points preceding and following the anchor point); (3) the truncated RR time-series 
were aligned (separately for DC and AC anchor points) and averaged to form the PRSA time-series; (4) DC and 
AC were calculated as [(X0 + X1) – (X−1 + X−2)]/4, where X0 and X1 are the averaged RR intervals at the anchor 
point and the immediately following point, and X−1 and X−2 are the two averaged RR intervals immediately 
preceding the anchor point. Group mean Acceleration and Deceleration vectors (used for visualization) were 
calculated after standardising the individual RR time-series (to minimize inter-individual differences in resting 
RR) – this was performed by subtracting the mean of the 12 RR intervals immediately preceding interval X−2 
from each RR value in the time-series. 
 
3.2.5.3 Statistical analysis of HRV and PRSA data 
Matlab (version 2017b, The Mathworks, Cambridge, UK) was used to perform descriptive statistical analysis of 
the HRV and PRSA data, and to evaluate the nature of their distributions. The One-Sample Kolomogorov-
Smirnov Test was used to test the null hypothesis that each group-wide HRV and PRSA-derived variable 
belonged to a standard normal distribution. If this assumption was violated then the influence of the 
rehabilitation intervention on each variable was assessed using Wilcoxon Signed Rank tests, and data were 
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presented as Median (M) and Lower/Upper Quartile (Q1, Q2) values. One-sample Kolmogorov-Smirnov tests 
showed that none of the quantified variables were Normally-distributed. Consequently, the Wilcoxon Signed-
rank test was used to assess the influence of PR on each variable. Statistical significance was assumed at the 
p<0.05 level. 
 
3.2.5.4 Oxygen uptake analysis 
Each participant’s V̇O2 response to the constant workload exercise test (day 3 protocol) was first plotted to 
check its structure, and to identify any artefacts in the data (which could arise, for example, owing to swallowing 
or coughing, or as a result of technical problems such as face-mask loosening). In accord with previous oxygen 
uptake kinetics studies [16] our intention was to model participants’ individual temporal V̇O2 responses using a 
single exponential model (Equation 1): 
 
                   V̇O2 = A * (1-e-(t-δ/τ)    (1) 
 
where “t” is time, A is the amplitude of the response (maximum value of V̇O2, with baseline V̇O2 immediately 
prior to exercise set to zero), δ is a time delay and τ is the time constant. However, we did not observe evidence 
of so-called Phase I type behaviour (an exponential rise in V̇O2 attributed to an increase in pulmonary blood 
flow at the onset of exercise [136] [137]) in any of our data so we chose to remove the time-delay (δ=0). Neither 
did we observe Phase III (V̇O2 slow component) behaviour, in common with previous work [16]. We therefore 
chose to perform our analysis solely in terms of the mean response time (MRT), which reflects the time course 
of the entire V̇O2 response (Equation (2)): 
 
                  V̇O2 = A * (1-e-t/MRT)     (2) 
 
The individually normalised V̇O2 responses were modelled using Matlab’s Curve Fitting Tool (non-linear least 
squares method) to determine variables A and MRT and their associated 95% confidence bounds, as well as the 
goodness of fit of the model. To facilitate group averaging of the individual responses all data were next 
interpolated so that V̇O2 was defined uniformly at 0.5-second intervals. The group-averaged V̇O2 response was 
then separately modelled (using equation (2)) for the pre- and post-PR conditions. Finally, the group-averaged 
responses were re-sampled at 30-second intervals to facilitate pre-PR vs post-PR statistical comparison at 12 
discrete time-points (over six minutes) during exercise. 
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3.2.5.5 Heart rate dynamics analysis 
Participants’ heart rate responses to the constant workload exercise test (day 3 protocol) were analysed 
analogously to the methods described for oxygen uptake analysis in Section 3.2.5.4 (using Equation 3):   
 
     HR = A * (1-e-t/MRT)    (3) 
 
 
3.2.5.6 Oxygen uptake efficiency slope  
OUES was calculated from the linear relationship between V̇O2 and the logarithm of VE, as measured during the 
incremental exercise tests (day 2 protocol). This relationship can be expressed as:  
 
   V̇O2 = a * log 10 VE + b    (4) 
 
where OUES is equal to the slope ‘a’ of the V̇O2 vs log 10 VE plot [18, 19].  
 
3.2.5.7 Statistical analysis of oxygen uptake dynamics, heart rate dynamics and OUES data 
Matlab (version 2017b, The Mathworks, Cambridge, UK) was used to model the temporal V̇O2 and HR data 
(Matlab Curve Fitting Toolbox) and to perform descriptive statistical analysis for each variable calculated from 
the modelling analysis (‘A’, ‘MRT’) and from the OUES analysis (‘a’). The One-Sample Kolomogorov-Smirnov Test 
was used to test the null hypothesis that data obeyed Normal distributions. If this assumption was violated, 
then the influence of the rehabilitation intervention on each variable was assessed using Wilcoxon Signed Rank 
tests. One-sample Kolmogorov-Smirnov tests showed that none of the quantified variables were Normally-
distributed. Consequently, the Wilcoxon Signed-rank test was used to assess the influence of PR for each 
variable. Statistical significance was assumed at the p<0.05 level.  
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Chapter 4 
Patients’ experiences of coping with Idiopathic Pulmonary Fibrosis and their 
recommendations for its clinical management 
 
4.1 Overview 
This chapter describes the results of an investigation that sought to assess the multiple impacts of being 
diagnosed, and then living with, IPF.  The primary aim of this study was to explore the idiographic (i.e. individual 
case-specific, as distinct from general) experiences of patients with IPF within our local health board in South 
West Wales (Abertawe Bro Morgannwg University Health Board), and thus to improve our understanding of 
the physical, psychological and social impacts of people living with IPF in this region. In so doing we sought to 
better understand patients’ individual stories and to more effectively identify common themes amongst the 
patient group. The methods used to collect, analyse and interpret the data presented were detailed in Section 
3.1.3. 
 
4.2 Results 
A total of 50 IPF patients registered in the support group were contacted by post and 10 volunteered to take 
part in the study. No replies were obtained from the other 40 individuals, and no explanations were sought 
from those who did not respond (in line with our ethical approval). After analysing the transcripts from these 
ten participants the research team considered that data saturation had been reached and so no additional 
patients were invited to participate. The study participants ranged in age from 53 to 81 years (mean = 70.5 ± 
10.4 years), one of whom was female. Participants reported durations of disease onset ranging from 7 months 
to 10 years: onset under one year – five patients; onset 3-5 years (two patients); onset 8-10 years – three 
patients. Only one participant used oxygen during the interview, while two participants reported using oxygen 
during strenuous activities in daily life. All participants were Caucasian. Eight participants attended the 
interview on their own (one of whom was interviewed at home) and two attended with their spouses. In these 
latter interviews, the participant’s spouse contributed to the discussion, simultaneously offering verification of 
the participant’s responses, but also often encouraging further reflection or interpretation from the participant. 
Transcripts of the discussions with each participant are presented in Appendix B.  
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Inductive analysis of the patient interviews led to identification of seven second order themes and eleven first 
order themes that are represented by two General Dimensions: Patient experience with the condition and 
Patient-led recommendations for practice. An overview of these themes and their hierarchical relationships 
with each other is shown in Figure 4.1.  
 
 
 
 
Figure 4.1: Key themes representing patients’ experiences of IPF and patient-led recommendations for practice 
 
4.2.1 General Dimension 1: Patients’ experiences of IPF 
This General Dimension was underpinned by 4 second order themes (Social perception, Depression, accepting 
facts, and Living with the condition) that mainly describe the psychosocial impact of the disease on the patient, 
how it has affected his or her life, and the impact of IPF on the patient’s family members. These second order 
themes were derived from (and reflect) both negative and positive responses from the participants and were 
categorised collectively as they relate to the same shared theme. The theme explanations below illustrate the 
positive and negative responses provided by participants in relation to each theme. 
48 
 
 
4.2.1.1 Social Perception 
In this context, ‘social perception’ describes an individual’s experiences of negotiating the social implications of 
IPF, including their feelings about how other people perceive and treat them and how these impacts on their 
psychological well-being. Across all the interviews, it was evident that participants and their close family 
members had little or no knowledge of IPF before diagnosis, and most had not even heard the phrase IPF 
previously. This lack of public awareness could be due to the limited availability of information about the 
disease: “A lot of people don’t know what it is. They understand lung cancer but when it comes to IPF they are 
like ‘what is that?’” (Patient J). This can lead to perceived prejudice: “When people see you coughing, they say 
‘take cough medicine, take this, take that’, they don’t understand it” (Patient B) and “they would say, ‘why you 
are panting when you are doing nothing literally?’” (Patient B). When patients face these kinds of responses on 
a daily basis they feel isolated and somewhat stigmatised, which appeared to be contributing factors to the 
onset of depressive symptoms in some patients.  
 
4.2.1.2 Depression 
Most of the patients interviewed displayed symptoms consistent with depression or low mood. This is likely 
attributable to the psychological trauma associated with their disease, as noted by one participant who 
commented on what their diagnosis meant to them: “Death. Certain, definite death.” (Patient H). Aside from 
feelings of depression a sense of vulnerability was also apparent among participants, adding to the feelings of 
depression, and this appeared to stem from their lack of knowledge about the disease. The comments of two 
participants illustrate this: “Lack of information always causes more worries” (Patient A) and “Well, I’m in the 
dark about what you can do to help the condition” (Patient B). Inaccurate or misinterpreted information about 
the nature and prognostic implications of IPF appears to be a common problem, as reflected in the perceptions: 
“If I was diagnosed with lung cancer it would have knocked me over, but knowing I have a fighting chance as 
things are, it’s not bothering me” (Patient E), and “I was pleased it wasn’t cancer” (Patient H). 
 
The psychological trauma caused by the disease also appears to derive from altered perceptions of self: “I feel 
like a battery; your energy levels go down and you would have to stop” (Patient J). When patients could not live 
up to their self-expectations and their previous self-perceptions of ability, they experienced feelings of self-pity 
that further fuelled their anxieties about the debilitating nature of the disease. As one participant commented: 
“Sometimes I feel ashamed about the things I can’t do” (Patient A). Another participant explained: “If I go out I 
have to plan a route, that I know which is flat. So that I know, if I got to that point I can get back. You have to 
think ‘if I can’t come back who am I gonna call to come pick me up?’ You know, things like that. It really takes it 
out of you, it’s surprising to see how much it takes out of you. After being there and doing something I feel like 
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an old man of 90.” (Patient G, age 53). Furthermore, these IPF patients often experienced regret and frustration 
mainly due to the morbidity of the disease and because they were being prevented from living their later years 
as planned: “I do get frustrated when it physically affects me, not being able to do things that I planned to do” 
(Patient J) and “You plan to do all these things that you wanted to do all these years. But here we are.” (Patient 
I).  
4.2.1.3 Accepting facts 
‘Accepting facts’ refers to the stage at which all participants indicated they had started to come to terms with 
the condition and attempted to move on with their lives. As the quotes below illustrate, usually this began with 
accepting the fact that they have the disease and it ended with the sense of achievement gained from being 
able to cope with (and adapt to) living with the disease. When accepting the facts about, and the consequences 
of, the disease, most participants were initially optimistic: “I was determined to live my life to the fullest” 
(Patient A) and “I told myself ‘you have to try anything and everything’” (Patient C).  
 
This positivity and optimism were enhanced further when individuals felt that their lives mattered, thereby 
nurturing their sense of self-worth. This derived in part from knowing that there are people and groups in 
society who care about them: “I’ve had a leaflet from the lung association” (Patient B). Once these participants 
had achieved acceptance of the disease, they were able to adapt to the disease accordingly: “I learnt a few 
things like when it comes to climbing steps it’s easier to breathe in when you take off the step and breath out 
when you land on the step” (Patient G) and “If I am going out I need to plan a route which I know is flat” (Patient 
G). 
 
Following on from this acceptance and adjustment, some participants attempted to engage in physical 
activities, the successful completion of which gave them a sense of achievement.  This was cause for renewed 
optimism, and an increased commitment to self-care as they looked to the future with hope: “It was keeping 
my lungs clear (now I have a lot of mucus and phlegm), and it felt better. When I was done, you felt that you 
have achieved something” (Patient F). Hearing participants’ experiences, it was evident that overcoming fear of 
the disease and accepting the facts about it represented the initial stage of moving towards an elevated quality 
of life; individuals had a sense of starting to live again, despite living with the condition, and of achieving some 
normality to their day-to-day lives. Once they had successfully navigated through this life experience, patients 
were often able to ‘move on’, overcoming the psychological trauma caused by the diagnosis and associated 
morbidity of the disease.  
 
 
50 
 
4.2.1.4 Living with the condition 
These themes describe how the disease affected the daily lives of the participants and the adaptations they had 
made to cope with the condition on a daily basis. Overwhelmingly, IPF had a huge impact on the participants’ 
lifestyles: “I used to play a lot of golf, swimming, cricket, you name it. I’ve had no problem, but now I’m a 
television viewer” (Patient B) and “I’ve sometimes found lifting whatever across the garden these days is difficult, 
but before it was easy” (Patient E). 
 
Most of the interviewees had to change their lifestyles completely following diagnosis, adjusting to living with 
the condition through planning and prioritizing activities. They mentioned “finding the simplest way to do 
things” and “I try to keep everything in precise order, so things at the same place all the time” (Patient A) and 
“It’s sort of reorganizing your life, try and do everything in one place before you move to another” (Patient B). 
Such modifications helped significantly in overcoming the obstacles they faced due to the debilitating nature of 
the disease. Participants’ comments showed that the disease also affected their family members: “Then my 
daughter read it and she was badly distressed, and she kept it from me. When it’s sitting there in front of you, 
you think OMG [Oh My God]” Patient H) and “My son had a shock when he saw me with the oxygen” (Patient 
F). Interestingly, the participants did not discuss coping strategies employed by their family members, but some 
did mention protective behaviour in both directions. Some participants mentioned protecting their family 
members, and others noted that family members protected them, from some of the stark realities of the 
disease: “My daughter knows, my husband knows. He has been very protective in a loving way. My son haven’t 
told him” (Patient H). 
 
4.2.2 General Dimension 2: Patient-led recommendations for practice 
The second general dimension was made by 3 second order themes (support, patient opinions and, exercise 
programme) which mainly describes patients’ opinion and thoughts on how to minimise the impact of IPF on 
daily life and the positives and negatives of support available for IPF patients. As above the theme explanations 
illustrates both the positive and negative responses given by the participants in relation to each theme.   
 
 
4.2.2.1 Immediate responses to diagnosis 
Receiving initial information about IPF at the point of diagnosis was a traumatic experience for participants. 
Most had never heard of the condition previously and the information presented a stark and upsetting 
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prognosis: “It came as a little bit of a shock. It affected me” (Patient I) and “Very shocked. Really upset at the 
time. Coming to terms with it slowly” (Patient H). Two participants commented about the way in which they 
were told about the disease: “They gave me a booklet and I wish I didn’t read it” (Patient H) and “To give it to 
someone as soon as they diagnosed it, I think it was not a good idea” (Patient G). The initial shock and 
unexpected diagnosis of a disease about which they were unaware left many patients looking for someone to 
blame, as they felt somehow victimised by their diagnosis. However, they were unable to attribute this blame 
to someone or something, which only added to the immense frustration and psychological trauma caused by 
their diagnosis: “I feel picked on, I feel I haven’t smoked for all these years, I don’t drink, I’m not overly fat, why 
is this happening to me?” (Patient G). 
 
Each of the study participants had an individual perspective on how to cope with the disease and suggestions 
on how to improve the care and support available for IPF patients. Overwhelmingly, one of the key factors 
identified was the lack of available and appropriate information on the disease. Both ignorance and ambiguity 
about the disease contributed to the trauma that they were already experiencing with their diagnosis: “They 
say you are like this and that’s how you are going to end up like. And you think, what’s going to happen in 
between?” (Patient G). Participants offered a number of suggestions on how to address this, including involving 
patients in developing materials for other sufferers and giving patients a role in educating health professionals, 
to help them to understand the patient’s experience of diagnosis and the disease trajectory. One participant 
suggested that “Initially I will direct them to our support group. Then I would ask someone who had experience 
of the condition and the rehabilitation programme to talk about rehab [sic], who can pass on their true feelings 
- not a clinical thing, somebody talking from the heart who had done it” (Patient D). Another commented “I 
think you need it in age groups, which would help” (Patient G), and another felt that “You should find out all the 
facts, face up to the facts, accept what is inevitable and live accordingly” (Patient A). They felt that these 
strategies would help future IPF patients to appropriately fill the information gap they had experienced when 
they were diagnosed with the disease. 
 
4.2.2.2 Support 
Participants’ comments indicated that support from others could be perceived as either a positive or a negative 
influence. Most of the participants experienced positive support after their diagnosis with IPF, from either 
family or peers and not surprisingly this was viewed as very important in helping them to accept the disease 
and to overcome the depression they experienced: “They would do anything if I ask my family” (Patient A). The 
peer support they experienced mainly came from the monthly support group that these participants attended 
and, as was the case with family support, support from others with the disease was perceived as vital in 
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overcoming feelings of depression and adapting to living with the condition: “The positive is that I’ve met people 
similar, some of them are very nice’ (Patient A) and “There was company, people with the same disease. I found 
I was looking forward to going. And I thought it was doing me good” (Patient H). Others discussed the informal 
educational role this peer support played: “We have a cup of tea; cake and we talk about how things are. They 
get people from different ways of life to talk about the problem” (Patient F) and “Just having a chat about 
families and how they are coping, you know that’s the biggest part of it. Getting together and talking to people 
with the same problem’ (Patient F). Some found comfort in just seeing other people who are in a worse 
condition than them: “…but it was nice to see there were people worse than I was” (Patient G). 
 
Although the support group was an incredibly powerful coping mechanism for the participants, its influence 
was not consistently positive: “I couldn’t help thinking that this is like Shipman’s waiting room*, waiting for each 
one to pop off you know. Because there is always news that somebody is gone and that’s a person you know 
and I think, my name would be there one day wouldn’t it?” (Patient A) [*Dr Harold Shipman was a notorious 
General Practitioner in the UK who was convicted of murdering (via euthanasia) several of his elderly patients]. 
This patient also discussed the impact of a shared common fate: “…down turn because you all know that you 
are going sooner than you’d like to be”. 
 
Family support was perceived in a similar vein: overall it was received positively but this was not always the 
case. For example, a number of respondents discussed that family members contributed to their lack of 
independence by making decisions about their lifestyles for them, or by doing things for them that (with some 
effort) they were still able to do for themselves. One participant commented “I got told off by my daughter for 
cutting the grass. But I got to do it. I got to do it when I get the chance” (Patient F), whilst another noted 
“Eventually she is talking about us moving downstairs and staying downstairs once it gets to a certain point - 
well I don’t want that. I’d rather take 10 minutes to go upstairs to go to bed than staying downstairs all the 
time” (Patient G).  
 
4.2.2.3 Exercise programmes 
Study participants felt that physical exercise could benefit them physically and could positively influence their 
mental well-being, helping them to deal with their feelings of depression and to simply carry on with life. They 
discussed the benefits they had experienced from exercise: “Mentally I feel good” (Patient D), “I find it useful 
for circulation on the legs” (Patient I), “I’m sleeping better on the days I was doing it” (Patient G) and “I found 
after exercising I slept better, woke up better and it improved my flexibility. Mentally you are feeling better too 
and it helps” (Patient I). However, participants’ experiences of exercise did not always remain positive over time 
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owing to the high oxygen demand of exercise and the negative effects of this for some patients: “I found it a 
struggle” (Patient C) and “I found it was a struggle, because I’m out of breath when I do it” (Patient D). 
 
Patients’ comments indicated that they preferred group activities when it came to exercise programmes, for 
example: “It was about meeting others too” (Patient C) and “You met people and after that you got a cup of tea, 
sat down and had a chat. It was nice. But you won’t get that in a gym” (Patient G) and “There was company, 
people with the same disease. I found I was looking forward to going. And I thought it was doing me good” 
(Patient H). 
 
4.3 Discussion   
IPF  is a life-limiting disease that has no curative options [36] and this condition is little-recognised and poorly-
understood by the general public. From a patient’s perspective a diagnosis of IPF is therefore often completely 
unexpected and confusing, provoking a range of psychological responses that cause much anxiety. A better 
appreciation of patients’ personal experiences of being diagnosed (and then coping) with IPF is critical to 
changing the way we educate and support newly-diagnosed patients about their condition. Our exploration of 
individual experiences of IPF offers insight into the psychosocial implications of IPF, its impacts on psychological 
and physical well-being, and the physical and psychological coping strategies that patients adopt to cope with 
these. This has enabled us to present here some patient-led recommendations for healthcare workers to 
support IPF patients from the point of diagnosis and throughout the progression of their disease. We analysed 
our data inductively to allow themes to be generated from the data rather than using a deductive theory-driven 
approach [110]. 
 
4.3.1 Patients’ experiences of IPF 
4.3.1.1 IPF and need-thwarting 
Our participants told us that they had experienced insensitive and unsympathetic comments regarding their 
condition and the struggles they faced each day, leading them to feel less related to (and more isolated from) 
others in wider society (reduced relatedness satisfaction). The majority of participants said that, because of 
this, they had limited their social interactions and confined themselves to a ‘safe space’ among family, close 
friends and sometimes the monthly IPF support group. Russel et al. [138] claimed that a poor understanding of 
IPF amongst the general public contributes to the emotional impact of IPF on patients (depression, fear, 
frustration and isolation), causing them to withdraw from social relationships. This reduced social interaction 
results in an unfulfilled need for relatedness (need-thwarting) in these individuals and negatively influences 
their overall well-being and quality of life. Schoenheit et al. [90] made similar observations, claiming that IPF 
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patients express difficulties in maintaining relationships owing to others’ lack of awareness and understanding 
of the disease. Sampson et al. [139] observed that deterioration in health caused patients to restrict their 
activities (by confining them to indoors) rather than seeking assistance to maximise their functional activities 
(through socialising and conducting outdoor activities), thereby increasing the risk of social isolation and leading 
to diminished possibilities. Similarly Swigris et al. [140] reported that some patients avoided engaging with 
crowds of people simply because of the fear of catching a respiratory disease that could lead to their demise. 
Bonella et al. [141] suggested that awareness of IPF among the general public should be increased through 
campaigns emphasising the chronic and debilitating nature of the disease. Our participants’ responses were 
consistent with depressed mood, indicating that their sense of incompetence, lack of autonomy and lack of 
intrinsic motivation were having a substantial negative impact on their well-being. 
 
Not surprisingly, given its physically-restrictive nature, IPF had a substantial impact on patients’ satisfaction 
regarding the need to feel competent. This impact was especially apparent in the execution of what were 
previously simple, taken-for-granted daily activities. The patients we interviewed often experienced signs of 
breathlessness and fatigue during the simplest of physical activities like walking or moving an object from one 
place to another. In addition, most of our participants had previously been involved in sport or other 
recreational activities such as walking prior to the onset of IPF, and no longer being able to participate in these 
activities further thwarted their need to feel competent. This need-thwarting leads to frustration and was one 
of the most common observations we made during our interviews, along with a sense of shame and self-pity 
that stemmed from the morbidity impact of IPF. Patients’ reduced competence satisfaction was fuelled by the 
thwarting of their need for autonomy as most had to seek help in carrying out the activities of daily living. Often 
family members stepped in to help these patients even before their help was solicited; whilst participants 
appreciated their help, family members were unknowingly undermining the individual’s sense of autonomy and 
thus their competence satisfaction. Previous studies have similarly reported that patients’ inability to perform 
routine daily tasks negatively impacts on their emotional wellbeing [90] [140]. Patients interviewed by Swigris 
et al. [140] commented that the most detrimental aspect of this disease is the fact that they are less 
independent than previously, leading to a loss of privacy because they needed help from others. 
 
A lack of understanding about the disease compounds this situation. Patients are reluctant to participate in 
physical activity because they are afraid of its possible impact on their condition, further reducing autonomy 
and competence-need satisfaction. Carers are often unsure how to help patients and express concerns 
regarding the monitoring of breathing, coughing and the use of oxygen [139]. Sampson et al. [139] reported 
that patient-clinician consultations are mostly disconnected from the demands of practical day-to-day life. 
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Patients often feel that they cannot interpret disease-focused assessments (like lung function tests) in relation 
to predicted future exercise capacity, causing them to simply avoid physical activity (presumably as a 
conservative approach to avoiding exacerbation). Cicutto et al. [142] also found similar attitudes to exercise in 
COPD patients, as did Fernandez et al. [143] in cancer patients, illustrating that this is a common observation in 
the literature relating to many chronic diseases. 
 
4.3.1.2 Coping mechanisms and re-establishing need-satisfaction 
 There was evidence that our participants had also developed coping mechanisms that employed emotion-, 
problem-, appraisal-, approach- or support-focused strategies that helped them restore need-satisfaction after 
diagnosis. It was apparent that for many individuals the key to coping with IPF was an acceptance of the reality 
of their condition, as this subsequently led to a sense of optimism. 
 
During the early stages of diagnosis (following initial emotional upheaval) participants used appraisal-focused 
coping strategies to purposely change their perspectives – this allowed them to start thinking more positively 
and to gain some determination to live the remainder of life to the fullest. One such example of this positive 
thinking and optimism was seen in a patient who had bought football tickets for the following season whilst 
knowing that his condition meant he had a relatively low likelihood of living to watch the games.  Others have 
also observed that patients and family members try to maintain a normal life for as long as possible by living in 
the moment, while acknowledging that this is difficult as the disease progresses [144]. 
 
Participants used emotion-focused coping to overcome depression and to face the reality of their condition, 
mainly through the opportunities for emotional expression that the IPF support group offered. As Folkman and 
Lazarus [113] suggested, emotion-focused coping was employed alongside social support from others who 
shared their experience in the support group. The simultaneous use of emotion-focused coping and social 
support was also evident in the participants’ discussions of how family and friends had helped them to 
overcome the initial trauma and fear of diagnosis. Importantly, their recognition of the support and care from 
others helped to restore both lost self-worth and relatedness-satisfaction. The support group also functioned 
to facilitate problem-focused coping as individuals could exchange knowledge and experiences about the 
disease and provide tips on how to cope with the condition, which they would be unlikely to receive from a 
medical professional. There are however some negative associations with support groups – for example,  
Sampson et al. [139] noted that seeing people who are further ahead in terms of disease progression threatens 
the ability of some patients to cope with the condition.  
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Participants’ effective employment of support-, appraisal- and emotion-focused strategies for coping with the 
wider psychological and personal implications of IPF meant that they were then able to use problem-focused 
coping to deal with daily challenges. They did so by adapting to their condition using small adjustments to the 
ways in which they conducted previously taken-for-granted activities. Sampson et al. [139] stated that patients 
use a day-by-day coping strategy to adapt to their condition. Swigris et al. [140] observed that the majority of 
patients in their study were forced to plan everything ahead, leading them to analyze every activity before 
starting it. Being able to accommodate the challenges IPF presents to once again conduct activities of daily 
living, such as going for a walk, provided a sense of achievement and led to a regained sense of competence 
and enhanced well-being. Some of our patients found comfort in a somewhat unorthodox manner by feeling 
good about themselves after seeing patients who were in a much worse condition than themselves.  
4.3.2 Patient-led recommendations for need-satisfaction 
4.3.2.1 Information 
Lack of information is one of the main issues that IPF patients face. This led many participants to feel uncertain 
about what they could and could not do after diagnosis. They felt uninformed and unable to make accurate 
judgements of their competence to carry out physical activities, resulting in the adoption of a sedentary 
lifestyle. The information given to these patients on IPF at the point of diagnosis was presented in an 
information booklet including general information on the disease, which emphasised life expectancy and what 
the patient could expect to happen towards the end of their life. However, it offered little information on what 
patients might expect to experience in the shorter term or how they might best cope with the condition. This 
often-caused shock, anxiety and trauma, and subsequently led to depression-like symptoms in these patients. 
It should be noted that our patents were perhaps advantaged in receiving such information: patients have 
previously commented that they do not receive sufficient information on the practical management of the 
disease (ranging from advice on oxygen therapy, nutrition, exercise, the management of cough, managing 
breathlessness and, most importantly, how to cope with the disease towards the end of life)  [90, 138, 139, 
141]. Others have noted that learning about the fatality of the disease is overwhelming for patients, and that 
they often find the amount of information they received overpowering; these patients instead prefer to be 
given information about the disease gradually [144]. In fact Bonella et al. [141] highlighted ‘improved 
information sources’ as one of the five unmet needs in IPF care after consulting eleven European patient 
advocacy groups (an initiative that led to the development of the European IPF Patients’ Charter).  Based on 
our participants’ stories we recommend that the information given by health professionals should focus on 
living with IPF, maintaining quality of life through lifestyle changes (planning and prioritising) and 
encouraging patients to remain as physically active as possible. This would help patients to maintain feelings 
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of competence and autonomy and would encourage a proactive coping approach in patients from the point of 
diagnosis.  
 
4.3.2.2 Support for need satisfaction 
Family support plays a key role in maintaining the well-being of IPF patients, so it would be beneficial if 
immediate family members also received education about IPF and its effects on the lives of both the patient 
and themselves. Russel et al. [138] found that caregivers were inadequately prepared for the role of the 
caregiver owing to a lack of information about the disease and the absence of psychological support, resulting 
in an inability to relate to the patient. Sampson et al. [139] recommended that the role of the carer should 
change from ‘passive observer’ to ‘active member’ throughout the patient’s healthcare pathway, and that they 
should have access to better advice and support to fulfil their role in managing the domestic environment for 
patients. This is an important aspect of providing appropriate social support for patients, especially in relation 
to being physically active. We suggest that an emphasis should be placed on how not to support these patients; 
for example, immediate intervention to help patients when performing physical activity or activities of daily 
living could thwart autonomy and competence satisfaction and lead to feelings of shame and subsequently 
depression. Instead, family members could be encouraged to help patients employ problem-based coping 
strategies, making lifestyle changes to enable continuation of activities that they performed prior to 
diagnosis. Furthermore, it is highly recommended that patients join an IPF-specific support group if such a 
facility is available. This will help them fulfil their needs for relatedness, while allowing them to obtain valuable 
knowledge about their condition from fellow patients who are experiencing different stages of the disease. 
Importantly, this will help increase patients’ awareness of what to expect in the future, and peer advice will 
assist them in employing proactive-coping strategies, with a view to maintaining competence and autonomy 
need satisfaction. Comments from participants in this study indicate that in general patients would benefit 
from participation in physical activities, especially in a group setting. Such benefits might include 
improvements in physical or psychological well-being (perhaps helping to restore competence satisfaction or 
to reduce feelings of social isolation), although further studies are needed to provide evidence of this 
 
4.4 Strengths of the study 
Our exploration of individual experiences of IPF aims to offer insight into the psychosocial implications of IPF, its 
impacts on psychological and physical well-being, and the physical and psychological coping strategies that 
patients adopt to cope with these problems.  
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As the psychological implications of an IPF diagnosis is an under-explored area ,we analysed our data inductively 
to allow themes to be generated from the data rather than using a deductive theory-driven approach [110]. 
Based on our emergent higher-order themes it is apparent that two key theories present particularly useful 
frameworks with which to interpret our results. These theories are SDT[111] [117] and 2)  transactional theory 
of stress and coping [118].  
A brief explanation of the transactional model of stress and coping illustrate its complementarity with SDT, 
thereby supporting our use here of both theories to improve our insight into patients’ personal experiences of 
IPF. Additional coping mechanisms that we looked for in this study were avoidance-coping (part of emotion-
focused coping) and self-regulation and proactive-coping [118]. Avoidance coping is defined as an effort to 
avoid facing the stressor and could in itself lead to depressive symptoms [119]. Self-regulation and proactive-
coping involve determination of potential future stressors and taking action in advance to negate the impact of 
these [120]. The transactional theory has been used across a range of contexts, for example to understand 
coping strategies following disaster [121] and the stress and burnout experienced by French elementary school 
teachers [122].  
 
4.5 Limitations of the study 
Of the 50 patients approached 40 did not respond and the nature of our recruitment process meant that we 
had no follow-up information about the reasons for lack of replies. Although our sample was therefore 
restricted to ten participants, we believe that data saturation had been reached at this level, so we are confident 
that our results are robust. The demographic of the participants was quite focussed, and this might bias our 
results to a degree: 1) Participants were all resident in Swansea (South West Wales) or its immediate 
surrounding areas; 2) Participants were recruited from a single IPF support group which was part of the 
palliative care pathway of the local health board. This type of support system might not be generally available 
across other health boards in the UK or in other countries, so our findings (especially those relating to opinions 
on the support group) will be biased to this demographic; 3) The stage of disease progression and the time since 
diagnosis for our patients ranged from 1-10 years and, although this range is wide, the relatively small number 
of participants means there was some clustering into early/late stages of disease progression. Recently-
diagnosed participants are likely to have different opinions about the disease and its impact on their lives 
compared to those who have been living with the disease for much longer. For each of these reasons we must 
be guarded in our interpretation of the results and in any attempt to generalise the findings to wider 
populations. 
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4.6 Concluding comments 
This chapter presented the results of a study that evaluated the health and wellbeing experiences of people 
living with IPF in ABMU Health Board. It offers novel findings that will help to inform much-needed changes in 
the practice of supporting IPF patients to cope with their diagnosis and disease progression. By interpreting 
these experiences within the theoretical frameworks offered by self-determination theory and the transactional 
model of stress and coping, the study has added insight into the mechanisms that underpin the impact of IPF 
on psychological wellbeing. Furthermore, the recommendations presented are strengthened by their grounding 
in both theory and practice, and by ensuring that we considered the varying personal experiences that are 
characteristic of living with IPF. Based on these findings, it is strongly suggested that future support services for 
patients with IPF would benefit from a clear focus on providing effective and considerate communication about 
the disease. In addition, there should be a focus on ensuring that patients and their families are better informed 
about the potential benefits of attending peer support groups, and about the types of coping strategies 
employed by their peers to ‘live better’ with their condition.  
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Chapter 5 
Heart rate and respiratory responses to incremental (slowly increasing, wide-
ranging) metabolic challenge 
5.1 Overview 
It has been shown previously that IPF patients’ peak V̇O2 values were half those of similarly aged healthy 
individuals, whilst their peak heart rates were 20% lower and their kinetic HR responses to heavy intensity 
exercise were 2.5 times slower [16]. These results provide evidence of reduced tissue oxygen utilization 
following the onset of exercise in people with UIP, which in large part results from impeded central 
(cardiovascular) oxygen delivery. It is postulated here that an exercise-based physical rehabilitation 
programme could reasonably be expected to influence cardiovascular function and thus improve systemic 
oxygen delivery (and peripheral muscle oxygen availability) in these patients.  
Heart rate dynamics are thought to provide a good proxy for the response of cardiac output and muscle blood 
flow to increased metabolic demand [26] [27]. HR responsiveness can be estimated using HRV analysis (HRV; 
the variation in beat-to-beat duration of the cardiac cycle) [28], which reflects autonomic nervous system (ANS) 
influences on heart rate. PRSA [29] yields averaged RR time series that separately characterize heart rate 
modulations that result in either accelerations and decelerations. HRV and PRSA each have their own 
advantages: HRV yields band-limited estimates of cardiac neural control, allowing separate analysis of 
sympathetic and parasympathetic modulation; Unlike HRV, PRSA does not require steady-state conditions so it 
can reflect the dynamic range of cardiac modulations across multiple and transient physiological states. 
Individuals with COPD display altered HRV during rest and exercise [30] but with a normal diurnal variation [31], 
and they have a tendency towards reduced PRSA-derived cardiac dynamic capacities that are ameliorated with 
oxygen therapy [105]. However, neither HRV nor cardiac acceleration/deceleration capacities have been 
evaluated in individuals with UIP. 
This chapter reports the findings of investigations into the influence of an eight-week, exercise-based PR 
programme on measures of cardiac autonomic control in patients with pulmonary fibrosis (either IPF or UIP). 
Specifically, validated measures of HRV and of cardiac acceleration and deceleration capacities are compared 
during periods of rest and exercise, pre- and post- rehabilitation. The methods of physiological measurement 
and data analysis used were reported in Section 3.2. 
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5.2 Participant characteristics 
Eighteen individuals (13 males, 5 females) agreed to participate in the study but three males later withdrew 
from the rehabilitation programme for personal reasons. The patients’ demographics (age, gender, body mass 
index) and diagnostic spirometry measures (forced expiratory volume in one second and forced vital capacity) 
are shown in Table 5.2. Patients continued with their usual medication regimens whilst participating in the study 
(Table 5.1). 
Table 5.1 Participants’ drug regimens during the rehabilitation programme 
 
PATIENT 
ID 
PRESCRIBED MEDICATION 
Respiratory Cardiovascular Diabetic Other 
P01 Nintedanib Ramipril 
Warfarin 
- Tamsulosin 
P02 Nintedanib - - Levothyroxine 
P03 Nintedanib - - - 
P04 - Ramipril 
Felodipine 
Metformin - 
P05 - Bisoprolol 
Candesartan 
- - 
P06 - - - Escitalopram 
Prednisolone 
Hydroxychloroquine 
Mycophenolate mofetil 
P07 Carbocisteine 
Pirfenidone 
- - - 
P08 - Atorvastatin - Bendrofluazide 
Pandesartan 
Omeprazole 
P09 Nintedanib - - 
 
P10 Carbocisteine - - Paracetamol 
P11 - - Metformin Hydroxychloroquine 
Mycophenolate mofetil 
Mirtazapine 
P12 Pirfenidone Simvastatin Metformin 
 
P13 Pirfenidone Bisoprolol 
Amlodipine 
- Citalopram 
Lansoprazole 
Uvistat 
P14 Nintedanib Simvastatin Empagliflozin 
Linagliptin 
Metformin 
Tramadol 
P15 - - Pioglitazone Omeprazole 
Fluoxetine 
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Table 5.2 Patient demographics. (BMI = body mass index, FEV1 = forced expiratory volume in one second 
[age-predicted %], FVC = forced expiratory volume [age-predicted %]; NA = data not available.) 
 
Patient 
ID 
Age 
(years) 
Gender 
(M/F) 
BMI 
(kg·m-2) 
FEV1 
(litre [%]) 
FVC 
(litre [%]) 
FEV1/
FVC 
DLCO KCO 
(% predicted) 
P01 72 M 36.7 1.92 [67] 2.33 [62] 0.82 50 95 
P02 73 F 47.7 1.46 [82] 1.66 [77] 0.87 35 70 
P03 74 M 26.3 2.34 [78] 2.78 [63] 0.84 40 77 
P04 67 F 34 1.48 [75] 1.81 [76] 0.81 43 87 
P05 78 M 32.7 2.93 [130] 3.95 [131] 0.74 46 93 
P06 60 F 32 2.73 [88] 3.49 [89] 0.78 55 62 
P07 68 M 32.3 2.53 [79] 3.22 [74] 0.78 57 75 
P08 83 M 28.7 2.21 [85] 2.90 [82] 0.76 42 78 
P09 73 M 23.1 1.93 [63] 3.13 [52] 0.62 52 67 
P10 75 M 20.8 2.22 [93] 3.37 [107] 0.65 NA NA 
P11 68 F 30.4 1.77 [60] 2.12 [53] 0.83 NA NA 
P12 72 M 25.3 2.00 [63] 1.46 [61] 0.75 NA NA 
P13 64 F 30.1 1.12[55] 1.46 [59] 0.76 NA NA 
P14 65 M 24.5 2.50 [78] 3.25 [78] 0.76 NA NA 
P15 55 M 29.8 NA NA NA NA NA 
Mean  69.8  30.2 2.0 2.6 0.76 46.6 78.2 
SD 7.1  6.4 0.5 0.8 0.06 7.3 11.4 
Range  55-78  20.8-47.7 1.12-2.93 1.46-3.95 0.62-
0.87 
35-
57 
67-95 
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5.3 Results of physiological assessment 
It was decided that the most appropriate approach to analysing the physiological data would be to aggregate 
the results for the entire group (rather than performing sub-group analyses, for example according to age, 
gender, disease stage or medication regime). This decision was taken mainly because of the relatively small 
sample size, which would not adequately support a robust statistical analysis of sub-group effects. 
Table 5.3 summarises participants’ physiological responses to maximal incremental exercise tests, pre- and 
post-rehabilitation. Individual data are presented in Appendix C (Tables C.3 and C.4). VE, peak V̇O2, time to peak 
work rate and OUES were all unchanged following PR, but the peak heart rates and peak work rates were both 
significantly reduced following PR. Example plots of V̇O2 vs. time (maximal effort) and of the OUES calculation 
procedure are provided in Appendix C (Figures C.1 and C.2). 
 
Table 5.3: Physiological responses to incremental exercise tests pre- and post-rehabilitation.  
 Pre-PR:  
Mean (SD); Range 
Post-PR:  
Mean (SD); Range 
p 
VE (mL·min-1·kg-1)  56.0 (20.78); 22.4-92.3 58.1 (18.0), 30.7-90.5 0.53 
Peak V̇O2 (L·min-1) 1.30 (0.28); 0.86-1.81 1.28 (0.30); 0.83-1.91 0.96 
Peak V̇O2 (mL·min-1·kg-1) 15.7 (4.4); 10.0-28.4 15.2 (4.4); 8.4-26.2 0.93 
Peak HR (bpm) 120 (24); 73-159 91 (28); 67-136 0.0002 
Peak Work Rate (Watts) 105 (35); 29-158 78 (25); 35-128 0.0005 
Time to Peak Work Rate (min.) 11.8 (2.2); 7.3-16.4 11.4 (3.0), 6.1-16.4 0.73 
OUES (ml·min-1·L-1) 1569 (206); 1275-1943 1509 (250); 1121-1929 0.14 
 
 
 
 
 
 
64 
 
5.3.1 Heart Rate Variability 
The HRV indices calculated pre- and post-intervention for the pre-exercise (Rest), Exercise (Ex) and Recover 
(Rec) periods are shown in Table 5.4 and Figure 5.1. The intervention did not influence any of the HRV variables 
during the Pre-Exercise (p=0.14-0.99) or Exercise (p=0.12-0.76) states. Heart Rate was greater (and RR was 
lower) post-intervention during the Recovery state (p=0.036; z=-2.10; ES=0.38) and both HFn (p=0.069; z=-1.82; 
ES=0.33) and LF/HF (p=0.047; z=1.99; ES=0.36) showed trends towards greater high-frequency dominance 
during Recovery post-intervention (other variables: p=0.21-0.72). The relative changes in HRV (HR, SDNN, 
RMSSD, LFn and TP) following the PR intervention are shown in Figure 5.2 (the remaining variables are largely 
redundant for this purpose as they are closely related to these five variables). 
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Table 5.4: HRV indices pre and post PR. Median (M) and the lower (Q1) and upper (Q3) quartile values are 
shown, separately for the pre-exercise (Rest), Exercise and Recovery states 
         HR 
(BPM) 
RR 
(ms) 
SDNN 
(ms) 
RMSSD 
(ms) 
VLF 
(ms2) 
LF 
(ms2) 
HF 
(ms2) 
LFN 
(%) 
HFN 
(%) 
LF/HF TP 
(mS2) 
P
R
E-
P
R
 
R
e
st
 
M 85.4 702.9 14.7 13.6 6.7 57.1 19.7 56.7 43.0 1.3 94.4 
Q1 74.3 586.0 8.4 11.8 3.1 10.6 11.9 41.4 30.4 0.7 35.2 
Q3 102.5 816.0 27.7 18.3 37.8 162.6 72.9 67.1 57.3 2.3 249.3 
Ex
 
M 101.0 594.2 13.5 19.9 2.9 20.0 20.0 39.6 59.4 0.7 63.0 
Q1 84.2 536.4 9.4 13.3 1.2 6.6 7.6 27.5 39.4 0.4 22.0 
Q3 111.9 712.0 32.9 40.9 20.9 191.4 117.8 60.1 72.0 1.5 347.2 
R
e
c 
M 94.0 638.1 16.0 15.6 18.7 60.9 48.6 47.5 52.3 0.9 136.0 
Q1 86.5 548.0 11.2 11.1 5.9 34.1 10.5 33.1 15.8 0.5 50.3 
Q3 109.6 693.3 34.6 50.8 41.0 322.6 222.9 84.0 66.4 5.6 606.3 
P
O
ST
-P
R
 
R
e
st
 
M 86.6 692.7 15.0 23.1 9.3 72.4 53.2 61.6 38.2 1.6 153.9 
Q1 79.4 641.2 12.3 15.1 4.2 42.2 15.3 39.5 19.6 0.6 93.1 
Q3 93.6 755.3 20.6 31.9 42.2 147.9 123.4 80.2 59.6 4.1 210.4 
Ex
 
M 112.5 549.4 23.6 34.9 7.1 45.1 73.8 36.3 62.3 0.5 119.6 
Q1 93.2 522.3 11.0 19.7 2.6 20.5 8.7 26.0 43.6 0.4 39.9 
Q3 115.4 638.8 31.3 43.6 13.9 110.4 316.8 56.3 73.4 1.3 527.1 
R
e
c 
M 110.9 541.2 16.5 26.2 5.3 60.5 43.2 34.4 64.9 0.5 143.1 
Q1 90.6 513.3 12.5 17.8 2.2 15.5 11.7 30.0 32.7 0.4 46.1 
Q3 116.9 665.9 30.0 43.3 12.2 146.4 173.2 67.1 69.2 2.2 349.0 
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Figure 5.1 HRV indices pre and post PR. Median (M) values are shown, separately for the pre-exercise (Rest), 
Exercise and Recovery states. 
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Figure 5.2 Percentage change in HRV indices following PR 
 
5.3.2 Acceleration and Deceleration Capacity Indices 
To illustrate the PRSA averaging procedure, Figure 5.3 shows the group mean responses (+/- SEM) of the 
normalized RR time-series around the identified acceleration and deceleration turning-points. Table 5.5 
presents the corresponding group mean Acceleration Capacity (AC) and Deceleration Capacity (DC) indices, pre- 
and post-rehabilitation. Individual AC and DC values are presented in Appendix C (Table C.5) for each 
participant, together with the Post-Pre changes in absolute (Δ) and relative (%) terms. Figure 5.4 is a box-and-
whisker plot of the pre- and post-intervention: the median (lower quartile, upper quartile) AC was -2.7ms (-1.8, 
-5.3) pre-intervention and -3.2ms (-2.5, -4.9) post-intervention; the median (lower quartile, upper quartile) DC 
was 2.3ms (1.8, 4.8) pre-intervention and 3.2ms (2.5, 4.3) post-intervention. Wilcoxon Signed Rank tests 
revealed no influence of the intervention on either AC (p=0.53; z=0.63; ES=0.11) or DC (p=0.73; z=-0.35; ES=-
0.06) indices. 
 
  
-20.0
HR SDNN RMSSD HFn TP
Pre-Ex 1.5 2.0 70.2 -11.1 63.1
Ex 11.4 73.9 75.2 5.0 89.8
Rec 17.9 3.0 68.2 24.2 5.3
%
 C
h
an
ge
 f
o
llo
w
in
g 
In
te
rv
e
n
ti
o
n
69 
 
(a) 
 
(b) 
 
 
Figure 5.3 Group mean (+/- SEM) of the normalized RR time-series around the identified (a) acceleration and 
(b) deceleration anchor-points (individual participants’ data were normalized by subtracting the mean of the 
12 RR intervals immediately preceding the anchor point) 
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Table 5.5 summary results for Acceleration Capacity (AC) and Deceleration Capacity (DC) pre and post PR. (Δ 
(%) = relative change following PR). 
 
Pre-PR: 
Mean (SD); Range 
Post-PR: 
Mean (SD); Range 
Δ (%) 
AC (ms) -4.5 (5.1); -1.1 to -18 -5.0 (5.0); 1.2 to -19.2 31.5 (61.3); 151.1 to -52.8 
DC (ms) 4.4 (4.8); 17.2 to 1.2 4.5 (4.5); 18.2 to 1.2 21.4 (56.0); 138 to -39.9 
 
 
 
 
 
Figure 5.4 Box-and-whisker plot of Acceleration and Deceleration Indices pre (PRE ACC, PRE DEC) and post 
(POST ACC, POST DEC) PR (absolute values are shown for AC; circles show individual values; horizontal lines in 
boxes indicate median, lower and upper quartile values; whiskers show range of values) 
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5.4 Discussion 
Traditional measures of pulmonary function (minute ventilation, peak rate of respiratory oxygen uptake) were 
not influenced by PR. Ramponi et al. [145] reported a 9% increase in OUES in COPD patients following 
rehabilitation, so we postulated that the OUES might be a more sensitive measure of aerobic performance 
plasticity in IPF. However, in this first evaluation of OUES in IPF patients we found that OUES was unchanged 
following rehabilitation (see Table Appendix C.3).  
 
This was also the first study to investigate the effect of a PR programme on HR responsiveness in people with 
IPF. We found that HR was elevated by 11-18% during Exercise and Recovery states post-rehabilitation, 
suggesting that participants’ heart function (heart rate increase in response to exercise) was improved by 
rehabilitation. Statistically, HRV was not altered by the rehabilitation intervention during any of the three stages 
of the day 3 protocol (rest, exercise, recovery). However, several substantial relative (post- vs. pre-
rehabilitation) changes were observed that are worthy of note: 1) an increased Pre-Exercise parasympathetic 
influence (RMSSD elevated by 70%), 2) increased sympathetic and parasympathetic influences during Exercise 
(SDNN and RMSSD elevated by 75%), and 3) an increased parasympathetic influence during Post-Exercise 
(RMSSD elevated by 68%, HFn elevated by 24%). Neither the Acceleration Index nor the Deceleration Index 
were statistically influenced by the intervention. However, trends for relative (post- vs. pre-rehabilitation) 
improvements in these indices (changes of 19% and 38%, respectively) were observed. 
 
The qualitative observation here of altered HRV following physical rehabilitation suggests that this intervention 
had a positive influence on patients’ cardiac autonomic regulation profiles. Conditions of stress (such as 
moderate physical exercise, a change in posture from supine to standing or mental processing tasks) alter the 
sympatho-vagal balance towards a more sympathetic-dominant state; this is reflected in frequency-domain 
HRV by a relative increase in LF power (reduction in HF power) and a reduction in Total Power, with a 
corresponding relative increase in SDNN (and reduction in RMSSD) in time-domain HRV [101]. During high 
intensity exercise LF, HF and Total power components are reduced compared with rest and low intensity 
exercise [146] [99] whereas HF and LF are reduced exponentially during progressive increases in exercise 
intensity [147] [148] [99]. Furthermore Tulppo et al. [147], Perini et al. [148],  and Lewis et al. [100] showed 
that the decay constants of HRV indices in each bandwidth are linearly related to the maximal work rate. In the 
present study, the 70% post-intervention increase in RMSSD during rest suggests that patients’ resting cardiac 
autonomic states became more typical of the relaxed (parasympathetic-dominant) states displayed in healthy 
people. Increases of similar magnitude (75%) in RMSSD and SDNN during exercise indicate that patients were 
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working at lower relative intensities following the intervention (they found the same activity easier to perform 
so the exponential-reduction in HRV power was not as great). Finally, following the intervention patients 
displayed a large (68%) increase in RMSSD during Recovery, and this faster return to the pre-exercise 
(parasympathetic-dominant) state likely reflects improved cardiac ‘fitness’. 
 
Previous studies on this theme observed significantly reduced values for AC and DC in older compared with 
younger healthy individuals: Older (mean age 66 years; AC = -5 to -7 ms; DC = 4.5 to 6.5 ms) and Younger (mean 
age 21 years; AC = –10 to -12; DC = 8 to 10 ms) [105]. In that study patients with COPD had qualitatively reduced 
values (AC diminished by 4-6 ms; DC diminished by 2-3 ms) compared with similarly aged healthy people. A 
further study by colleagues in Swansea added to these data, showing that AC and DC are reduced in middle-
aged (mean 45 years of age) compared with younger (mean 24 years of age) healthy individuals (mean values 
AC = -8.4/-10.3 and DC = 7.6/9.5 ms, respectively) and that both AC and DC are enhanced in aerobically superior 
individuals [149]. The AC and DC values observed for patients with IPF in the present study (AC = -2.7 to -3.2 
ms; DC = 2.3 to 3.2 ms) are around 50% lower than those of similarly aged healthy people and are similar to 
those of individuals with COPD who have not received oxygen therapy. Visualisation of the RR time-series 
around the identified acceleration and deceleration anchor-points enabled the following observations: 1) 
acceleration anchor-points occurred at larger RR values after rehabilitation, 2) deceleration anchor-points 
occurred at smaller RR values after rehabilitation, 3) immediately post-anchor acceleration was greater (RR 
values achieved were smaller) after rehabilitation, and 4) immediate post-anchor deceleration was greater (RR 
values achieved were larger)  after rehabilitation. These observations mean that, following rehabilitation: 1) 
heart rate was allowed to reach lower values before triggering a larger tachycardic response and 2) heart rate 
was allowed to reach higher values before triggering a larger bradycardic response. We suggest that these 
results provide evidence that the physical rehabilitation intervention may have improved the dynamic range of 
heart rate responsiveness in our patients with UIP. We further speculate that this would have enhanced 
patients’ physical function during everyday tasks (being mindful that the AC and DC indices were calculated as 
an ensemble across each of the three physiological states in our protocol).  
 
The diminished cardiac acceleration and deceleration capacities in IPF patients reflect the autonomic 
dysfunction that is also indicated qualitatively by the HRV variables for this group of individuals. Post-
intervention improvements in AC and DC indices appear to reflect the observed shift towards ‘healthy’ HRV 
values for these patients. Taken together, these changes suggest that physical rehabilitation had a positive 
‘normalising’ influence on cardiac autonomic modulation of heart rate in people with UIP. 
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5.5 Limitations of the study 
Whilst we consider our sample of 15 patients to be representative of people with UIP (IPF), this relatively small 
number of participants reduces the statistical power of our analyses. The study also excluded patients who had 
co-morbid conditions that might influence cardiac or autonomic nervous system function. Whilst this removes 
the potential confounding influence of other pathologies, it reduces our ability to generalise our results to the 
wider population of people with UIP (IPF). We also chose not to perform sub-group analyses, for example to 
examine the impact of age, gender, and disease stage or medication regime on the measured physiological 
variables. Such analyses would require a much larger study population and would presumably offer useful 
insight into the relative efficacy of PR programmes for defined sub-groups of the IPF population.  
 
 
5.6 Strengths of the study 
At the beginning of the study we were mindful of the potential influence of too strict a set of exclusion criteria 
on both recruitment and the applicability of our results to a wider population of people with UIP. With this in 
mind we took the decision to not exclude individuals with controlled diabetes from the study: five (27%) of our 
patient cohort were taking medication to treat Type II diabetes. Furthermore, patients acted as their own 
controls and care was taken to ensure that the only change between the monitoring days was the intervening 
rehabilitation intervention.  Patients’ drug regimens were not changed during the study, so the results reflect 
patients’ ‘usual’ health status.  This study demonstrated the feasibility of employing a demanding physiological 
assessment protocol in this acutely unwell population. The results will enable sample-size calculations for 
appropriately-powered statistical evaluations in future, larger-scale studies. 
 
5.7 Concluding comments 
To our knowledge this is the first study of its kind to use both HRV and PRSA analyses to assess the outcomes 
of a physical rehabilitation programme. The results of this study provide initial evidence that physical 
rehabilitation improves heart rate dynamics (via modulation of autonomic control of heart rate) in IPF patients, 
even when respiratory and physical functions are unchanged or diminished. 
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Chapter 6 
Heart rate kinetics and respiratory responses to extreme (rapid-onset, high workload) 
metabolic challenge  
6.1 Overview 
The ‘oxygen uptake efficiency slope’ quantifies the body’s oxygen uptake and extraction efficiency (the rate of 
increase in oxygen uptake (V̇O2) in response to increases in minute ventilation (VE) during incremental exercise. 
The OUES has several advantages over other measures of aerobic exercise performance: it can be determined 
accurately from submaximal exercise protocols (below 60-75% functional reserve) [17] [18] [20] yet is strongly 
correlated with VO2 max; it is completely objective (tester-independent) and it has better inter-protocol 
agreement [17] [18]. An alternative to OUES is the analysis of so-called ‘pulmonary oxygen uptake kinetics’ 
which involves mathematical modelling of the rate of change of oxygen utilisation in response to a sudden 
change in exercise workload. This provides insight into an individual’s ability to absorb and utilize oxygen to fuel  
a change in metabolic activity [23]. The procedure involves fitting either a mono-exponential or bi-exponential 
model to the empirical temporal data, with the time-constant of the best-fit model reflecting an individual’s 
oxygen utilisation response rate. This chapter reports the findings of investigations into the influence of an 
eight-week, exercise-based PR programme on dynamic pulmonary function (oxygen uptake kinetics) and 
cardiac function (heart rate kinetics)  
 
6.2 Results  
6.2.1 V̇O2 responses to maximal/incremental and constant workload exercises 
In this section a summary of the procedure for determining the individual constant work rate values used in the 
day 3 protocol is first presented. Figure 6.1 shows a typical V̇O2 response to the maximal incremental exercise 
(day 2) protocol for an individual participant. The gas exchange threshold (GET), also known as the aerobic 
threshold (AT) was determined as the V̇O2 value where a nonlinear increase in CO2 production (V̇CO2) relative 
to VO2 was observed together with an increase in minute ventilation (VE)/V̇O2  without an increase in VE/V̇O2 
[16]. The workload intensity for the constant work rate test was calculated as the resistance that elicits a V̇O2 
of 40% of the difference between the GET and the peak V̇O2 (Δ 40%) [16]. Figure 6.2 shows a typical V̇O2 
response to the constant workload (day 3) protocol for the same individual. Data from the interval ‘Start of 
constant work rate’ to ‘Start of Recovery’ were extracted and used for subsequent analysis (modelling) of the 
V̇O2 response (Section 6.2.4).  
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Figure 6.1: Example of an individual V̇O2 response during the pre-exercise (starting at the red point), exercise 
(red-to-green) and post-exercise phases (starting at the purple point) of the day 2 protocol (maximum work 
rate test). The Gas Exchange Threshold is represented by the yellow point.  
 
  
Figure 6.2: Example of an individual V̇O2 response during the pre-exercise, exercise and post-exercise phases of 
the day 3 protocol (constant work rate test) (no phase 1 or phase 3 changes were observed). The orange point 
indicates start of exercise, red indicates the start of the constant work rate test protocol, and green represents 
the start of the recovery period.  
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6.2.2 Responses to the constant work rate (day 3) exercise protocol 
Table 6.1 summarises the physiological responses to constant work rate exercise tests, pre- and post-
rehabilitation. VE, the highest recorded V̇O2 and the highest recorded heart rates were all unchanged following 
PR. 
 
Table 6.1: Physiological responses to constant workload tests (Day 3 protocol), pre- and post-rehabilitation 
(these values are reported for twelve patients only, owing to equipment malfunction and the absence of pre-
/post-PR data for two participants.) 
 Pre-PR 
Mean (SD); Range 
Post-PR 
Mean (SD); Range 
p 
VE (ml·min-1·kg-1)  54.0 (15.8); 30.3-87.1 48.1 (18.5); 21.6-78.8 0.25 
Highest V̇O2 (L·min-1) 1.27 (0.29); (0.85-1.81) 1.17 (0.35); (0.63-1.90) 0.21 
Highest V̇O2 (ml·min-1·kg-1) 15.0 (4.6); 9.1-28.1 13.8 (4.9); 6.4-25.6 0.35 
Highest HR (bpm) 117 (22); (90-151) 120 (26); 70-148 0.70 
 
 
Figure 6.3(a) shows the V̇O2 responses to constant workload exercise for a selection of participants (prior to 
PR). Individual responses were then normalized to the end-exercise value: all breath-by-breath V̇O2 values were 
divided by the maximum V̇O2 value (determined within the last 30 seconds of exercise) for that individual (Figure 
6.3(b)). Figures 6.4(c) and (d) show the equivalent data for these participants following PR. 
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Figure 6.3: (a) Individual V̇O2 responses to constant workload exercise for a selection of participants before PR 
(data are shown for 12 individuals); (b): Normalised individual V̇O2 responses for the same participants as in (a); 
(c): individual V̇O2 responses to the constant workload test, post PR; (d): normalised V̇O2 responses for the same 
participants as in (c). 
(a) 
 
(b) 
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(c) 
 
(d) 
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6.2.3 Heart rate responses to constant workload exercise 
Figure 6.4 (a) shows the HR responses to constant workload exercise for a selection of participants pre 
rehabilitation. Individual responses were then normalized to the end-exercise value: all HR values were divided 
by the maximum HR value (determined within the last 30 seconds of exercise) for that individual (Figure 6.4(b)). 
Figures 6.4(c) and (d) show the equivalent data for these participants following PR. Figure 6.5(a) shows the 
group mean HR responses to constant workload exercise for pre and (b) post PR.   
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Figure 6.4: (a) Individual HR responses to constant workload exercise for a selection of participants (data are 
shown for 05 individuals) after PR; (b): Normalised individual HR responses for the same participants as in (a); 
(c): individual HR responses to the constant workload test, post PR; (d): normalised HR responses for the same 
participants as in (c). 
(a) 
 
 
(b) 
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(c) 
 
(d) 
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6.2.4 Modelling the V̇O2 and heart rate responses to constant workload exercise 
Figure 6.5 shows the curve fitting process (using the Matlab curve fitting toolbox, as described in Sections 
3.2.5.4-3.2.5.7) used to model the group mean V̇O2 data (a; pre-PR, b; post-PR). The same process was used to 
model the HR data (Figure 6.6: a; Pre-PR, b; post-PR). Table 6.2 summarises the results of curve fitting for the 
participant group. Curve fitting results for individual participants’ V̇O2 and HR responses are shown in Appendix 
D.1 and Appendix D.2. 
 
 
Table 6.2: Results of group-averaged, normalised V̇O2 and HR modelling 
Model 
Attribute 
V̇O2 HR 
Pre-PR 
(95% 
CI) 
Post-
PR 
(95% 
CI) 
Pre-PR 
(95% 
CI) 
Post-
PR 
(95% 
CI) 
A (nu) 0.994 
(0.990, 
0.998) 
0.956 
(0.954, 
0.959) 
0.97 
(0.964, 
0.976) 
1.022 
(1.014, 
1.029) 
MRT 
(sec.) 
107.9 
(106.6, 
109.1) 
85.2 
(84.4, 
86.0) 
60.5 
(58.9, 
62.0) 
115.5 
(113.2, 
117.8) 
SSE 0.287 0.226 1.862 0.822 
R2 0.994 0.995 0.940 0.983 
RMSE 0.020 0.018 0.051 0.034 
SSE = Summed square of residuals (sum of squares due to error); R-squared = squared correlation (coefficient 
of multiple determination); RMSE = root mean squared error (standard error of the fit); nu = normalised units 
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(a) 
 
 
 
(b) 
 
Figure 6.5 The curve fitting process used to model the group mean V̇O2 data (Matlab curve fitting toolbox): (a) 
Pre-PR and (b) Post-PR 
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(a) 
 
 
(b) 
 
 
Figure 6.6 The curve fitting process used to model the group mean HR data (Matlab curve fitting toolbox): (a) 
Pre-PR and (b) Post-PR 
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Figure 6.7 shows the group-averaged, normalised temporal V̇O2 response to constant work rate exercise. Visual 
inspection of Figure 6.7 (a) suggested an increase in V̇O2 post-rehabilitation during the first two minutes of 
exercise. Statistical comparison (Wilcoxon signed rank test of V̇O2 at each of the 12 time-points in the re-
sampled time-series; Figure 6.7 (b)) confirmed that V̇O2 was significantly greater post-rehabilitation at times t 
= 60, 90 and 120 seconds (p = 0.028, 0.008 and 0.034 respectively). 
 
Visual inspection of the group-averaged HR responses during the constant work rate tests (Figure 6.8(a)) 
suggested a reduction in HR post-rehabilitation during the first four minutes of exercise. Statistical comparison 
(Wilcoxon signed rank test of HR at each of the 12 time-points in the re-sampled time-series; Figure 6.8 (b)) 
confirmed that HR was significantly lower post-rehabilitation at times t = 30, 120 and 210 seconds (p values = 
0.043) and approached a significant difference at times t = 90, 180 and 240 seconds (p values = 0.079).  
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(a) 
 
(b) 
 
 
 
Figure 6.7 (a): Group-averaged normalised temporal V̇O2 response to constant work rate exercise: pre-
rehabilitation (red, dashed line) and post-rehabilitation (blue, solid thick line) and corresponding SEM values 
(pre: red, dotted: post: blue, solid thin); (b): V̇O2 responses from (a) resampled at 30 second intervals; arrows = 
significant difference pre vs post (p<0.05) 
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(a) 
 
(b) 
 
Figure 6.8 (a): Group-averaged normalised temporal HR response to constant work rate exercise: re-
rehabilitation (red, dashed line) and post-rehabilitation (blue, solid thick line) and corresponding SEM values 
(pre: red, dotted: post: blue, solid thin); (b): HR responses from (a) resampled at 30 second intervals; sold arrows 
= significant difference pre vs post (p<0.05); dashed arrows = difference pre vs post (p<0.10) 
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6.3 Discussion  
To better understand the influence of physical rehabilitation on cardiorespiratory function in IPF we quantified 
dynamic respiratory and cardiac responses to metabolic challenge. We found that following exercise-based PR 
IPF patients’ rates of oxygen uptake improved significantly during the first two minutes following the onset of 
heavy-intensity exercise, and their heart rates were similarly reduced during (and beyond) this period. 
 
We modelled the temporal oxygen uptake (V̇O2) response to heavy intensity exercise, characterising the 
response dynamics in terms of the mean response time (MRT). The MRT for V̇O2 in our participants was 108 
seconds prior to rehabilitation, similar to the findings of McNarry et al. [16] who noted an MRT of 92 seconds 
(2SD range 73-111 seconds) in three IPF patients during heavy cycling exercise. This mean response time is 
substantially slower than that observed for similarly aged healthy individuals (McNarry reported an MRT of 
52(12) seconds [16] whilst Breese et al.  [150] reported an MRT of 66 seconds in healthy males). We also 
observed a 21% reduction in MRT to 85 seconds in patients who completed our PR programme. This 
demonstrates a substantially faster oxygen uptake response to metabolic challenge following exercise 
rehabilitation, which was notably most statistically significant within the initial two minutes of exercise.  
 
Although the peak heart rates we observed during heavy-intensity exercise were similar before and after 
rehabilitation, the rate at which heart rate attained this peak value was almost twice as slow following 
rehabilitation (MRT = 60.5 vs. 115.5 seconds). McNarry et al. [16] previously recorded values in a similar range 
(2SD range = 49-125 seconds) in three IPF patients; these values are substantially greater than those they 
reported for healthy individuals (2SD range = 12-60 seconds). Furthermore, we noted sustained post-
rehabilitation reductions in heart rate within the first four minutes of the start of exercise.  
 
Suggestions of the mechanisms by which exercise rehabilitation might have improved the oxygen uptake 
responses in this study are, of course, speculative. The candidate pathways likely to have a role in such 
adaptations are those influencing i) pulmonary mechanical function, ii) alveolar-capillary gas-exchange, and iii) 
systemic arterial-tissue oxygen exchange. It is also likely that direct adaptations in cardiovascular function could 
influence systemic oxygen delivery (and usage). Exercise-induced adaptations of any of these might be 
contributing factors to the improved oxygen uptake dynamics we observed during exercise. Previous studies 
with COPD patients suggested that oxygen delivery to muscles might be the limiting factor in V̇O2 kinetics [20] 
[150] [151] , this being attributed to impaired HR kinetics (a proxy for cardiac output and blood flow) [152]. 
Similarly, McNarry et al. [16] interpreted slower HR and V̇O2 kinetics as an indication of central oxygen delivery 
limitation in both COPD and IPF patients. In the present study we observed a combination of improved (faster) 
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oxygen uptake and diminished (slower) heart rate in response to exercise in patients who had completed 
exercise rehabilitation. We suggest that these alterations together suggest an improvement in cardiac pumping 
efficiency, which might reflect a myocardial training effect or the normalisation of intrathoracic pressures 
following rehabilitation. Notably, OUES (the ratio of oxygen uptake to minute ventilation) was unchanged by 
rehabilitation.  
 
6.4 Strengths and limitations of the study 
The current study extends our knowledge of the respiratory and cardiac responses to a structured PR 
programme. This was a two-hour programme which was conducted twice per week for a duration of eight 
weeks, each structured into two sessions. The first session was the exercise component and the second session 
focused on educating participants about IPF and living with the condition. This programme was conducted by a 
multidisciplinary team which included physiotherapists, physical trainers, occupational therapists, dieticians 
and specialist nurses. The study was conducted using a fairly heterogeneous but well-characterised group of 
IPF patients. During the recruitment process each patient’s medical history was examined the exclusion criteria 
mentioned in Section 3.2.2 were strictly adhered to. Each participant fulfilled the 2011 American Thoracic 
Society and European Respiratory Society criteria [2] for diagnosis of IPF. Furthermore, these individuals had 
undertaken spirometry testing followed by high resolution computed tomography (HRCT) during the diagnosis 
process at an early stage by the specialist clinicians at Morriston Hospital, Swansea. HRCT scans indicating a 
predominant honeycomb pattern in the subpleural regions of the lung confirmed the presence of IPF. When 
this wasn’t easily confirmed, surgical lung biopsy was conducted to confirm the presence of IPF. This study also 
took a novel approach to evaluating the oxygen uptake dynamic response in IPF patients (using MRT to analyse 
the data) since our empirical patient data showed no evidence of the ‘fast’ and ‘slow’ components that are 
present in the V̇O2 responses of healthy individuals. The study also had some limitations. Whilst we consider 
our sample of 15 patients to be representative of people with IPF, the relatively small number of study 
participants will have reduced the statistical power of our analyses. The present study used heart rate kinetics 
as a tool for estimating oxygen delivery to tissue; we did not directly assess muscle deoxygenation as a method 
of measuring muscle oxygen saturation.  Furthermore, we did not used an age-matched control group since the 
purpose of the study was to look at the effects of rehabilitation on the same patients using identical methods 
pre- and post-testing.  
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6.5 Concluding comments  
 
As far as we are aware, this is the first study to assess physiological changes in cardiorespiratory function before 
and after a bespoke programme of PR, in people with UIP/IPF. We applied novel approaches to evaluate these 
changes and to provide a comprehensive profile of cardiorespiratory performance in UIP before and after PR. 
Specifically, PR improved the rate of oxygen uptake during heavy-intensity exercise, despite heart rates being 
substantially lower during this time, implying improvement in cardiac pumping efficiency. This suggests that PR 
might increase systemic arterial-tissue oxygen exchange and/or influence cardiovascular function to improve 
systemic oxygen delivery. Our findings suggest that individuals with UIP should find it easier to perform the 
activities of daily life, including those requiring substantial metabolic demands, after undertaking an 
appropriately-designed PR programme. 
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Chapter 7 
Summary and concluding comments 
 
7.1 Main outcomes 
7.1.1 Patient perspectives 
It was evident that many IPF patients experience psychological trauma and depression following diagnosis. 
Patients indicated that the main causes of this were a lack of public awareness about the disease, poor or 
ambiguous information given to patients, and the unpredictable progression and prognosis of the disease. The 
absence (or inadequacy) of information about the disease is a major worry amongst patients, especially with 
regard to information on life expectancy, which makes them feel vulnerable. A key message on ‘coping’ that 
emerged from speaking to these patients was that acceptance of their condition led to a sense of optimism. 
Participants reported using appraisal-focused coping strategies to change their perspectives (thinking 
positively) and emotion-focused strategies to overcome depression (the main opportunity for emotional 
expression being an IPF support group). Family and support groups were also important mechanisms in helping 
patients to overcome depression and to change their lifestyles in order to help cope with the disease. The 
support group also facilitated problem-focused coping: individuals exchanged knowledge and experience and 
gave one another tips on how to live with their condition. 
 
Based on these findings it is recommended that care should be taken when providing patients with information 
about the disease for the first time. Information should be more detailed, and it should be delivered to the 
patient through a medical professional who can emphasise that IPF is a subjective condition that affects 
individual patients differently. Patients and family members should also be guided towards counselling in order 
to better help with the management of trauma associated with the disease. Support groups should be added 
to the ongoing palliative care that these patients receive, and effective, evidence-based rehabilitation 
programmes should be made available to these patients.  
 
7.1.2 Physiological assessments 
This was the first study to assess the impact of a physical exercise rehabilitation programme on 
cardiorespiratory function in individuals with IPF. We quantified resting cardiac and respiratory system 
functions, and their dynamic responses to physical exercise across individuals’ maximal exercise ranges. The 
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study used novel approaches to functional evaluation, and it has provided the most comprehensive profile to 
date of cardiorespiratory performance adjustments in IPF. 
 
Changes in HRV during the day 2 exercise protocol (gradually increasing workload to exhaustion tests) suggested 
that PR had a positive influence on patients’ cardiac autonomic regulation profiles. Their resting cardiac 
autonomic states became more typical of healthy people, whilst enhanced parasympathetic influences during 
exercise suggested that they found the same exercise easier to perform after rehabilitation. There was also an 
indication (from acceleration and deceleration indices) that rehabilitation had improved the dynamic range of 
heart rate responsiveness in our patients. These changes suggest that physical rehabilitation had a positive 
‘normalising’ influence on the cardiac autonomic modulation of heart rate in our patients. We speculate that 
this would be reflected as an improvement in patients’ physical function during everyday tasks. 
 
PR significantly improved the rate of oxygen uptake in response to the day 3 protocol (rapid-onset heavy-
intensity exercise), despite heart rates being substantially lower during this time. This suggests that our patients 
were achieving similar work outputs following PR but with a presumed improvement in cardiac pumping 
efficiency (i.e. meeting the required increase in cardiac output via stroke volume rather than heart rate 
changes). Individuals with IPF might therefore be expected to perform the stop-start activities of daily life (even 
those which represent substantial metabolic demands) more easily after undertaking an appropriately-
designed exercise rehabilitation programme.  
 
7.2 Clinical relevance and impact 
 
The current study extends our knowledge of the respiratory and cardiac responses to supervised exercise 
rehabilitation in IPF patients. It should be borne in mind that IPF patients are acutely unwell and so the prospect 
of completing a physically- and physiologically-challenging study protocol would have been formidable. 
Therefore, although the number of recruited participants who completed the study was relatively small, this 
sample still allowed the compilation of a unique multivariate data set. Clinical colleagues verified that these 
participants were representative of individuals with IPF, and this provides confidence in generalising the results 
to the wider patient population. 
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7.3 Future perspectives and recommendations  
IPF is a relatively under-researched area compared with other chronic respiratory diseases (such as COPD). This 
was the first study to consider patients’ cardio-respiratory responses to exercise at a physiological level. 
employing two very different exercise protocols that challenged their metabolic responses. This was also a 
highly novel study in that it explored the combined psychological, sociological and physical impacts of PR on IPF 
patients. Future work will hopefully use this study as a foundation to confirm the results presented here and to 
further develop our knowledge of this important clinical area.  
It is highly recommended that future studies aim to recruit larger, heterogeneous groups of patients, enabling 
their categorisation according to age, gender, disease severity, medication regime and smoking status. Sub-
group analyses based on these categories will yield further useful information regarding the relative efficacy of 
PR in the palliative care of IPF patients. 
Future research will hopefully also employ additional methods for the accurate assessment of patients’ cardiac 
output dynamics, their muscle oxygen saturation levels, and their muscle strength and fatigue levels. These 
studies should again include carefully-conducted interviews with participants (pre and post PR) to evaluate their 
personal opinions and experiences of PR: together with participant categorisation (as discussed above) this will 
facilitate a more detailed appreciation of the differential impacts of age, gender and disease severity on 
patients’ perspectives regarding PR.  
Finally, the IPF staging system presented in Appendix E could be used to record and interpret the impact of PR 
for individual patients, using our three-day assessment protocol. A description of this staging system and 
instructions on how to use it is given below and in Appendix E.  
 
7.4 Staging and tracking system  
In general, a staging system aims to define a classification criterion that is practical, informs prognosis and 
impacts the choice of therapeutic modality. Staging systems are commonly used in healthcare for guiding 
medication and the management of a disease (for example, as used in cancer, HIV/AIDS and COPD [153] 
[154]). Staging in IPF is an important part of diagnosis to allow health professionals to guide treatment 
methods and counselling for patients [155] [156]. Some of the baseline parameters that could be useful in 
this regard includes FVC, DLCO, 6MWT distance and dyspnoea score. Although not globally used, several 
groups have attempted to provide a basis for a more complex approach for staging systems to IPF [2]. Bois 
et al.  [157] developed a point-based system that consisted of four predictors (age, recent respiratory 
hospitalization, baseline FVC and-24 week change in FVC), which gives a composite score that can accurately 
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predict the 1-year risk of death [157]. Another system [158] used a multidimensional risk prediction model 
called the “GAP” comprising of four baseline variables (gender, age, FVC and DLCO) and an associated scoring 
system knows as the GAP index, linked to the three traditionally-used  disease stages (Stage 1, 2 and 3 or 
mile, moderate and severe) [158]. 
 
Extending the concept of a staging system, we suggest that a system for ‘staging’ and ‘tracking’ a patient’s 
physiological responses to PR would be clinically useful. Such a system would enable evaluation of the benefit 
derived by individual patients who engage in a PR programme. PR can be considered as a palliative approach   
to easing the physical limitations experienced by these patients, thereby improving their QoL. On the 
presumption that post-rehabilitation benefits are likely to be influenced by disease severity, a ‘PR outcome 
staging’ system should provide indicative ranges of expected physiological improvement according to an 
individual’s disease stage.  We attempted to accomplish this by dividing our study population in to three 
different categories based on their FVC: 1) FVC > 80% predicted (low disease severity), 2) FVC of 55-80% 
predicted (moderate disease severity) 3) FVC < 55% predicted (high disease severity). Next, we separated 
male and female participants in each group and averaged each of the   physiological variables which we 
selected for inclusion in the staging system (Table E.1). The physiological variables included were chosen to 
make the system practical to use in a clinical setting  by health professionals (variables requiring a more 
complicated or secondary calculation, such as HRV, were excluded).  
. 
 
Figure E.1 shows the format of a possible patient record that uses the proposed rehabilitation staging and 
tracking system: 
• The red, yellow and green coloured columns represent low, moderate and high disease severity 
respectively.  
• Patients are required to undergo standard spirometry testing to measure their FVC before PR. 
Depending on the FVC result they would be categorised into one of the three coloured columns (FVC 
above 80, FVC between 80-55, FVC below 55). The physiological variables in the respective columns are 
the disease severity-specific values expected for the individual.  
• Next the patient would undertake an incremental bicycle test with an increase of 10-15 Watts per 
minute, and the results would be reported in the pre-rehabilitation column. 
• Once the PR is completed by the patient, the same procedure would be followed and the results would 
be recorded in the post-rehabilitation column (new FVC value). 
• Next, the change in the physiological values (pre vs post) would be calculated and would be reported 
in the % change column. 
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As the final step, post-PR values would be compared with the reference values, and the outcome of the 
rehabilitation programme on the patient could then be assessed 
 
7.5 Knowledge transfer IPF is a relatively unrecognised disease in Sri Lanka (SL). One of the future possible 
extensions of this study is to conduct collaborative work between Swansea University and General Sir John 
Kotelawala Defence University in SL (the author’s home university). Some of the possibilities of such 
collaboration include working with the Collage of Respiratory Physicians (SL) to improve the knowledge base 
about the disease in SL and to encourage medical professionals in the curative sector to introduce PR as a 
method of treatment for the disease. Another possibility is to work with the Ministry of Health (SL) to develop 
policies and awareness campaigns to identify and treat IPF patients found among the general population in SL. 
The knowledge gained from the studies reported in this thesis would be of great importance (and directly 
transferable) to SL: it would help in establishing physiological assessment laboratories (both in the healthcare 
and university sectors) to train future researchers about UIP/IPF, whilst the newly-established qualitative 
understanding of UK patients’ perspectives would be invaluable in establishing patient-centred support 
systems. 
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Appendix A: Ethical Approvals 
 
 
Applied Sports Technology Exercise and Medicine Research Centre (A-STEM) 
Sport and Health Portfolio, College of Engineering 
 
 
 
APPLICATION FOR ETHICAL COMMITTEE APPROVAL OF A RESEARCH PROJECT 
 
In accordance with A-STEM and College of Engineering Safety Policy, all research undertaken by staff or students 
linked with A-STEM must be approved by the A-STEM Ethical Committee.  
 
RESEARCH MAY ONLY COMMENCE ONCE ETHICAL APPROVAL HAS BEEN OBTAINED 
 
The researcher(s) should complete the form in consultation with the project supervisor.  After completing and 
signing the form students should ask their supervisor to sign it. The form should be submitted electronically to 
Prof Mike McNamee (  and Dr Melitta McNarry ( ). 
Applicants will be informed of the Committee’s decision via email to the project leader/supervisor. 
1.   TITLE OF PROJECT 
Investigating the perceptions and opinions of patients with IPF regarding pulmonary rehabilitation 
programmes 
 
 
2.   DATE OF PROJECT COMMENCEMENT AND PROPOSED DURATION OF THE STUDY 
26/04/2016 to 26/4/2018 
 
 
3.   NAMES AND STATUS OF RESEARCH TEAM  
State the names of all members of the research group including the supervisor(s).  State the current status of 
the student(s) in the group i.e. Undergraduate, Postgraduate, Staff or Other (please specify). 
Prof. M.J. Lewis (Staff) 
Dr. M. Mcnarry (Staff) 
Dr. J. Hudson (Staff) 
Mr. S.P. Senanayake (PG Student) 
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4.   RATIONALE AND REFERENCES 
With reference to appropriate sources of information (using the Harvard system), describe in no more than 
200 words the background to the proposed project. 
The two major classes of chronic respiratory disease are chronic obstructive pulmonary disease (COPD) and 
interstitial lung disease (ILD). COPD is characterised by obstructed air flow in the airways, whilst ILD is 
characterised by the build-up of scar tissue (fibrosis) in the lungs. Patients with ILD are less able to transfer 
oxygen from the air they breathe into the blood vessels within the lungs, making them feel breathless during 
simple everyday activities like walking. COPD patients also become breathless during activity but unlike the 
situation in ILD this is caused by the obstructed airflow. 
 
Treatment options consequently differ for COPD and ILD patients: COPD patients typically take medication 
to relieve the airflow restriction whilst ILD patients typically require oxygen therapy. Pulmonary rehabilitation 
(PR) programmes are also used to help alleviate symptoms in both COPD and ILD. PR is well-established in 
the management of patients with COPD and is effective in improving exercise performance (Spiruit et al., 
2013). However, the benefit of PR for ILD patients is less clear (Dowman, 2014). According to Spiruit et al. 
(2013), pulmonary rehabilitation has little effect on ILD and the small amount of improvement that is 
achieved is not sustained beyond six months. A possible reason for this discrepancy between COPD and ILD 
responses to PR is that rehabilitation programmes have typically been designed to address the needs of COPD 
patients.  
 
Abertawe Bro Morgannwg University (ABMU) Health Board runs a series of PR programmes lasting eight 
weeks. Patients who have been referred for PR, together with associated healthcare professionals, are also 
invited to participate in a monthly ‘PR support group’. The group provides an informal setting within which 
patients and professionals can discuss issues relating to their condition and PR participation. 
 
The overall aim of this study is to seek opinion and comments on PR from the members of a monthly PR 
support group. This will include (1) patients with either COPD or the most common form of ILD, idiopathic 
pulmonary fibrosis (IPF) and (2) the health professionals who are responsible for running the PR programme. 
Some of the patients will already be participating in PR and others will be awaiting enrolment into a future 
PR programme.  
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5.   OBJECTIVES 
State the objectives of the project, i.e. one or more precise statements of what the project is designed to 
achieve. 
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The objective of the present study is to ascertain patients’ and physiotherapists’ opinions and perceptions of 
PR. Specifically, we wish to investigate patients’ expectations of PR prior to undertaking it, what their feelings, 
opinions and perceptions are during the 8-week PR program and, following its completion, what their 
reflections are on the program. We also wish to obtain insight from the physiotherapists’ perspective with 
regard to its apparent effectiveness, practicalities and areas they would like to change in the future. 
 
 
6.1 STUDY DESIGN 
- outline the chosen study design (e.g. cross-section, longitudinal, intervention, RCT, questionnaire etc)  
Qualitative study utilizing focus groups  
 
6.2 STUDY DESIGN 
-  state the number and characteristics of study participants  
- state the inclusion criteria for participants 
- state the exclusion criteria for participants and identify any requirements for health screening 
- state whether the study will involve vulnerable populations (i.e. young, elderly, clinical etc.) 
- state the requirements/commitments expected of the participants (e.g. time, exertion level etc) 
 
• Approximately 20 individuals (either patients with COPD or IPF, or healthcare professionals) will be invited to 
participate 
• Participants will be patients who are attending the ABMU PR support group held at Penuel Chapel, 
Loughor and the healthcare professionals (physiotherapists) involved in their treatment.  
• Inclusion criteria - All participants must (1) have been diagnosed with either IPF or COPD, (2) be aged 
18 years or older and (3) be able to write and converse in English (to facilitate data collection). 
• Exclusion criteria - Inability or unwillingness to provide informed consent to participate in the study. 
• Participation in these focus groups is independent of patient care/treatment and will not influence 
their selection for participation in PR by the physiotherapists at Morriston or Singleton hospitals. 
 
Study Design 
  
The participants will be invited to attend a small focus group session in groups of 4-5 participants. These 
sessions will be arranged at a time and location convenient for the participants; the location will be a quiet 
but public area and two members of the research team will be present at all times. The groups will be chosen 
according to those who are waiting to take part in PR, those who have already completed PR and those who 
do not wish to take part in PR. Each focus group will take approximately 45-60 minutes and will be conducted 
according to the Chatham house rules. 
 
• Participants will be free to withdraw from the study at any time they wish  
• To maintain anonymity, pseudonyms will be given to individual participants before commencement 
of the audio and video recording 
• Participants will be asked to wear a badge showing their ‘identity’ and to state this identity before 
speaking  
• If a participant wishes to leave the study at any point, their comments will be removed from the 
transcripts and from the audio and video recordings.  
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6.3 PARTICIPANT RECRUITMENT 
How and from where will participants be recruited? 
A monthly support group is held for patients with IPF at Penuel Baptist Church, Glebe Road, Loughor, 
Swansea. We will initially attend one of these monthly meetings and present an overview of the study. 
Attendees who will be invited to participate in the study. Permission will be sought from the chairman of the 
support group (Mr. David Rees) to attend this meeting. Those interested in participating will be provided with 
an information sheet and consent form and given a week to decide if they wish to take part in the study.  
If a patient wishes to take part in the study after this time, they may still do so by contacting one of the 
members of the research team (provided in the participant information sheet). It will be made clear to the 
potential participants that participation is entirely voluntary, that they are free to withdraw at any point and 
that participation will not influence their selection for PR. 
 
 
 
6.4 DATA COLLECTION METHODS 
- describe all of the data collection/experimental procedures to be undertaken 
- state any dietary supplementation that will be given to participants and provide full details in Section 6.5 
- state the inclusion of participant information and consent forms (in appendices) 
- refer to the use of the ACA/ACSM health screening questionnaire where appropriate (usually for maximal effort 
exercise) 
Data collection will involve interviewing participants in focus groups with patients with IPF. An example of 
the semi-structured interview guide is provided in Appendix 1 which follows the steps outlined by Rubin and 
Rubin (2012), whereby the interviews start with introductory questions, followed by transition questions, 
then the main questions and finally summary questions. Krueger and Casey (2000) have defined focus groups 
as “carefully planned series of discussions designed to obtain perceptions on a defined area of interest in a 
permissive, non-threatening environment”.  We will use their guidelines to facilitate the focus group 
discussions. An exact list of questions to be asked in this study cannot be provided as the questions will be 
led by the participants’ responses. Interviews will last approximately 45-60 minutes and will be audio and 
video recorded to assist with transcription at a later date. All participants will be fully debriefed at subsequent 
IPF support group meetings. 
 
• If a participant indicates that they do not wish to be video recorded, only audio recordings will be 
made 
• If a participant does not wish to be audio recorded, they will be given an explanation of the 
importance of the recording and what the research team will do with the data along with how we 
will store and eventually dispose of this.  
• If participants still do not consent to interview recording, they will be excluded from the study.  
• We will not define a minimum number of participants required to conduct each interview (i.e. no 
‘quorum’). In the event of a participant ‘dropping out’ of a group, the interviews will still continue as 
planned.  
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All focus groups will be conducted by two named members of the research team. One of the two members 
is Mr. SP Senanayake (PhD student) and the other member would be either Prof. M.J. Lewis, Dr. M. McNarry 
or Dr. J. Hudson. The senior member of the team will be present along with the inexperienced student to 
ensure that a high and consistent standard is maintained throughout the interviews.  
 
 
6.5 DATA ANALYSIS TECHNIQUES 
- describe the techniques that will be used to analyse the data 
Qualitative analysis of the data from the focus groups will use a thematic approach (see Braun and Clarke, 
2006) to illustrate common themes pertaining to an under researched area.  Using this approach, notes and 
initial impressions are taken by the researcher during the focus groups. These ideas are then tracked and 
continually revised throughout transcription, and later themes are developed based on underlying meaning. 
Furthermore, all focus groups will be transcribed verbatim and pen-profiles will be produced to provide a 
quantitative analysis of the key themes raised. 
 
6.6 STORAGE AND DISPOSAL OF DATA AND SAMPLES 
- describe the procedures to be undertaken for the storage and disposal of data and samples 
- identify the people who will have the responsibility for the storage and disposal of data and samples 
- Identify the people who will have access to the data and samples 
- state the period for which the data will be retained on study completion (normally 5 years, or end of award) 
• The recordings and verbatim transcripts will be kept on password-protected hard drives.  
• Video recordings and verbatim transcripts will be stored in different computers.  
• The hard copies of the participants’ information will be stored separately under lock and key within Swansea 
University premises.  
• All the electronic copies of data from the study will be encrypted using appropriate software.  
• All participant names will be removed and replaced with pseudonyms to ensure confidentiality. 
• The data will be accessible only by the research team and will be retained for seven years following the 
student’s academic award. 
• Prof M.J. Lewis will be responsible for deletion of all copies of material following this point. All recordings will 
be deleted from recording devices immediately on transfer to a password-protected hard drive and on the 
same day as the interviews. 
 
6.7 HOW DO YOU PROPOSE TO ENSURE PARTICIPANT CONFIDENTIALITY AND ANONYMITY? 
If patients mention their names or those of others during focus groups their names will be replaced with 
pseudonyms during transcription.  
Given the public nature of focus groups it is not possible to guarantee anonymity of participants. However, 
we will seek to ensure confidentiality by introducing Chatham House Rules at the outset of the focus group, 
asking participants to indicate that they will not share information outside of the room. If participants are 
not comfortable taking part in a focus group, we will provide them with an opportunity to complete an 
individual interview to further protect their confidentiality. 
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All the data generated from this study will be treated in the strictest confidence and patient anonymity will 
be maintained throughout. All patient data will be anonymized with regard to any future publications relating 
to this study and data will be accessible only by the research team.  Data will be stored in University 
computers (including the student’s work computer), which are password protected.  
 
 
6.8 PLEASE PROVIDE DETAILS OF ANY DIETARY SUPPLEMENTATION (DELETE IF NOT APPLICABLE) 
Not applicable  
 
7.   LOCATION OF THE PREMISES WHERE THE RESEARCH WILL BE CONDUCTED. 
- list the location(s) where the data collection and analysis will be carried out 
- identify the person who will be present to supervise the research at that location 
- If a first aider is relevant, please specify the first aider 
 
Penuel Baptist Church, Glebe Road, Loughor, SA4 6QS or at a convenient public location for all participants 
in the focus group. 
 
The interviews will be conducted by Mr. SP Senanayake in the presence of either Prof. M.J Lewis, Dr. M. 
McNarry or Dr. J. Hudson. 
 
8.   POTENTIAL PARTICIPANT RISKS AND DISCOMFORTS 
- identify any potential physical risk or discomfort that participants might experience as a result of participation 
in the study. 
- identify any potential psychological risk or discomfort that participants might experience as a result of 
participation in the study.  
- Identify the referral process/care pathway if any untoward events occur 
In the focus groups, participants may potentially experience discomfort sharing personal experiences, but 
this will be minimized by the above confidentiality measures and by not coercing people to say anything they 
don’t want to. This will be reinforced at the start of each focus group. If they feel any sort of discomfort 
during any stage of the study, they can withdraw from the study without any explanation anytime they wish. 
If they wish to talk to someone about their experiences, they can talk to their consultant (Dr Kim Harrison), 
the physiotherapist (Angharad Ladd) or the chair of the REC (Prof M.J. McNamee). The procedures to be 
followed in the event of participant distress during Interviews/Focus Groups are described in Appendix 2. 
 
9.1   HOW WILL INFORMED CONSENT BE SOUGHT?  
Will any organisations be used to access the sample population? 
Will parental/coach/teacher consent be required? If so, please specify which and how this will be obtained and 
recorded? 
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An initial introduction to the study will be given by the chairman of the group, followed by a summary of the 
study by Dr Melitta McNarry. Participants will be invited to take part and those who express an interest with 
be provided with an information sheet. Written informed consent of the participants will be obtained by the 
research team prior to data collection. 
 
 
9.2   INFORMATION SHEETS AND CONSENT/ASSENT FORMS  
• Have you included a Participant Information Sheet for the participants of the study? YES 
• Have you included a Parental/Guardian Information Sheet for the parents/guardians of the study? N/A 
• Have you included a Participant Consent (or Assent) Form for the participants of the study? YES 
• Have you included a Parental/guardian Consent Form for the participants of the study? N/A 
 
10.   IF YOUR PROPOSED RESEARCH IS WITH VULNERABLE POPULATIONS (E.G. CHILDREN, PEOPLE WITH A 
DISABILITY), HAS AN UP-TO-DATE DISCLOSURE AND BARRING SERVICE (DBS) CEHCK (PREVIOUSLY CRB) IF 
UK, OR EQUIVALENT NON-UK, CLEARANCE BEEN REQUESTED AND/OR OBTAINED FOR ALL RESEARCHERS?  
EVIDENCE OF THIS WILL BE REQUIRED. 
Not applicable  
 
11.  STUDENT DECLARATION 
Please read the following declarations carefully and provide details below of any ways in which your project 
deviates from these.  Having done this, each student listed in section 2 is required to sign where indicated. 
• “I have ensured that there will be no active deception of participants. 
• I have ensured that no data will be personally identifiable. 
• I have ensured that no participant should suffer any undue physical or psychological discomfort 
(unless specified and justified in methodology). 
• I certify that there will be no administration of potentially harmful drugs, medicines or foodstuffs.  
• I will obtain written permission from an appropriate authority before recruiting members of any 
outside institution as participants. 
• I certify that the participants will not experience any potentially unpleasant stimulation or 
deprivation. 
• I certify that any ethical considerations raised by this proposal have been discussed in detail with 
my supervisor. 
• I certify that the above statements are true with the following exception(s):” 
Student/Researcher signature:     
Date: 08.04.2016 
12. SUPERVISOR’S APPROVAL 
Supervisor’s signature:   
Date:  22/05/16 
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Appendix 1a 
 
 
 
Applied Sports Technology Exercise and Medicine Research Centre (A-STEM) 
Sport and Health Portfolio, College of Engineering 
 
  
 
 
PARTICIPANT INFORMATION SHEET 
(Date: 03/05/2016) 
 
       
Project Title: Patients prospective in pulmonary rehabilitation 
Contact Details: Sameera Peumal Senanayake –  
 
1. Invitation Paragraph 
I would like to invite you to take part in our research study. My name is Sameera Senanayake and I’m a first-
year PhD student in the A-STEM (Applied Sport Technology Exercise and Medicine) Research Group at 
Swansea University. In order to help you decide whether you would like to participate in the study, it is 
important to understand why the research is being done and what it will involve for you. Please take your 
time to read the following information carefully and discuss it with someone else if you wish. If there is 
anything you do not understand or about which you would like more information, please do not hesitate to 
ask for further information.  
 
2. What is the purpose of the study? 
To talk to patients with IPF about their thoughts regarding pulmonary rehabilitation programmes. We would 
like to talk to you regardless of whether you have already completed the programme, are waiting to or do 
not want to complete it. The information obtained from the interviews will be used to help design new 
rehabilitation programmes that are more effective for IPF patients. 
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3. Why have I been chosen? 
You have been chosen because you have been diagnosed with IPF and you have already completed, are 
waiting to complete or do not wish to complete a pulmonary rehabilitation programme.   
 
4. What will happen to me if I take part? 
If you are happy to take part, you will be invited to participate in a focus group session with 3-4 other people 
with IPF. During this session, we will discuss your opinions and thoughts about pulmonary rehabilitation. This 
session will be audio and video recorded but there are no right or wrong answers, we are just interested in 
what your thoughts and opinions are.  
 
5. What are the possible disadvantages of taking part? 
At first, you might feel a little shy talking about your feelings and thoughts about pulmonary rehabilitation 
and IPF. However, we will do our best to put you at ease - everyone is likely to be feeling the same way. If at 
any point you would like to stop taking part, you are free to withdraw from the study with no fear of penalty. 
Furthermore, you might potentially experience discomfort sharing personal experiences within the focus 
groups. We will make every effort to avoid this - for example we will not try to make you talk about anything 
that you don’t want to. If you do feel any sort of discomfort during any stage of the study, you can withdraw 
from the study without any explanation if you wish. 
 
 
6. What are the possible benefits of taking part? 
Your opinion and feedback will provide us with important information that we will use to help shape future 
rehabilitation programmes for those with IPF. 
 
7. Will my taking part in the study be kept confidential? 
All the data gathered will be treated in the strict confidence and patient anonymity will be maintained 
throughout the study. If names are mentioned during the focus groups, these will be replaced with 
pseudonyms during transcription to ensure anonymity and confidentiality. Given the public nature of these 
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discussions it is not possible to absolutely guarantee anonymity of participants among the focus group. 
However, we will seek to ensure confidentiality by asking you to indicate that you will not share information 
outside of the group. If you are not comfortable taking part in a focus group, we will provide you with an 
opportunity to complete an individual interview instead. 
 
8. What if I have any questions? 
If you have any further questions, we encourage you to contact the research team to discuss them. If you 
have any concerns regarding this study at any point, please let us know or talk to your consultant (Dr. Kim 
Harrison) or the chair of the research ethics committee who approved this study (Prof Mike McNamee, 
). 
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Applied Sports Technology Exercise and Medicine Research Centre (A-STEM) 
Sport and Health Portfolio, College of Engineering 
 
 
PARTICIPANT CONSENT FORM 
(Version 1.1, Date: 3/05/2016) 
 
Project Title: 
Patient feedback and opinions on a programme of pulmonary rehabilitation 
Contact Details: 
Sameera Peumal Senanayake –  
Prof. M.J. Lewis –  
                   Please initial box 
 
1. I confirm that I have read and understood the information sheet dated 
  03/05/2016 (version number 1.1) for the above  
 study and have had the opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
3. I understand that sections of any of data obtained may be looked 
at by responsible individuals from the Swansea University or 
from regulatory authorities where it is relevant to my taking part in  
research.  I give permission for these individuals to have access to 
these records. 
4. I agree to take part in the above study. 
_____________________________ ________________ ________________________ 
Name of Participant   Date   Signature  
_____________________________ ________________ ________________________ 
Name of Person taking consent  Date   Signature  
_____________________________ ________________ ________________________ 
Researcher    Date   Signature  
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PARTICIPANT DISTRESS 
 
Procedures to follow in the event of participant distress during Interviews/Focus Groups 
 
Prior to the interview: 
Prior to conducting interviews, pilot interviews will be conducted in liaison with the supervisor. These 
interviews will provide the researcher with an opportunity to identify any questions that might lead to 
distress and where appropriate, take steps to rephrase or change these questions.  
 
Before conducting the first formal interview, the student will meet with their supervisor to discuss to 
procedures that are in place in case a participant becomes distressed during an interview. The supervisor will 
also ensure the student feels prepared for the interview. The supervisor must be satisfied that the researcher 
is competent in conducting interviews before giving approval for the commencement of data collection. 
 
Students will inform their supervisor where and when they are completing all interviews and in turn the 
supervisor will ensure the student has a means of contacting them when they are conducting interviews.  
 
During the interview: 
At the beginning of the interview the student will remind the participant that they can stop the interview at 
any time, that they can choose not to answer questions, and that there are no right or wrong answers to 
questions (so there is no fear of ‘saying the wrong thing’). 
  
Once the interview begins, the researcher will be required to be aware of any potential indications of distress 
(e.g., withdrawing, visible upset, declining to answer numerous questions, shifting in seat, looking away from 
the interviewer, asking for the interview to end) and should air on the side of caution in all instances. If there 
is even the slightest indication that participants might be distressed students must immediately follow the 
procedure below: 
 
1) The recording will be immediately stopped, and the participant will be asked if they are ok. At this 
point the participant will be asked if they want to take a break/end the interview/continue talking – 
the participant’s decision will be final. If the participant decides to take a break and continue with 
the interview, confirmation will be sought that the participant is actually comfortable continuing, 
and they will be reminded there is no penalty for withdrawing.  
 
2) If the participant wishes to continue but remains distressed, the interviewer will make the decision 
to draw the interview to an end. At this point, the interviewer will commit to providing the participant 
with an opportunity to talk and ensure the participant is not visibly distressed when leaving the 
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interview.  
 
3) If the participant remains distressed and the researcher does not feel capable of managing the 
situation, they will contact their respective supervisor who will be available at all times during 
interviews by phone contact. Depending on the situation, the supervisor will either provide guidance 
to the student, speak directly to the participant over the phone, or make attempts to go and meet 
with the researcher and the participant.   
 
4) If the participant has become distressed at any point in the interview, the student will ensure the 
participant has the contact details of the rest of the research team and remind them that they are 
free to contact any member of the research team if there is anything further, they would like to 
discuss.  
 
5) The interviewer will also offer to provide the participants with a list of local contacts (e.g., counselling 
services, sport psychology services) if they would like them.   
 
6) Following the interview, the student will debrief the interview with their supervisor and (if necessary) 
other senior members of the research team. A written record of the incident and the procedures 
followed will be made. 
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Questions to direct the support group towards achieving the aims of the study. 
 
First of all, let me thank you for taking part in this focus group discussion and agreeing to take part in this 
study.   
 
1. If you think back to your life before being diagnosed with your medical condition, what are the 
things that you did before but are prevented from doing now? 
2. What does have IPF mean to you? 
3. How does IPF make you feel on a day-to-day basis? 
4. In your own words, could you explain what you think pulmonary rehabilitation is? 
a. What do you think is involved on a daily/weekly basis? 
5. What do you think the possible effects of this type of pregame might be? These can be positive or 
negative! 
a. Physically? 
b. Mentally? 
c. Socially? 
6. What are your thoughts about participating in PR? 
a. What are you looking forward to? 
b. What are you worried about? 
c. PR normally lasts 8 weeks, what do you think about this duration? 
7. What do your family/friends think about the PR programme and participating in it? 
8. Have you or do you know anyone who has undergone PR? 
a. What did you/they think of it? 
b. Would you/they do it again? 
c. What would you/they change? 
9. Away from PR, what do you do on a daily basis? What is your average week like? 
a. What sort of physical activities do you enjoy/dislike? 
b. What is your perception of exercise?  
c. What would you change about your daily routine? 
10. PR generally includes an educational component, what do you think it would be useful for this to 
include? 
a. Who do you think the best people would be to attend this element? 
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Management of Distressed Participants During Interviews 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immediately stop 
interview & check 
whether participant 
wants to continue
Participant wants to 
stop interview
Provide opportunity 
for participant to talk
Provide participant 
with research team 
contact numbers
Provide numbers for 
local counselling 
services/childline if 
needed
Contact 
supervisor/research 
team if need advice
If struggling ask 
supervisor to talk to 
participant/come to 
interview
Participant wants to 
continue interview
Participant continues 
being distressed -
researcher MUST stop 
interview
Provide participant 
with research team 
contact numbers
Provide numbers for 
local counselling 
services/childline if 
needed
Contact 
supervisor/research 
team if need advice
When concluding 
interview confirm 
participant is ok
Provide participant 
with research team 
contact numbers
If participant has become distressed at any point you must debrief with supervisor and write up the 
steps that were taken throughout to manage the situation. 
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Gwasanaeth Moeseg Ymchwil  
Research Ethics Service 
 
 
 
Wales REC 6  
First Floor 
Institute of Life Science 2 
Swansea University 
Singleton Park  
Swansea 
SA2 8PP 
 
Telephone : 01792 606334  
E-mail : penny.beresford@wales.nhs.uk 
Website : www.hra.nhs.uk 
 
03 November 2016 
 
Professor Michael J Lewis 
College of Engineering 
Swansea University, Bay Campus  
Crymlyn Burrows 
SA1 8EP 
 
 
Dear Professor Lewis 
 
Study title: 
 
 
REC reference:  
Amendment number: 
Amendment date: 
IRAS project ID: 
 
Physiological and physical changes in patients with  
Idiopathic Pulmonary Fibrosis (IPF) following an eight-week  
pulmonary rehabilitation program 
16/WA/0272  
AM01 
12 October 2016 
206031 
 
The above amendment was reviewed 02 November 2016 by the Sub-Committee in 
correspondence. 
 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
Document Version Date 
Notice of Substantial Amendment (non-CTIMP) [inclusion of a AM01 12 October 2016 
physical activity monitor]   
Participant information sheet (PIS) 1.3 12 October 2016 
   
Research protocol or project proposal [exercise protocol flow 1.3 12 October 2016 
chart]   
Membership of the Committee    
 
The members of the Committee who took part in the review are listed on the attached sheet. 
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Gwasanaeth Moeseg Ymchwil  
Research Ethics Service 
 
 
 
Wales REC 6  
First Floor 
Institute of Life Science 2 
Swansea University 
Singleton Park  
Swansea 
SA2 8PP 
 
Telephone : 01792 606334  
E-mail : penny.beresford@wales.nhs.uk 
Website : www.hra.nhs.uk 
 
11 October 2016 
 
Professor Michael J Lewis 
College of Engineering 
Swansea University, Bay Campus 
Crymlyn Burrows 
SA1 8EP 
 
 
Dear Professor Lewis 
 
Study title: Physiological and physical changes in patients with Idiopathic  
Pulmonary Fibrosis (IPF) following an eight-week pulmonary 
rehabilitation program  
REC reference: 16/WA/0272 
IRAS project ID: 206031 
 
Thank you for your email of 11/10/2016, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chairman. We plan 
to publish your research summary wording for the above study on the HRA website, together with 
your contact details. Publication will be no earlier than three months from the date of this opinion 
letter. Should you wish to provide a substitute contact point, require further information, or wish to 
make a request to postpone publication, please contact the REC Manager, Ms Penny Beresford, 
penny.beresford@wales.nhs.uk. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission must be obtained from each host organisation prior to the start of the 
study at the site concerned. 
 
Management permission should be sought from all NHS organisations involved in the study in 
accordance with NHS research governance arrangements. Each NHS organisation must confirm 
through the signing of agreements and/or other documents that it has given permission for the 
research to proceed (except where explicitly specified otherwise). 
 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System, www.hra.nhs.uk or at http://www.rdforum.nhs.uk. 
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Dyddiad/Date: 17th May 2017  
 ABMU Health Board Research & Development 
Professor Michael J Lewis 
Swansea University 
Floor 1, Institute of Life Science 2 
Swansea University 
Singleton Park 
College of Engineering 
Swansea 
Fabian Way 
SA2 8PP 
Crymlyn Burrows   
Swansea 01792 530888   
SA1 8EP abm.rd@wales.nhs.uk 
 
Dear Professor Lewis,  
 
Re: Physiological and physical changes following pulmonary rehabilitation 
IRAS Ref: 206031 
Sponsor: Swansea University 
 
Thank you for submitting the above named research proposal to ABMU Health Board for NHS R&D 
permission. The attached listed documents were reviewed. 
 
Health Board R&D Governance checks have been completed and passed. Please accept this letter as 
confirmation of local NHS R&D Health Board permission. 
 
As part of Research Governance, you are required to:  
1. Adhere to the protocol approved and inform the R&D office and the relevant Research Ethics 
Committee of any changes to the study, including the end date, for review/approval and 
record update.  
2. For Health Board Sponsored studies, notify the R&D office of serious adverse events 
immediately upon knowledge, in accordance with local Standard Operating Procedure on 
Pharmacovigilance and as outlined in your Study Initiation meeting.  
3. For Externally Sponsored studies, the Health Board should only be notified of SAEs or 
Suspected Unexpected Serious Adverse Reaction (SUSAR) arising in local ABMU Patients.  
4. Complete any interim and final reports requested by the R&D office. If sponsored by ABMU 
Health Board, you will be asked to complete a 6 monthly progress report for submission to 
the Joint Scientific Review Committee along with your final report at study completion.  
5. Ensure that your research complies with any relevant regulatory requirements and legislation 
relating to: Clinical Trials, Data Protection Act 1998, Health & Safety, Caldicott Guidelines, the 
use of Human Tissue for research purposes, Mental Capacity and ICH Good Clinical Practice 
(GCP). The R&D team can advise you on applicable regulatory and statutory requirements 
relevant to your study.  
6. Comply with Data Protection requirements, notably no personal or patient identifiable data 
should leave the Health Board unless explicit consent from the individual or patient has been 
taken and documented. Unless consent is present, all study related documents must be either 
fully or linked anonymised. ‘Identifiable patient data includes name, address, full postcode, 
date of birth, NHS number and local patient identifiable codes as well as photographs, videos, 
audio tapes or other images of patients. Personal identifiable information includes the 
member of staff’s name, address, full post code, date of birth, NI  
 
 
Bwrdd Iechyd ABM yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Abertawe Bro Morgannwg  
ABM University Health Board is the operational name of Abertawe Bro Morgannwg University Local Health 
Board Pencadlys ABM / ABM Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR. Ffon / Tel: (01639) 683344 
www.abm.wales.nhs.uk 
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Appendix B: Data accompanying Chapter 4 
 
PATIENT INTERVIEW TRANSCRIPTION 
(patient 1)  
Age: 81 
Interview date: 11.07.2016 
Location: residence 
Conducted by: Dr. Joan Hudson and Mr. Sameera Senanayake  
 
START OF THE TRANSCRIPT 
Interviewer: What do you think caused your IPF condition?  
Patient: In my younger days there when I started working up the promotion ladder I was a junior 
charge hand, it was a working position, a working charge hand and one job that I had to do; (it all 
sound double dutch to you) there was a small ladies section 10, but there was a small course that was 
made of sand, they are going to overhead they baked to 600 degrees, 34 dive down, if they want to 
go around twice they twice and they come off. I may have to be sprayed with a mixture of water and 
coal dust. So, for the time I was being work for the 1st two hours, even though you are given a mask 
you spit out after two hours it was solid black. But I think I get paid for the job and I did it for the best 
part of two years, and I think the amount of cold dust I must have swallowed then. That’s one thing.  
But the last job I had was in BP chemicals. Obviously, we deliver petrochemicals and in one occasion I 
had a very bad report, where we used to work with Benzene, and at the end of each late shift at the 
end of the month we would be tested for our urine. I had three tests taken and had results over a 
hundred and they should be around 100 or less, so they said if that continued, they would have to kick 
me off that job, but it felt away, and I was alright.  
But when I spoke to the doctor down there, I asked what target you really want, was it bellow 100 and 
he said really, we would like zero he said. So, they really didn’t want that in your system at all. So, I 
think one of those two  
 
Interviewer: So, it sounds like, well I guess you got a history in you know in those kinds of 
environments that might cause, so were you surprised that you were diagnosed with IPF  
Patient: Yes, but they weren’t sure at 1st, I suppose they suspected lung cancer or either it’s a form of 
lung cancer, they had no idea and I didn’t particularly want to know. I’ve got a friend with lung cancer 
at the moment. By coincidence, about two minutes before I was diagnosed there was an article on the 
paper about this young man who was about 45 who said he now can’t play with his children and things 
because he got this, and I read his diagnosis and I thought I felt exactly like that you know and I’ve 
never heard about IPF and when they diagnosed me I thought I’ve got what this chap got and he is 
only 45 and I was already what? 76. And umm I’ve had a good run anyway, I mean because my heart, 
the time I found about my heart was when I was in national service as a young man, because as an 
apprentice you don’t go at 18 and the at the time you finish your apprenticeship you were nearly 21 
and I was engaged to my fiancé and she was going to wait for me till I do my two years of national 
service etc. etc. 
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I was fit as a fiddler, I was playing rugby, soccer and I used to do running 400, 800 meter, I was a fit 
young man, or so I thought. And I went down, and I was grateful. So, they told me that I have a 
murmur, a leaking valve, and meant nothing to me at the time till I was referred to Morriston hospital, 
this goes back to 1956. So it was a long time ago and I was diagnosed with a leaking valve of course  
they didn’t do heart surgery in those days, they couldn’t stop the heart and um and I had to give a 
chance to my fiancé to drop me as I was not a very good prospect then, she didn’t I’m glad. Anyway, 
at that time I didn’t know I was going to life till 40, 50, 55, 60 if I was very lucky but at 81, I am still 
talking to you.  
 
Interviewer: Ya, really you are still going strong.  
Patient: I lost my wife 15 years ago, she had leukaemia. If she would have been there, she would have 
been a very attractive girl and pretty talented, sang semi-professionally for 35 years. She was a non-
smoker as I. when I say I’m a non-smoker it not that I 100% smoke, for about perhaps 10 years I know 
I dint like cigarettes as such but when I have a couple of pints particularly when my wife was singing 
with her band and I was with other people and ide have couple of pints and my wife had to drive me 
home, anyways I was enjoying a cigarette or perhaps three but I wasn’t an addict, I wasn’t addicted I 
was never ever addicted, I just had a couple of cigarettes. Perhaps I shouldn’t have because even that 
could have caused it.  
 
Interviewer: Well you don’t know do you, there are so many factors like you say all the industries 
that you have worked in  
Patient: My wife told me one day when I was smoking, you know you look like a monkey with one of 
those things, and I stopped, and I smoke never again for 25 years.  
 
Interviewer: if you were addicted you could have never stopped like that.  
Patient: I’m talking too much 
 
Interviewer: No that’s ok, that’s what we are here for. That’s lovely, we are really interested to hear. 
So, when you were diagnosed it was still a surprise.  
Patient: Very much a surprise. Particularly by confusedness in to what it was exactly. Of course, I soon 
learned and told them don’t hold back, I don’t want to hold back, I want to know what it is as it is? 
And they said they don’t know. And I said what about this article, I read that article and later on I saw 
another article found on internet and I bothered my children to do it and I’ve read enough to realize 
that on average there is a three year life span and some are lucky and get a bit further and others have 
8 months. So, I knew it was a wide scope that I’ve got. Anyway, I’m glad to say I’ve got lot of friends 
and when I was diagnosed, I was struggling as I have never been struggling with walking and it 
coincides with onset of this one. And I’m thinking it may be this which is making my walking difficult. 
And I told I’ve been given a bad diagnosis and I have a limited time, and some say you are bloody 
around u said you are going, I’m glad that I’m not but sometimes days I don’t mind going.  
 
Interviewer: So, u said a few things which were quite interesting there, so when you 1st got your 
diagnosis and you found that it was a varied life span, how did you feel when you heard the news 
about your condition? 
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Patient: I was determined to live my life for the fullest, for as long as possible. By this stage, I said I’ve 
lost my wife 15 years ago, after a couple of years I was terrible and I lost my way, I had to be treated 
for depression and I started out I was missing the ladies company, I’m not about the physical side, I 
had a couple of relationships one was almost five and a half years. I was quite surprised by the 
diagnosis and that there was no treatment at all. I thought surely there is something. I’m on painkillers 
now but those are for my back not my lungs, they may be allied, I have no idea. It is surprising that 
there is no treatment as such and now I am more aware about the situation particularly after joining 
this group (support group). It is nice actually to meet some people with the same disease, I thought at 
least I was not alone. But when I was up there last Monday, I couldn’t help thinking that this is like 
shipman’s waiting room, waiting for each one to pop off you know. Because there is always news that 
somebody is gone and that’s a person u know, and I think I my name would be there one day wouldn’t 
it.  
 
Interviewer: Ya I mean the fact that there is no treatment for it, did you kind of deal with that in a 
certain way? Have you tried to approve things?  
Patient: I understood the few treatments that they did have in mind like lung transplant and etc. it 
was completely out for me at my age anyway. And with the new laws to transplants from people, I’m 
for it personally, because if you can save somebody else’s life you should.  
 
Interviewer: So, I mean u mentioned previously you are a sportsman and you are very active and so 
on. And you mentioned you use your walker now, how does the condition has affected your daily 
activities?  
Patient: Oh, greatly in fact. My dog died two and a half years ago but one of the delights of life was 
walking my dog. I think he went at the right time because I’m not able to now. I couldn’t look after 
him, I couldn’t brush him so in a way I’m glad that he went. But that aspect of my life, just going out 
for a walk no problem up until six months ago. I still drive and once I’m settle down, I’m ok and once I 
get to somewhere, I have to plan everything. Even looking after myself here. I don’t eat a lot at home 
because I eat with these ladies, but I would be doing lunch my self today. And I my dishes and I try to 
avoid walking as much as possible. You got to be thinking all the time you know and that thus affect 
me.  And another thing, because of my interest in sport my wife took me bowling and I was bowling 
up till two years ago three years ago and I joined the club eventually for about five years and I miss 
that the companionship. My son-in-law is the captain in the team, and I would have loved to play 
under him.  But I’m still, I’ve got a season ticket to the swans and I’m going there by my wheel chair 
because I’ve graduated from an excellent seat up in the stand to lower regions until they found me a 
spot on the side, and I’ve been lucky, I’ve got a good spot there and I’ve been watching them for the 
last two seasons. I’ve got a ticket for the next season but weather I’m there to see it or not, I don’t 
know. One of the things I’ve found particularly after losing my wife I’ve never got board because I’ve 
always got things on whether its singeing, sports or general life I’ve never board been, I think the 
boredom will kill you. That’s why I don’t like staying in too much.  I honestly feel that it has helped me 
because I would rather go with a band than sitting here waiting for it.  
 
Interviewer: you’ve been talking about staying active and looking to the future and planning things 
for the future. I guess it digs in with couple of these questions, on a day to day basis how does having 
IPF make you feel.  
Patient: I attend chapel every Sunday morning, I’m not the best Christian. I’ve had heart issues since I 
was 30 and even for this, I don’t feel paranoid, because I keep thinking about other things. I’ve started 
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staying in a bit more. But I get up night to go to the toilet and I get pain I don’t think it’s IPF, but I might 
be wrong. I went to a course of physiotherapy and honestly, I think it’s too much for me, when I came 
home, I was knocked out I wasn’t even able to do simplest things. Now my strength is gone and 
sometimes I feel ashamed about the things I can’t do, perhaps it could be because of getting old.  
Interviewer: I want to come back to the support group. But you’ve mentioned the rehabilitation 
programme, so when that was proposed to you, your 1st thoughts were that’s too much I can’t do 
that?  
Patient: No actually, I thought my input will be valuable because the people there are surprised that 
I’ve lasted five years. And I thought I can’t actually take part in physiotherapy, I’m pretty sure I can’t 
also because of my heart problem.  
 
Interviewer: you mentioned the support group and you mentioned some positives and negatives 
being involved in that 
Patient: The positive is that I’ve met people slimier, some of them are very nice. There was this one 
lady who I felt I really cheered her up. I would imagine she is approximately my age and I said to her 
I’ve been diagnosed for five years. And she said h Fred had it for three years (her husband) and I felt 
that she’s thinking that there is hope for Fred for another couple of years. So that’s the upturn. 
Downturn is every week they announce the deaths to me. And that is a bit of a down turn because u 
all know that you are going sooner than you like to be.  Another down side I felt last time I was there. 
I went there fairly early and as people were coming in a chap came and sat with his wife and it was his 
first time and he wasn’t getting involved and I thought I felt like that in my 1st time and I didn’t feel 
that good coming out of that one because I thought do I really have to come here and perhaps get 
depressed. But I kept on going because if we could do anything for 20-30 years down the line…who 
knows.  
 
Interviewer: you said a couple of things that I just wanted to follow upon, you said about you don’t 
like to live with it, but you have to live with it, I’m just interested to know how do you live with it? 
Is that a question you could answer? 
Patient: Putting it out I don’t mind, oh no that’s wrong, I do mind it every day. Challenge is living with 
it. As I described earlier, finding the simplest way to do things and I try to keep everything in precise 
order.  So, things at the same place all the time. Matter infect the lady who come on Friday said you 
are so obsessed with everything, but I find life is easier that way. That is also because of my mind and 
I’m a great believer in keeping the mind occupied, I mean I’m not a couch potato when it comes to 
telly, but I love watching interesting programmes. 
 
Interviewer: going back to the support group, the thoughts that time when you went and thought 
you didn’t want to come again. Was that because it reminded you how you feel, you know about 
your condition? 
Patient: May be, it’s just the days because the feelings were too varied. I got days where I’m feeling 
reasonable and life is full of hope and there have been days where I thought I won’t see tomorrow 
when there is no company around me, those were the down days. I didn’t have lot of those, but I don’t 
get deeply depressed though, it’s just that accept the fact that my time is limited but sometimes going 
to support groups brings some hope to you, you know because everyone else’s is time is limited. So 
yes, I’m glad they got it and I certainly will support it, I might miss out occasionally, but I will go as long 
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as I’m able to and it surprising that new members are showing up all the time. So, it’s a good set up 
and yes it been ignored probably because many medical professions don’t understand it. They don’t 
know what is causing IPF, they are guessing its work, smoking, genes, life style, I’ve always enjoyed a 
pint but I’m not a boozer, I’ve never been a smoker as such, and I’ve always been reasonably fit.  
Interviewer: You talked a little bit about lack of awareness in medical profession about IPF, what 
causes it you know and so on. How does that make you feel, the fact that there is so little 
understanding and knowledge of your condition?  
Patient: The patient did not give an answer relevant to the question  
 
Interviewer: You know, you sorted mentioned that it’s an untreatable condition has anybody 
suggested any ways to help you manage it to make life more comfortable and prevent the decline?  
Patient: In a way yes. Because I’ve learnt in two occasions in the last five years, I’ve had people come 
and install things like grab handles in my shower and alternate steps from a larger step to a smaller 
step, those type of things. Things like that help you with life. This thing was given to me (walker). But 
do I like too much of items, No, but I’m old now and I can’t get around here without any support. And 
I’ve got two alternate sticks if it is in and out of shops or the club. I got a walker and a wheelie, and 
I’ve got an electric one out there, second hand I’ve bought it and I would love to go around doing 
walks with my dog,  
 
Interviewer: do you rely on other people?  
Patient: I’ve got a gardener, he was meant to come last Thursday but he hasn’t. I keep the back gate 
open, but I don’t like doing, in case he turns up. And then I’ve got two daughters and a son, they are 
always there if I call them but one of my daughters is in Scotland, but she would be down in the next 
plane if necessary. So, I’m not short of support. I’m very sorry for people who haven’t got back up and 
I’ve got a couple of those.  
 
Interviewer: you mentioned your family; how did they support in your condition. Did they 
encourage you to do anything to look after yourself? 
Patient: They’ve always said to me, I would never have to worry about being on my own. But I want 
to be on my own as long as possible. Even as you get older you like to have your independence. I like 
to feel the king of my kingdom. They would do anything if I ask my family, but they prefer me to ask 
them because they know what I’m like, I’m stubborn. I couldn’t have asked for a better daughter in 
law for my son, unfortunately she can’t have children, there in their 40s now and she is excellent. She 
always cared about me. And I’ve got these systems, my daughter who is a teacher sends me a text 
“OK Dad”, and she knows that I’m OK. So there caring and we got these system because there is 
nothing worse if you collapse and you are on your own. So, the family is so good being not pushy.  
 
Interviewer: I just want to ask you a few questions about pulmonary rehabilitation, so that was 
something that you felt, you don’t have the strength to do?  
Patient: I don’t think so  
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Interviewer: what’s your view on what it includes? 
Patient: Going by what I did with the heart, I guess they are using some weights, running or semi 
running and the rowing machine, bicycle and all, I enjoyed doing all that, and it did me good and I 
know that it will probably do good to me now.  
 
Interviewer: I think, the rehab programme, if you were offered that while ago, right at the start of 
your condition, do you think you would have felt differently?  
Patient: Having a look back most patients haven’t got my back problem.ve got these elastic bands at 
the back for exercise, I don’t do it to be honest because I’m already overtired to what I am. So, I think 
it’s a case of yes it would do me good or it would, or it will finish me off. But if it was for other physical 
things, I would be the 1st to say yes  
 
Interviewer: when you were talking about different types of exercise that you did in your cardiac 
rehab programme and then you talked about doing seated exercise with your therapy band, if you 
were to design a rehab for programme for people with your condition, what would you recommend 
that it would include?   
Patient: Some patients are 40- 50 and most of them are fitter than me. I think it’s a good thing and I 
think people should be encouraged to do it. And if it was 10 -15 year ago, I would have given it a go.  
 
Interviewer: are there any other thing that you think will be useful to include? I mean you 
mentioned seated exercise, is that something that would be helpful? 
Patient: There are quite a lot of exercises that I know that you can do sitting down. People might be 
put off coming or might be encouraged by sit down for these things, there are plenty of exercises that 
could be done sitting down.  
 
Interviewer: I suppose this is a bazar question for me to ask, but obviously it’s an untreatable 
condition and the exercise won’t cure it so from your point of view, what would be the benefit of 
exercise with somebody with IPF?  
Patient: I think it will prolong your life, because the fitter you are the more it’s going to help your lungs 
anyway. There are lot of people who don’t realize that. The other side of the coin I’ve seen people 
dropping dead during their walking, and they are quite fit people. So, it doesn’t automatically mean if 
your body is fit you are not going to pop something else. But basically, I do subscribe to keep as fit as 
possible. I’ve done it by not necessarily doing exercise but being active (doing daily activities like 
cutting grass).  For those who would say I want to sit down, certainly there is enough can be done.  
 
Interviewer: and part of the rehab programme is kind of education about IPF, you’ve had IPF for 5 
years, which is a long time, what kind of things do you think will be useful to educate people? 
Patient: I’ll show you, because I write to different charities (shows an article on IPF by BTS). You know 
that was sent to me, it explains what it is and implications of it. I think something like that could be 
handed to people so they would understand it, particularly in the early stages.  
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Interviewer: so, do you think information is useful, and you’ve got a case study here on somebody 
called John, he’s got IPF. Was that helpful for you to have read? 
Patient: In the early days when I knew nothing about it, I thought it was only matter of years with it 
that would have been very helpful, as some people are. Lot of people need to know what the disease 
is and understand it and they can accept it then. You understand the news and you know you won’t 
be around in 7-8 years’ time. Unless it’s somebody who disintegrate with the news, as long as people 
know the full facts, you could expect it, life with it and live accordingly. I lived normal as I could.  
 
Interviewer: what would be your advice to somebody if they were diagnosed today with IPF? 
Patient: You should find out more facts, face to the facts, accept what is inevitable and live accordingly. 
Whatever you want to be, if you want to be cocooned in the house watching telly so be it.  I don’t 
subscribe to that but try to keep your mind active as well, as I always believe an active mind helps the 
body.  
 
Interviewer: Do you think having IPF have changed you as a person? 
Patient: It’s a damn darn question. I like to think, I’ve got lot of friends who show lot of affection 
towards me, and certainly I’m bit shorter tempered now, partly because I feel bit of a grievance that 
why this after all the years of struggling with my heart and everything. I think I’m the same person I 
used to be. Lot of people like to see me especially the ladies.  
 
Interviewer: as an IPF patient was it easy for you to get hold of all the information? How did you 
find that process? 
Patient: 1st of all there was that paper which gave me insight before I was diagnosed, I’ve never actually 
been given written information other that what I have picked up myself. Information is good and 
eventually more people would understand what this is. Lack of information always causes more 
worries thank being told the hard facts. No one has given me enough physical advice on it. Not 
everybody wants to be known but I do.  
 
Interviewer: Thank you for taking part in the study 
 
END OF TRANSCRIPT 
 
  
 121 
 
PATIENT INTERVIEW TRANSCRIPTION 
(patient 2)  
Age: 80 
Interview date: 14.07.2016 
Location: Swansea University Bay Campus 
Conducted by: Dr. Joan Hudson and Mr. Sameera Senanayake  
 
START OF THE TRANSCRIPT 
 
Interviewer: can you tell me a little bit about the onset of your condition and a little bit about it? 
Patient: looking back I think probably about three years ago, we were on holiday and then um, and I 
happen got a chest, never thought more of it. And then we went on a cruise, 2014 February/march 
and again I had a chest problem. And we went to Spain, I had a really bad chest there and I was putting 
it down to picking something up from travelling on the plane. I went to see a chemist and she 
prescribed antibiotics, which took and when I got home, I went to see the doctor and he was a bit off 
and asked why I hadn’t gone to see a doctor in Spain.  And I said well I’ve seen the chemist which was 
free of charge and she did the job well, she gave me the anti-biotics which worked but I came to see 
you as my own doctor. So anyway, he checked me over and he wasn’t sort of very keen on going any 
further. My wife was with me at the time and she said this has happened two or three times, so in the 
end he decided that I should go and have a chest x-ray. Following the chest x-ray at the singleton 
hospital and the consultant referred me to Dr. Harrison in Morriston Hospital. When I saw he came 
out and said I have pulmonary fibrosis. And since then I’ve been seeing him fairly regularly.  
 
Interviewer: and then did you get much information about pulmonary fibrosis?  
Patient: I firstly understand that there is no cure, it’s a disease which lot of people don’t recognise and 
my doctor was a little short at the time but after he found out that I was diagnosed with this he was 
exceptional after then, especially at the time my wife had a brain tumour and his attitude from then 
on was absolutely fantastic.  
Interviewer: but initially is was like a mystery it sounds like? 
Patient: It was a mystery, he didn’t think somehow, though I was complaining about chest, I know one 
thing I’ve missed out a lot now just thinking back, a year last September (2014 September) we’ve gone 
to Madeira and we were swimming normally, and we are both good swimmers and I would swim 
behind my wife and being a man I would always have to accelerate and pass her, but I found out that 
I was struggling to do a length. That’s I’ve supposed why. I went to see the doctor and said there is 
something wrong because I’ve never had any trouble swimming at all or distances, that was the main 
thing you know 
 
 
Interviewer: so, you were quite active before? 
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Patient: Oh yeah, I used to until this, I’m on crutches now for the last three years and I’ve had balance 
problems before and I used to play a lot of golf, swimming, cricket you name it. I’ve had no problem, 
but now I’m a television viewer.  
 
Interviewer: so there has been a change in your activity’s levels  
Patient: I find I’m tired if I got down to put my shoes on, I become breathless. The other problem is 
my balance and walking and I find it a great struggle in the last two years I’ve gone from a wheel chair 
which I use, because when we are away with my friends I was slowing them down, so I got a wheel 
chair and my wife had a problem pushing it because she had arthritis in her hand, so I got a scooter.  
 
Interviewer: other than the way you get around in places and getting breathless when you bend 
down to do your shoes, how else has it affected your daily activities?  
Patient: I would say, people would say I am lazy but when I walk to the kitchen now I leave plates, 
knives and everything, where I’m preparing the meal, I’ll leave them and wash them all in one go and 
put them back, rather than put them away because I’m not going to get up and walk 5 yards to get 
the plates and come back. I’ve sort of try and do everything in one place so I don’t go somewhere and 
I would have to back for something, can’t be helped but sometimes you forget, I sort of, it’s like I go 
in to the lounge and the kitchen, I always go in the bathroom because I think of getting to the lounge 
and I don’t wana go back because it not on the way, it’s sort of reorganize your life, try and do 
everything in one place before you move to another.  
 
Interviewer: is there any other way how it affects what you do and where you go?  
Patient: The next doors neighbours invited me few weeks ago on a Saturday night, because I was on 
my own at the time and I was coughing quite a bit which was a bit embarrassing and it seemed to 
persist, and I thought this is no good but um I couldn’t do anything about it. That’s the problem, I find 
quite often at night I start coughing and sort of like there is medicine. The only thing that I found 
helpful is menthol sweets which seemed to help a little.  
 
Interviewer: Is it only you in Swansea or do you have your family here 
Patient: no, I’m on my own here. (Rest of the answer is deleted from the transcript because it was off 
topic and irrelevant)  
 
Interviewer: What does have IPF mean to you? As an individual. 
Patient: um, I suppose really, it’s just something carped on over the years. I’ve always like doing 
everything by myself. I’ve always been very sporty, now I don’t go golfing, I don’t play tennis, I don’t 
go swimming, it’s limited that side, the only thing is I can walk in water because I’ve got crutches so 
I’m OK in the swimming pool, but I suppose now I need somebody with me and I’m general it’s sort 
of, wouldn’t say its lazy but I tend to leave things for a bit till they all get together and as I’m on my 
own now I just please myself. It’s like I don’t make the bed every day because I can’t stand so I leave 
it and I would leave my clothes on the side of the bed at one end so they are ready for me to put on 
in the morning (Rest of the answer is deleted from the transcript because it was off topic and 
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irrelevant).  I suppose everything is very slow, but one has to accept that’s the problem and make the 
most of it.  
 
Interviewer: How do you make the most of it? 
Patient: I suppose, since I came back from Canada, there has been a lot of sports on, so I’ve tended to 
watch that and left things which is needed to be doing, these days there is not much in the television 
now so I’m getting on with my paper work. Last few days I feel a lot better about myself. I’ve seen Dr. 
Harrison three months ago the day my wife passed away. (Rest of the answer is deleted from the 
transcript because it was off topic and irrelevant).  
 
Interviewer: Is there anything positive come out from the diagnosis of IPF? 
Patient:  Difficult to say isn’t it. I’ve lost my wife and I’m still alive. So that’s positive. (Rest of the 
answer is deleted from the transcript because it was off topic and irrelevant). When people see you 
coughing, they say take cough medicine, take this take that, they don’t understand it.  
 
Interviewer: Does it make is sometimes difficult then, because people doesn’t understand it? 
Patient: Because it’s invisible, they think, or get some cough medicine or do this and that, when I called 
Dr. Harrison it was completely different. I don’t think they believe there is anything wrong with you in 
a way but quite often they would say why you are panting when you are doing nothing literally, or you 
don’t realize you are. 
 
Interviewer: How does that make you feel? 
Patient: When my wife was in the care home and I used to sleep and I used to have a phase about two 
weeks when I felt out at night, as soon as laid down to go to sleep, I was getting sort of, I couldn’t 
breathe properly or had that feeling that I wasn’t able to get my breath which I found difficult to 
handle for a bit. That’s disappeared now. I didn’t know if oxygen was working at the time, but it is 
worrying when you are on your own. Every time you lie your head down and in 10 minutes you can’t 
breathe properly and it’s a bit worrying, and you wonder if it will get worse.  
 
Interviewer: What is your understanding in pulmonary rehabilitation is? 
Patient:  I’ve had a leaflet from lung association and about exercise and I have not done anything about 
it now. There is one in Swansea. I do go to a physio class, I go in twice a week now doing regular 
exercises and I can agree with that. I can see doing all the exercises without being a couch potato and 
it’s good.  
 
Interviewer: so, what kind of exercises can you do, could you give me couple of examples? 
Patient: yes, you do march on the spot moving your legs to each side forwards backwards, starches 
and walk one foot in front of the other which I can do with support. Some of them I can’t do like I can’t 
get on my toes or heals but that due to my balance problem. They work through your whole body like 
exercising your arms use the tuber to put pressure to your joints, especially to your arms and wrists. 
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You do exercises where you do stretch out the tension and hold for five seconds and repeat it for 5 
times. I can understand it and what it is doing.  
 
Interviewer: When you said it was doing you good, what type of benefits do you think you got? 
Patient: I can’t walk very much, everybody says you should walk here walk there so it has given me 
exercises to do with 10 or 12 people and you tend to say right, I’ll do it all I’m not going to sit down 
you know not give in, otherwise in sitting in all the time. I can’t go out for a walk, I’m struggling with 
my crutches and the idea is that it will be tired you for a bit and get the heart rate going and get your 
lungs working and everything.   
 
Interviewer: Do you think it’s kind of helping with your condition?  
Patient: It could be because, I don’t know how the condition goes and the leaflet you have given me 
is very nice, it says 50% only make it for three years, mine is staying static at the moment. It’s nice to 
get a reading which confirms you are not deteriorating. And looking back my wife and I took a full 
MOT few years ago and I didn’t take any notice of it but they said there is spot on your lung which 
could have been the beginning of it, as I thought I don’t smoke and I was fine for years afterwards but 
it come on in the last 18 months, it must have been there and the last few months I have been at a 
point where nothing is happening. But I’m reasonably happy ATM.  
 
Interviewer: do you actually enjoy the exercise sessions that you do? 
Patient: yes, the only thing I find, the original one I went to was run by NHS for 8 weeks and at the end 
of that you pay as you go, I think a couple of pounds. The 1st one had tea and biscuits and at the end 
of it you get talking with other people, especially if you are sort of a single person in your own it’s nice 
to have some company. But the second one there are no company you are on your own. It gives you 
something to look otherwise you will be sitting in home all day.  
 
Interviewer: If there was a Morriston would you be interested to attend? 
Patient: yes 
 
 
Interviewer: what kind of think would you like in it in terms of exercise? 
Patient: well, I’m in the dark about what you can do to help the condition and I’m open to suggestions 
you know, anything that might help is going be good.  
 
Interviewer: What would be the things that would put you off going like exercises as you said? 
Patient: Nope 
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Interviewer: are there any kind of other exercises that you like to do, or environments may be like 
mixed groups?  
Patient: yes, it doesn’t worry me I mean in the past I’ve done exercises and I’ve been the only man 
around 10 women. 
 
Interviewer: You are open to exercise so how often do you think you can manage doing exercise on 
a weekly basis? 
Patient: I’ve only started to go for the physio twice a week instead of once. But to me pulmonary one 
would be more important compared to the physio one so I would choose pulmonary over physio. Rest 
of the answer is deleted from the transcript because it was off topic and irrelevant) 
 
Interviewer: Do you think there would be wider benefits doing pulmonary rehabilitation? 
Patient: It’s meant to make your breathing easier whereas the other one is a more arthritic one on 
joins and muscle.  
 
Interviewer: You mentioned your family in Canada, do they have any view on about your activity 
level? 
Patient: no, they have never said anything at all. You can’t expect me to do a lot, if I need them, they 
are at the end of the phone. But they have their own life.  
 
Interviewer: If you can see yourself going on the pulmonary rehab programme, are there certain 
things you look forward to or something might worry you?  
Patient: I don’t think that anything will worry me. I’ve always thought myself as somebody who doesn’t 
worry, and things happen in life and you get on with it.  
 
 
 
Interviewer:  because you weren’t aware of the pulmonary rehab programme, you haven’t talked 
about it with anyone? 
Patient: No. the only thing I got was a leaflet from British lung foundation saying about classes but 
that’s it 
 
Interviewer: when we talk about pulmonary rehabilitation there are different components like 
exercise and education. What kind of things would you like to see in it or is exercise is just enough 
to you? 
Patient: to me exercise seems to be the only thing. Unless it is explaining the problem, what’s causing 
IPF there is no point. I’d rather be told things you know.  
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Interviewer: If you were given a choice of doing an exercise sitting down, would you…? 
Patient: I find it easier doing exercises sitting down.  
 
Interviewer: so, sitting down exercises would encourage you to attend? 
Patient: yes probably.  
 
Interviewer: looking back in life do you think may be something that you did caused your condition? 
Patient: Dr. Harrison sort of dug in to this. I had a family motor business and I thought looking back in 
the sixties when you look at the breaks, when you take the brake drums off and you have asbestos 
and you blow it off and may be when u paint cars u cam puffs it. He said it doesn’t cause IPF and this 
came 40 years after I breathe asbestos (the spot on the lung).  
 
 
END OF THE TRANSCRIPT 
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PATIENT INTERVIEW TRANSCRIPTION 
 (patient 3)  
Age: 81 
Interview date: 14.07.2016 
Location: Swansea University Bay Campus 
Conducted by: Dr. Joan Hudson and Mr. Sameera Senanayake  
START OF THE TRANSCRIPT 
 
Interviewer: You’re IPF, when did it 1st got diagnosed? 
Patient: well, I was diagnosed year last May. Year last January / February, I was with my doctor. Think 
all this after losing my wife in July. I didn’t let the grass grow on my feet because I’ve never been too 
morbid. In October I went to north of Organya but this year it’s so bad I can’t go anywhere. But as I 
said I was going to the doctor in February last year and I said I want to see a specialist and they refused 
so I booked to see a consultant and on one morning I got a call saying we had a cancellation and a spot 
opened up so I went to see this doctor in Morriston. He checked me up and said I have clamping 
fingers, got x-rays and said I think you have IPF. I have never heard it before, so he arranged a CT scan 
and then saw Dr. Harrison about a year ago.  
 
Interviewer: it has affected how mobile you are, has it affected your other daily activities, way you 
do things around the house? 
Patient: Oh, I can’t do anything. (The rest of the conversation was deleted from the transcript because 
it was irrelevant to the question). 
 
Interviewer: driving long distances with your oxygen on is quite difficult for you?  
Patient: never tried it. But if I was driving on a cushiony seat and I’m only driving and not talking. This 
is what rehabilitation is going. If your muscles are fitter you need less oxygen, this is what they do 
there strengthening muscles and it marvellous.  
 
Interviewer: so, you have been doing the rehab exercises have you and for how long? 
Patient: I’ve done that. About six weeks of it but I lost 4 days, 2 weeks.  
 
Interviewer: how did you find it?  
Patient: well, as I said to you earlier what they teach you are the basic exercises to keep your muscles 
toned up. By toning your muscles up, you get stronger muscles and use less oxygen up. It’s easier said 
than done sometimes, if you are struggling for it. I mean a year ago I was doing all the grounds on my 
tractor cutting grass but this year I can’t do anything.  
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Interviewer: what kind of exercises did you do in the class, what could you manage? 
Patient: we would sit in a chair, they put weights around your legs and lift it up like that and you stand 
up and sit down and you step up and stretching and bicycling. I did what I could.  
 
Interviewer: did you enjoy it? 
Patient: yes because, I found it struggling but as they said to you do it to your own phase. They never 
pushed you. Yes, and it was about meeting other too.  
 
Interviewer: some people actually do not go to rehab programmes, what encouraged you to go? 
Patient: I told myself you have to try anything and everything. I have an oxy meter and I check it during 
my activities.  
 
Interviewer: when you were doing the exercise session, do you ever worry that your oxygen levels 
would get too low.  
Patient: no because I’m on this and if I feel like it, I turn it up a bit and I take a full cylinder when I go.  
 
Interviewer: you said about doing exercises, you know doing what you can. Do you think it helping 
your condition other than the extra oxygen going in to your muscle? 
Patient: I don’t think so. I just don’t know. I know the difference, from last year it it’s a huge difference 
and I’ve gone down.  
 
Interviewer: How do you fell having to use oxygen all the time? 
Patient: I’ve got no choice you know. It’s like a tie. You are stuck at an end of a tube really. I try and 
manage without it. I don’t want it any more than its necessary you know unfortunately. I don’t sleep 
with it, so I go down quietly.  
 
Interviewer: how does your family help you? Do they help you to manage your IPF? 
Patient: My daughter came in some time ago and helped me to slip in to bed. (The rest of the 
conversation was deleted on patient’s request).  
 
Interviewer: going back to your family, do they encourage you to be active or do they say dad sit 
down, take a rest? 
Patient: well, it’s not a matter of encouraging me because they know what sort of a person I am. If I 
can do it, I’ll do it. I’m a very independent person.  
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Interviewer: what do they think about pulmonary rehabilitation, do they think it’s a good thing? 
Patient: I don’t know, I haven’t talked to them about it. They know I’m going, and I have finished it 
now.  
 
Interviewer: having gone through that programme. Do you think its missing anything? Doesn’t 
necessarily have to be exercise, may be lifestyle or diet? 
Patient: No, because you see, you did an hour of excising and then you are sitting down having a cup 
of tea and biscuit and chatting with others. There was a dietitian there and I saw her because I got a 
stomach problem as well. I don’t know if it is affecting. I had that for a long time (rest of the 
conversation was deleted because it was irrelevant).  
 
Interviewer: do you believe that something u did caused you IPF, like smoking? 
Patient: never smoked other than a few cigarettes as a young boy. Never was a drinker, drank very 
little. If you google IPF you would find acid reflexes could cause it and it makes sense to me because 
I’ve suffered from it in the 90s. So maybe it’s a contributing factor. I don’t know  
 
END OF TRANSCRIPT 
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PATIENT INTERVIEW TRANSCRIPTION 
(patient 4)  
Age: 71 
Interview date: 14.07.2016 
Location: Swansea University Bay Campus 
Conducted by: Dr. Joan Hudson and Mr. Sameera Senanayake  
 
START OF THE TRANSCRIPT 
 
Interviewer: How were you diagnosed with IPF? 
Patient: Here comes the start of the problem, In February 6th of February I fell down the stairs from 
top to bottom and went to Morriston hospital. They were going to operate, and they found me not fit 
enough to undergo anaesthetic and I was in there for a month. Mr Harrison did a multitude of tests 
and eventually I was diagnosed with IPF. Gave me something like a short period. It was like months or 
three years to live. Because it came so quickly, and I had no indication that id suffered from this 
condition. My background is working in an office environment not the same office, but different places 
for 26 years. I was in for a month, I have oxygen in my house and in my car and after a month I came 
out, knowing I have possibly a short period to live, I started to arrange the inevitable, but I also took 
to drinking too heavily and end of June I got jaundice. By September I finished taking oxygen and then 
I started the rehab in September same year, three years ago. It was 7 weeks twice a week (14 sessions). 
I found it extremely helpful. And that’s the introduction.  
 
 
Interviewer: so, you’ve been through the programme, what kind of experience to you have, the 
positives, and the negatives? 
Patient: I didn’t have any preconceived ideas. I had no idea what’s it going to be like. They said it going 
to be a light weight circuit training. It wasn’t the important thing, I think. It was mentioned that it’s 
not a competition although there were around 10-15 people, you would do exercises to your phase. 
Yes, you were trying to do routines of 10 pullups but if you couldn’t do it you do as much as you could. 
It wasn’t to gain strength, but it was to exercise your lung and mussels to help your blood and air to 
go to the lung. There were people who supported it. it must have been very good, well I know it was 
good. Because the dropout rate was minimal. If you miss a day people were coming with doctor’s 
letters the next day. All thought they should participate. It did get a group of people working to gather 
with similar conditions. I prefer to say a condition rather than a disease because it sounds less when 
you say condition.  
So, no preconceived fears and the results were good. Initially your heart rate and oxygen recovery 
time were taken, and they were periodically recorded just to see if you have improved and most 
people did, so I was more than happy to participate. But after I completed you couldn’t do it again and 
I guess that’s a draw back. But I was referred by my GP to group down in Port Talbot. There were all 
of mature age and was having COPD. It wasn’t a gym, but they had dumbbells and weights and it was 
professionally run, so we did that twice a week and I’ve been doing that ever since. I find lifting weights 
easy but anything to do with breathing like waling, I find it difficult.  
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Interviewer: you don’t exercise regularly now 
Patient: yes, because I’m out of breath when I do. (Rest of the conservation was deleted from the 
transcript because it was irrelevant). The exercise programme had 14 work stations, 2 minutes at each 
station which alternate from chest, breathing, legs or arms and it works. All the participants were 
elderly, and it was great listening to them. It’s important as well as the exercise because we were all 
suffering from the condition COPD or IPF and again people like to come talk and socialize and mentally 
it helps as physically. You don’t feel like you are doing for the exercise but to meet other people. I find 
that rewarding and everybody in the group find it satisfying as well 
 
Interview: So, do you find other mental benefits, so is that kind of social connection element that 
you were talking about? 
Patient: I’m not a words smith, I’m more figures and maths. I love the gardens, but I can’t go much 
gardening any more, but mentally I feel good. I do loose concentration when people are talking 
especially when they are talking about death. 
 
Interviewer: can I ask how old you are? Sorry to be rude. 
Patient: I’m 71. We had our 1st granddaughter last October. She has a quite a character now. So, 
exercise from rehab I would highly recommend.  
 
Interviewer: would you go for rehab if different types of exercises were offered? You know you 
talked about warming up circuit training and cool down. Is there kind of other exercises that you 
would feel you could manage better? 
Patient: I don’t know what is available. Seated exercise may be beneficial. I don’t want it to be one to 
one because you take away the group feeling. But I will be going back on Monday with my oxygen and 
I find it easier to do exercises with my oxygen on.  
 
Interviewer: How would you encourage the other people to take part in pulmonary rehabilitation? 
Patient: initially I will direct them to our support group. Then I would ask someone who had experience 
in the condition and rehabilitation programme to talk about rehab, who can pass on their true feelings 
not a clinical thing, somebody talking from the heart who had done it.  
Advertising- there are lots of leaflets with the doctors regarding lung cancer and diabetes. But there 
seems to be little knowledge in advertising IPF. Maybe it because it only effects a small group of 
people. Notices in hospitals would be good. Not making feel frightened from it, it’s not a competition, 
u r not to achieve a certain level but any exercise is good for you. You should be encouraged not forced 
by the trainers. You shouldn’t be the bust, but you should be doing your best 
Interviewer: it sounds like you have started the rehab very early on when you were diagnosed, you 
think being active all that time had helped keep you avail?  
Patient: that is true. I don’t know.  
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Interviewer: How does it make you feel to have a condition that there is very little information 
about? 
Patient: privileged! I’ve got a rare blood good. Feel special. I don’t think why me. There are positive 
things a million things that are good. And this s going to be resolved in years in the future although it’s 
now untreatable. I don’t have bad days. I have good days and not so good days.  
Interviewer: in terms your family, what’s their view on you exercising, are they supportive? 
Patient: Oh, very much so. Extremely supportive. My wife says there is nothing wrong with me, but 
she supports me. I love cooking, doing the prep work but I get tired, but my wife supports me because 
she knows I love cooking. My grand child can sit on me, but I can’t lift her up, is surprising because I 
can lift dumbbells.  
Interviewer: do you think that you did something that provoked this condition? 
Patient: I smoked. One a day and was up to 15 a day and 20 a day in the weekends. Then I gave up. 
My office environment was a non-smoking place.  
 
Interviewer: Thank you for coming today  
Patient: we all know we are going to pop out one day, so be it but life is good as we are living it.  
END OF TRANSCRIPT 
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PATIENT INTERVIEW TRANSCRIPTION 
(patient 5)  
Age: 65 
Interview date: 19.07.2016 
Location: Swansea University Bay Campus 
Conducted by: Dr. Joan Hudson and Mr. Sameera Senanayake  
 
 START OF THE TRANSCRIPT  
Interviewer: could you tell me a little bit about how you were diagnosed with IPF? 
Patient: it was in 2008, didn’t realize I had a problem it was found by chance because I had an 
operation in my eye. Before the operation the anaesthetist checked me and said you have a rattle in 
your lungs and you really need to get it seen to. So, it was diagnosed then. And I’ve been attending 
the clinic ever since every six months. It was an oddball in some ways because the results of the lung 
function tests hardly changed. The Dr. was expecting to see deterioration and it doesn’t appear to 
have happened, thankfully. When he sees me, he says I would expect to see deteriorate with your 
age. I’m 74 you see. And he said I’m not seeing that. From the beginning its being don’t change 
anything. But I put stability down because of the exercises regime that I’m doing, which I have always 
done. I don’t go to the gym, I don’t pump ion but I’m active in other ways. I go for a walk for two hours 
with the dog and its quite tuff walking, you couldn’t walk in shoes, you need boots, and it’s that sort 
of walking. And when I do walk with people who haven’t got the condition, they get you know. So, it’s 
kind of vigorous work.  
 
Interviewer: so, you didn’t have any symptoms beforehand? 
Patient: I was having some Flem. But not severely though. And there was a slight cough. Other than 
that, I didn’t know really. I was never really out of breath. Also, with the lifestyle I mean, now widowed 
and just having finished work you can imagine how busy I am from Monday and Friday, with the 
grandchildren, those two days are blown away. I’ve been working Tuesday, Wednesday and Thursday 
and that left me Saturday and Sunday to do pink jobs and blue jobs you know. Where previously I was 
doing blue jobs. There are also lot of house work and stuff like that. So, I was busy. I’ve got three 
children and they are all in the 40’s and I have five grandchildren. And I’m seeing them quite regularly.  
 
Interviewer:  what do you do for your occupation?  
Patient: I was working as an engineer (a sales consultant) and I was only working for this company for 
eight years and they offered me a job when I was 65 and I retired.  
 
Interviewer: before that what did you do? 
Patient: for lot of years I was hands on machining and for a number of years I worked with graphite. If 
I was not near a machine, I was near a machining facility and there is a lot of dust there. This is 
manmade graphite with lot of resins and oil.  
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Interviewer: did you wear a mask? 
Patient: Not really, I mean we did but no one did it really. Because it was carbon at it was meant to 
pass through your system. Whether that was the cause of the damage, I don’t know, maybe not. It 
would be interesting to know about other employees in the industry. (The rest of the conversation 
was not included because the patient was talking about graphite).  
 
Interviewer: when you were diagnosed were you given any information about IPF? 
Patient: only that the disease won’t go away. Its life threating. I’ve seen life expectancy is between 
three to five years. But it’s not my case thankfully. I remember asking Dr. Harrison if the results of my 
lung function test are stable, why would you want to see me every six months? And his words were 
it’s a disease I won’t trust. I also understood it could be caused by really any foreign body. (The rest of 
the conversation was removed for the transcript because it was irrelevant). I smoked up until 1969 
and in the late 90’s early 2000 both my sons were smoking cigars and I would have an occasional cigar, 
but other than that I never smoked. I’ve never had a lung injury but had asthma as a child, but it went 
away. I don’t think there is enough information out there to make people sit up and think about it and 
prevent this.  
 
Interviewer: when you were diagnosed, how did you feel about that? 
Patient: I didn’t get particularly bothered you know. I thought if that is the way it is, I should give 
myself the opportunity I can, stay fit which I have done. And since my wife died, I have lost 10 pounds. 
I thought it was grief, but it never came back. It doesn’t bother me, I think one of my fails is I have a 
flat scotch and a glass of wine, I guess that’s my only health fault. I don’t take any medication, I’ve got 
small aches and pains. Last 18 months I have had 5 operations and that itself could be a trauma. But 
other than that, I’m tip top.  
 
Interviewer: so, your life style hasn’t changed much? 
Patient: no 
Interviewer: has it affected what you are able to do? 
Patient: I haven’t tried running so far. Every now and then I would go up the stairs and I would think 
woof, I would feel that. Back in February was one of the worst times with regard to this. I felt really 
sorry for myself. I think I had a chest infection without any other symptoms. I was walking the dog and 
I wanted to go home. It was never like that, I could see myself going down a spiral and it lasted about 
a week. So, I was feeling sorry for myself but other than that it never bothered me.  
 
Interviewer: what does it mean to you to be diagnosed with IPF? 
Patient: as long as my results are normal, I feel that I’m on top. Sometimes it could be a little 
depressing like during February thinking is it gona incapacitate me you know, when life ends are this 
what I’m gona die from, but overall not too bad. I’m aware of its daily basis but it doesn’t bother me 
or restrict me. If was diagnosed with lung cancer it would have knocked me over, but knowing I have 
a fighting chance as things are, it’s not bothering me. I worry about my children worrying so that’s 
why I take care myself and it’s a concern.  
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Interviewer: if you were given a chance to take part in an exercise programme would you be keen 
to take part in it? 
Patient: ya, I’m keen to put in anything I can. There could be something which benefits me personally.  
 
Interviewer: are there any particular exercises that you find beneficial that you are keen on doing? 
Patient: no, I’ve never been a keep fit for nothing sort. I’ve been playing football and all that. I’ve 
always done walking and being active. I’ve had a garden, a house, kids, dogs, so I’ve always been busy 
you know. I don’t need to go to the gym.  
 
Interviewer: you talked about the physical benefits of exercise, do you think there are any other 
benefits of exercise related to you condition? 
Patient: I don’t know. I think it might be beneficial to the upper body. I can’t lift things much these 
days. I’ve sometimes found lifting whatever across the garden these days, but before it was easy. So 
that side of it may.  
 
Interviewer: form you’re prospective what do you think encourage people with IPF to do exercise? 
Patient: when I see some people in the support group I think, you know you are much younger to me 
but look older to me and I think if it is the condition or the life style prior to the condition. Maybe they 
have been diagnosed as the same point as I was and did, they thought that’s it. And when I had that 
shortness of breath in February it was quite depressing. So, if they are feeling like that there is no 
going back for them. If they were diagnosed at the same point as I was, much encouragement should 
be given to exercise and maybe role models are what they need. The exercise wouldn’t stop the 
disease, but it might slow it up. (The rest of the conversation was deleted because it was irrelevant to 
the question). When I went there 1st it was depressing maybe it was bad timing with things with my 
wife and all.  
 
Interviewer: apart from exercise and support group do you think there are any other elements to 
be added to a rehab programme?  
Patient: I don’t really know. (The rest of the conversation was deleted due to irrelevance to the topic). 
The other thing is when you tell people about an exercise programme, they say this and that, but if it 
was a walking programme it might be more attractive to some. The fact that you are taking the to a 
gym environment it might put them off.  
Interviewer: how does your family feel about you going on to do an exercise programme? 
Patient: they will be like get on with it. They would say I’m an inspiration to them. I don’t think anyone 
would object it. (The rest of the conversation was not included because it was irrelevant to the 
question).  
Interviewer: that’s amazing.  
 
END OF THE TRANSCRIPT 
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PATIENT INTERVIEW TRANSCRIPTION 
(patient 6)  
Age: 73 
Interview date: 19.07.2016 
Location: Swansea University Bay Campus 
Conducted by: Dr. Joan Hudson and Mr. Sameera Senanayake  
 
START OF THE TRANSCRIPT 
Interviewer: thank you very much for coming today. Could you tell me a little bit about IPF and how 
it was diagnosed? 
Patient: Yes, diagnosed in 2006, purely by chance. I had a cough and had two sets of antibiotics and it 
didn’t get shifted as all. So, I went back to the doctor and he said you have a lung problem, you should 
go for an x-ray and see a chest consultant. Then I met Dr. Harrison and he said that I have IPF, which 
I’ve never heard of. 1st thing which came in to my mind was lung cancer because I was a smoker but 
after having x-rays and biopsy it was confirmed what it was. And I managed it very successfully until 
March. Up until then I went to the gym twice a week and I was not on any medication, I’m still not on 
any medication but tomorrow Dr. Harrison is going to put me on some tablet.  
 
Interviewer: OK so, you were going to the gym a couple of times a week and what sort of things 
were you doing there? 
Patient: the bike, treadmill and occasionally using weights.  
 
Interviewer: when did you stopped smoking 
Patient: 2005 
 
Interviewer: so, the exercise was helping you to manage your condition 
Patient: yes definitely, I stopped going when I was ill, and I haven’t been back since. I took part in the 
pulmonary rehabilitation programme in Moriston for six weeks and from there I got referred to 
another local council. 
 
Interviewer: so, you stopped doing exercises on your own 
Patient: I used to go for walks, but I haven’t got energy to do it anymore  
 
Interviewer: how far would you walk typically? 
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Patient: I walk down the marina a couple of times to get coffee. I walk the dog twice a day and I had 
no problem. But since March its really knock me.  
 
Interviewer: has it affected any other aspects of your life? 
Patient: I’ve lost some weight and I can’t seem to put it back on, that seems a problem.  
 
Interviewer: when you were doing exercise what kind of benefits was it giving you? 
Patient: it was keeping my lungs clear but now I have lot of mucus and flem. And it felt better. When 
I was done you felt that you have achieved something.  
 
Interviewer: so, when you said it made you feel better, did it make you feel better about having IPF? 
Patient: IPF is a disease I can’t do anything about. All I can do it is to prolong it as much as I can. And 
whatever I can do to do that I will. I know a few people that are going to the rehabilitation course and 
they complain about being depressed. Well I’m not depressed, vie accepted what I have got. And try 
to be positive.  
 
Interviewer: Did you feel like that from right at the start? 
Patient: oh yes. I mean I possibly didn’t realise how serious it was, but I got lot of knowledge over the 
years.  
 
Interviewer: so, when you were 1st diagnosed, what kind of information did you get? 
Patient: I got information from Dr. Harrison and the rest from the internet. Since we started the group, 
I realize so many people in the area had the same problem. We talk about how it affects different 
people in different ways and for me I find it difficult to walk when it is windy and when it’s hot, wet 
and cold it affects you. It seems whatever the weather condition is it affects you. You feel lethargic, 
you have no energy and you cough. It’s not an easy disease to get along with.  
 
Interviewer: so how do you get along with it? 
Patient: I carry on how I am you know, I except what I have got, and I adjust in to it.  
 
Interviewer: So, you said you built up information as you went. What sort of information would 
have been useful at the start when you were diagnosed? Not just information, what else could have 
been offered to you? 
Patient: I think there is more awareness now, I don’t think there was a great deal available at the time. 
So, I can’t see it that way. As I said I was surprised to see how many people got the problem.  
 
Interviewer: so, when you meet with other people, what’s it like at the support group? 
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Patient: we have a cup of tea; cake and we talk about how things are. They get people from different 
ways of life to talk about the problem. Rest of the conversation was deleted because it involved a 
political figure and is not relevant). There was a lady from wales health, and she talked about the 
problem and what is happening. We had a talk about what benefits we are entitled to. It’s just people 
getting to gather and talk.  
 
Interviewer: what do you think the biggest part? 
Patient: just having a chat about families and how they are coping, you know that’s the biggest part 
of it. Getting to gather and talking to people with the same problem 
 
Interviewer: so, it’s a positive thing? 
Patient: Oh yes.  
 
Interviewer: do you experience any negative result? 
Patient: No, not really. I’m a half glass full person.  
 
Interviewer:  what kind of industries have you worked in the past? 
Patient: I worked in the steel industry. I worked in templates section. I had to go to the plant quite a 
bit, talk to people out there so if that had to do with anything I don’t know. I used to work in an old 
building with asbestos walls, sometimes when you move a chair to the wall and the asbestos sheet 
cracks and if it’s a part of the problem, I don’t know. The house I am living in has plaster ceilings and 
it had black motor (type of a dust) and I don’t know if it caused the problem.  
 
Interviewer: going back to the rehab programme, how did you find that? 
Patient: very good. It was on Tuesday and Friday, 1st hour was exercises and the second hour was a 
cup of coffee and talk about the illness.  
 
Interviewer: the exercises you did, was its weight based, was it standing, seated? 
Patient: there was a treadmill, a rowing machine and a couple of bicycles which I didn’t like. The 
weights the medicine ball things, the stretch band, leg weights, so there was plenty there. But you did 
what you wanted alternating between arms and legs.  
 
Interviewer: what did you like about it? 
Patient: again, it was the people with the same problem, finding about how they coped. (Deleted from 
the transcript because the patient was talking about another patient in the rehabilitation programme)  
 
Interviewer: did you enjoy the exercise part of it?  
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Patient: yes. Some of them were hard work. I mean the treadmill is fine, I was happy with that but it’s 
hard to do with the oxygen on.  
 
Interviewer: what kind of benefits did you feel from that? 
Patient: it was nice to see people, it became a close gathering eventually. At the end we were missing 
each other. It was about talking the problem with the people who are aware about it. When I talk to 
people from work, they have no idea what they are talking about, because they don’t have a clue.  
 
Interviewer: so, you are looking forward to the next one? 
Patient: yes.  
 
Interviewer: what would encourage you to go to an exercise class? 
Patient: I want to go back. To be honest o don’t need encouragement. But I was going to a private 
gym, but I don’t know if they would allow me to use oxygen because it is a private gym. But the local 
gym the trainers have been trained to handle oxygen and aware of it, so I feel safer.  
 
Interviewer: are there any exercises that you would prefer to do? 
Patient: the treadmill. I walk uphill on it. I go on it for 25 minutes and I go on weights for 25 minutes 
and that will be it then.  
 
Interviewer: there are some people in your situation that don’t want to do exercises. What do you 
think that will encourage them to start doing exercises? 
Patient: I think lot of them have depression. I don’t know if it is the medication or how they are. They 
have a different look of life.  
 
Interviewer: what does have IPF mean to you? 
Patient: I accept the illness. I can’t avoid the end of it because I know what is coming. But I make the 
most of what I got with whatever the time I have got left. It’s a condition which affect all ages and 
areas of life. (Rest of the conversation was removed because the patient was talking about other 
patients involved in the rehabilitation programme).  
 
Interviewer: what does your family think about your diagnosis? 
Patient: my daughter worries, but my son had a shock when he saw me with the oxygen. He didn’t 
realize how bad it was. (Rest of the conversation was deleted because the patient was talking about 
personal matters relating to his son).  
 
Interviewer: are they supportive of you being active and doing exercise? 
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Patient: I got told off by my daughter cutting the grass. But I got to do it. I got to do it when I get the 
chance.  
 
Interviewer: what do they think about the exercise classes? 
Patient: they think it’s quite good. And the grandchildren care a lot. They encourage me to go. I think 
it does me good.  
 
Interviewer: is there anything you would like to add? 
Patient: I think when I was diagnosed little was known about the illness. So, it’s only in the past 5-6 
years that they have known more about it. If I can help in anyways, I try to do it.  
 
 
END OF THE TRANSCRIPT 
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PATIENT INTERVIEW TRANSCRIPTION 
(patient 7)  
Age: 53 
Interview date: 19.07.2016 
Location: Swansea University Bay Campus 
Conducted by: Dr. Joan Hudson and Mr. Sameera Senanayake  
 
START OF THE TRANSCRIPT 
Interviewer: 1st thing which will be really useful for us is to get an idea of the context of IPF, when 
you were 1st diagnosed with IPF. 
Patient:  First I was having all this trouble last year and I had a medical problem from that I went to 
get sort it out and they took a scan and dealt with it. The doctor said besides that “I had a look at your 
lungs and I’m not happy with it and I’d like to refer you”, and I thought nothing of it to be honest, I 
thought ya fine no problem.  
Two months down the line I got referred to a guy called Dr. Shetty. He gave me a few tests to take and 
said he thinks it IPF, but we need to diagnose it to see what it was. So, I had a biopsy in January or 
February, and it came out to be what they thought it was.  He said because of my age I could be a 
good candidate for a new set of lungs, but he had to take it to the committee and put my name 
forward. So, at the moment I’m in limbo. There is this new medication which stops your lungs repairing 
itself, but you have to be in a certain percentage. At the moment I’m in the good side rather than the 
bad side and what will happen is, when I drop to the bad side, I start taking the medication and that’s 
when I will be there and the next line. And if I don’t get a lung transferred at that point and they will 
say it’s too late and that’s where I am at the moment. So, flight of stairs panting like a bulldog. Anything 
uphill panting like a bulldog. It’s horrible. If I bend down quickly, I feel dizzy. It’s been really restrictive 
what I want to do in the house, garden, if I carry anything heavy it’s too much, things like that. It’s a 
nightmare.   
 
 
 
Interviewer:  so, it’s quite resent for you? 
Patient: ya, quite resent. After operation I went back to work, and they made major changes to my 
job to make it easier for me. It been really good work wise, they encourage me to work because if you 
push the lung its better because if you sit and work your lungs will go bad faster. So that’s the position 
I’m in now.  
 
Interviewer: what do you do for work? 
Patient: I’m a refuse carrier and walking 15-20 miles a day picking up rubbish, I couldn’t do that 
anymore. So, they put me on to sweeping side where they gave me a van where I go around the shops 
and do the bins. That what I do which is a lot easier now. So, I’m walking 20-30 yards maximum back 
in the van go to the next one. 
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Interviewer: is that what you have always done? 
Patient: I have done that for the last 25 years. Before that I was delivering bread and before that I 
worked for Sainsbury.  
 
Interviewer: was that doing manual work? 
Patient: yes.  
 
Interviewer: in a factory? 
Patient: in a supermarket running produce and frozen foods. 
 
Interviewer: have you ever been a smoker? 
Patient: was a smoker, a 20 man a day up till the age of 26. As soon as we had our 1st daughter I 
stopped. Don’t drink don’t smoke.  
 
 
Interviewer: How old are you  
Patient: I am 53 now.  
 
Interviewer: being diagnose with IPF last year, how did you feel about that? 
Patient: pretty depressing, I’ve got to be honest, I’ve look it up on the internet got some scary bits and 
told my wife there are some scary things out there that I don’t want to know about, so if we are going 
anywhere you are going to come with me and when they we start talking about horrible things I’m 
gona get up and walk out because I don’t want to be worrying about it. So, she has taken all of that. I 
think I’ve got 5 years if I don’t get a set of new lungs and on medication it may extend it to ten years. 
But when it going to go to that stage and have to carry a bottle around like that I don’t know. It’s pretty 
scary. Because what I was doing, with all the rubbish I was picking up, I thought ill blame the council, 
and when they did the biopsy, they didn’t find anything. Now they have all the health and safety rules, 
totally different ballgame. Couple of years ago I was picking up stuff where people come and dump 
thigs off vans and it was building stuff like plater board, so I think that could have caused it as well. 
But I can’t prove it, so I have no case against the council.  
 
Interviewer: it a difficult condition isn’t it 
Patient. Yes, sitting here I look fine. They say there is nothing wrong with you, try walking flight of 
stairs it’s really horrible.  
 
Interviewer: what kind of information did you get? Did you get right information, lot of information? 
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Patient: No, my wife saw what the doctor was writing, and she got some letters off it and looked it up 
1st to see what we were getting in to, and it’s nasty. There are things that I don’t wana know down the 
line. She knows I don’t, I would rather keep it that way.  
 
Interviewer: sounds like she is great support.  
Patient ya, she is.  Really good support.  
 
Interviewer: you also mentioned some advice that you got about keeping the lungs moving  
Patient: they offered me a course at Morriston for 7 weeks where you go twice a week for an hour, 
basically it was doing different exercises. I thought with the work I do I don’t need to do exercises. I 
got a dog and I walk with him up and down a canal and get quite a distance. At the end of that term 
my improvement worked out to be 33% in my lung capacity. I was doing rowing machine, steps, 
treadmill and I was really getting breathless, but I went really hard. May be there is something in it.  
 
Interviewer: what type of exercise would you like to do? 
Patient: I could probably do biking, walking, running is out, that’s about it actually, but if I am going 
out, I need to plan a route which I know is flat. I want to get somewhere I want to get back and if I 
can’t get back, I want to call somebody to ask to come and pick me up. I feel like an old man in 90. I 
think what’s going on here, it’s not right you know  
 
Interviewer: given this diagnosis, what does it mean to you to be diagnosed with IPF? 
Patient: I feel picked on, I feel I haven’t smoked for all these years, I don’t drink, I’m not overly fat, 
why is this happening to me? There are lot of people who are older than me who haven’t got it. My 
father died when I was very young, so I don’t know if he had it, my mother didn’t have it, if it a trait in 
the family, I don’t know. My brother is OK, so it looks like I’m the 1st to have it in the family.  It’s not 
good but you would have to get on with it.  
 
Interviewer: obviously there are lot of negatives associated with the conditions, do you see any 
positives?  
Patient: positives would be my age, I’m a good candidate for a lung transplant.  
 
Interviewer: are there any kind of stipulations about your suitability 
Patient: No. It’s just a case of how bad it gets. At the moment I’m too fit to have them, it wouldn’t 
benefit me. It’s a fine line. If you go below where you are not fit enough to handle it, they won’t do it 
either. That where I don’t want to get to. That’s my main fear.  
 
Interviewer: going back to the exercise programme you did, you said it improved your lung function. 
Were there any other benefits from it? 
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Patient: I’m sleeping better on the days I was doing it. Social thing was OK, it’s nice to say, it’s a horrible 
thing to say, but it was nice to see there were people worse than I was. Because lot of people were 
carrying the bottles around and they had tubes up their nose and they were hardly doing anything. 
And I told myself I am not that bad yet. That was a bonus. I also had few good discussion about what 
happens, what you get, because there are so many different varieties of it. And I learnt few things like 
when it comes to climbing steps it’s easier to breathe in when u take off the step and breath out when 
you land on the step. Ya little things like that.  
 
Interviewer: would there be more things like that, which would be useful do you think?  
Patient: don’t know 
 
Interviewer: What types of exercises do you think that will be useful in an organised programme? 
Patient: doing weight was quite useful because that’s all breathing as well. Treadmill was OK, because 
you could go on speeds you want to go. Rowing was a bit hard because it crunches and make it hard 
to breath.  
 
Interviewer: you mentioned things that are good to do and not good to do, and the reasons, are 
there any others like rowing?  
Patient: rowing is not good, we did cross trainers and it was a killer because you use so many limbs at 
the same time. I tried doing that and in 3-4 minutes I was done for the day.  
 
Interviewer: are there any others that are useful? Any daily activities? 
Patient: bending thangs up is a problems, carrying things is a problem, heavy weights area a problem.  
 
 
 
Interviewer: what do you think motivates people to go and take part in exercise training 
programmes? 
Patient: if thy carried on what I was doing with this twice a week I would have carried on doing it.  It 
was disappointing that it ran for a limited time. Because you met people and after that you got a cup 
of tea sit down and had a chat. It was nice. But you won’t get that in a gym.  
 
Interviewer: does your wife encourage or discourage you to exercise? 
Patient: she can go both ways. If she sees me doing something I shouldn’t do, she would ask the girls 
to do it. Other than that, if I say I need to do it she would let me. If I go up the stairs and I forget 
something she would ask the girls to do it and I would say I will want to do it because I need to do it. 
Some. Eventually she is talking about us moving downstairs and stay downstairs once it gets to a 
certain point, well I don’t want that. I’d rather take 10 minutes to go upstairs to go to bed than staying 
down stairs all the time. That’s just me  
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Interviewer: so, you are trying to stay active in your day to day life style? 
Patient: ya, I’m not pushing it too much, but I want to push it to a point where you start getting 
breathless.  
 
Interviewer: about the exercise programme, are there any other important elements that you think 
relevant? 
Patient: there were lot of attitude, mentally how you look at it.  Don’t look at it half empty and but 
half full. I suppose in a way that does help.  
 
Interviewer: was that a structured session? 
Patient: no, it’s just patients talking while exercising. Its informal thing.  
 
Interviewer: is there any other thing that you would add to it? 
Patient: I would make it a bit longer. The individual session. Because there was a warmup and you 
would lose 20 minutes and it was a lot of time lost. I like to see that extended for a couple of hours.  
 
Interviewer: is there anything more to add? 
Patient: no, I don’t think so. There are not lot of information out there and there are many varieties 
of it. So, what’s good for me might not be good for someone else. And that’s a big things. And what 
information out there it’s scary. They say what you have and what will happen in the end and that’s 
it. There is no information on what will happen in between.  
Interviewer: if you were to tailor how information would look like, is there a better way to present 
it? 
Patient: I think you need it in age groups, which would help. When I went to the doctor he said if you 
were 20 years older, I would say you can’t do anything, but since you are such a young age you have 
options. So, you need it in age groups. If you have that my route will be there to there to there and in 
10 years it will be there to there.  
Interviewer: thank you for taking part in the study.  
END OF THE TRANSCRIPT 
 
  
 146 
 
PATIENT INTERVIEW TRANSCRIPTION 
(patient 8)  
Age: 73 
Interview date: 26.07.2016 
Location: Swansea University Bay Campus 
Conducted by: Dr. Joan Hudson and Mr. Sameera Senanayake  
 
START OF THE TRANSCRIPT 
Interviewer: when did you get your diagnosis on IPF? 
Patient: it was about 12 months ago now, very shocked, nearly upset at the time. Coming to terms 
with it slowly but that’s life. I was please it wasn’t cancer. Because I wasn’t able to stop coughing at 
that time.  
Interviewer: so, the shock was about your life style? 
Patient: well no, I just had this cough, it went on and on, so I went to the doctor. I also get this pain in 
my chest. She sends me for an asthma test, and it was negative. Then a heart scan and it was OK. And 
I was still coughing I thought I have cancer. Then she sent me to Dr Harrison, and I had all these tests. 
After that I met his registrar. He went in met Dr. Harrison and he came out and I though oh god its 
cancer and he said you have got a lung disorder. But I want to discuss it with my colleagues before I 
diagnose what it is. And after my holidays I came back, and he said you have fibrosis in the lung. I 
though thank god it’s not cancer, but I was upset at the same time. They gave me a booklet and I wish 
I didn’t read it. It said I would life for 3 years, but I’ve since heard that people live for 7-10 years and I 
calm down a bit. That came as a great shock. I used to be a smoker, but they said that day don’t know 
that smoking caused it. (Rest of the answer was removed because it wasn’t relent to the topic) 
Interviewer: what do you do for living? 
Patient: I’ve done all sort of things. I was a supervisor at CNA’s for a year. I was on the management 
programme. Then I worked in a solicitor’s office, then I was a receptionist at a doctors before I retired.  
Interviewer: but no kind of heavy industry? 
Patient: no, never, nothing like that. I’ve had a stressful life, don’t know if that had anything to it. 
Interviewer: at the time did you get enough information or right kind of information on IPF? 
Patient: to give it to someone as soon as diagnosed it, I think it was not a good idea. I read it and saw 
three years I though oh my god. Then my daughter read it and she was badly distress and she kept it 
from me. When it is sitting there in front you think OMG.  
Interviewer: you said you have come to terms with it.  
Patient yes, I have started to come in terms with it. These days I think oh god what is going to happen 
to me, am I going to end up in a nursing home or dead and my daughter says you will never go in to a 
nursing home but you know these days you can’t say that, you never know what’s going to happen. 
My husband is not well too. And if I get up thing I get more out of breath.  
Interviewer: have you got any way of coping it? 
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Patient: well to be honest I carry on and tell myself I live another 20 years and I get on with it. That’s 
the only way I could cope with it.  
Interviewer: how old are you? Patient: 73  
Interviewer: on a day to day basis how does your condition affect you? 
Patient: I find it very difficult going upstairs, I get out of breath. I’m overweight and have knee 
replacement and that doesn’t help. But my draught helps me change the beds because I find that 
difficult. And if I walk a lot I get out of breath. But other than that, I go out and have a nice time. I just 
came back from Spain last month and I was a different, the weather was so nice and the moment I 
came back it was so bad. I was veezing and it was so bad. The weather makes a difference without a 
doubt. 
Interviewer:  Although you get out of breath, do you do what you normally do? 
Patient: Oh no. I used to play golf and I can’t do that anymore. I can’t dance. I play bridge a lot and 
that’s my saviour. Other things I manage to do. Like walking the dog on the flat. 
Interviewer: how often do you walk the dog? 
Patient:  I don’t do it mush these days because they are with my daughter, but when we have the dogs 
it at least three time a week.  
Interviewer: does anybody in the hospital talked about any exercise or rehab programme? 
Patient: no. I’ve been on the rehab programme. I enjoyed it. I thought it was good. (The rest of the 
conversation was removed because she was talking about other patients). I think if you are going 
somewhere (rehabilitation programme) the people you are going to should know about the illness 
and should know how far you could go. I’m waiting to go to one of the programmes and I don’t know 
what it’s like. The nurses who is sorting this out should check what they do before they push you out. 
But I think it was good, the one in the hospital.  
Interviewer: what was good about the hospital one? 
Patient: I felt safe. There were people there watching you and when you had enough you could stop. 
There was company, people with the same disease. I found I was looking forward to going. And I 
thought it was doing me good.  
Interviewer: did it help you physically? 
Patient: ya it was.  Can’t put a finger on it, but I feel better in myself. I also lost half a stone.  
Interviewer: did you feel any better in any other way? 
Patient: not really no. talks afterwards, I found it stressful. I didn’t find it useful because I wasn’t able 
to cope with that, the stress I have gone through. The breathing exercise was good. There was a lot of 
good. The actual gym I enjoyed.  
 
Interviewer: dis you find the exercises they had useful? 
Patient: yes. They had the walking machine, the bike. They had starch bands. And I found them help 
in some ways.  
Interviewer:  what type of exercise would you like to see in the programme in panarea? 
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Patient: the bicycle, the walking machine. I like the elastic band. The medicine balls. Weights. I found 
them very helpful.  
Interviewer: did you manage to do weight standing? 
Patient: yes. (The rest of the conversation was removed due to irrelevance)  
Interviewer: was there anything that you would add to it? 
Patient: no, I don’t think so.  
Interviewer: what’s it like to your family (the disease and exercise)? 
Patient: my daughter knows, my husband knows. He had been very protective in a loving way. My son 
hasn’t told him.  
Interviewer: what does your husband and daughter think about you exercising? 
Patient: they want me to do it.  My husband thinks it’s good. He wants to go on walks and then I worry 
about him because of his situation. But we do go for walks. 
Interviewer: do you think the time duration of the individual workout session was enough.  
Patient. Yes. May be 15 minutes more on the exercise part would have been better and cut down the 
talking session. And I would like to carry on the programme for more than six week.  
Interviewer: what are your thoughts about the support group? 
Patient: I like going there. They have people coming in and talk about the illness. Dr Harrison is there 
all the time. And it nice to chat with people with the same problem. When I see people with oxygen 
that what I dread. I don’t know if I could cope with it. If you want to live you live but it’s not me. (Rest 
of the conversation was deleted on patient’s request).  
 
Interviewer: what does have IPF mean to you?  
Patient: Death. Certain definite death. That’s what it means to me.  
Interviewer: is there anything positive that come out of your diagnosis.  
Patient: no, unfortunately no.  
Interviewer: were you able to find information on IPF easily? 
Patient: yes, I got that booklet. Even without that there are lot of thing in the internet.  
 
Interviewer: thank you for taking part in the study. 
 
END OF THE TRANSCRIPT 
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PATIENT INTERVIEW TRANSCRIPTION 
(patient 9)  
Age: 65 
Interview date: 16.08.2016 
Location: Swansea University Bay Campus 
Conducted by: Dr. Joan Hudson and Mr. Sameera Senanayake  
START OF THE TRANSCRIPT 
Interviewer: When were you 1st diagnosed with IPF? 
Patient: 1st time I realized that something was wrong. I entered this cycling competition with my son 
that was a year ago. There were couple of young boys cycling around us. These boys accelerated and 
I thought I can do that and so I went couple of yards and I felt something was wrong.  So, I took some 
rest on the pavement. My son told let’s stop and I don’t like giving in, so I walked rest of the way. I 
took some rest, had a banana and I was completely fine. And that was the beginning of it. (Rest of the 
conversation was deleted due to irrelevance).  
Interviewer: so, it sounds like you were very fit back in the day? 
Wife: you were when you were in the army because you had to do all those exercises and walk 
everywhere. 
Patient: Yes. I used to walk on every Friday to see my girlfriend.  
Wife: you haven’t been too bad have you? 
Patient: when I get it it’s not very pleasant. I get breathless, can’t talk properly, my voice goes for some 
strange reason and it’s not very good. But I live  
Wife: He rides the bicycle indoors so that’s good. Sometimes he is not very good, but he is ok.  
Interviewer: so everyday life hasn’t changed a lot? 
Wife: not really. He does get quite breathless. What it does really is that he can’t walk too far. Also, 
his throat goes. I think there is a problem with his throat as well. Sometimes he can’t speak. We went 
on a trip to Australia and new Zeeland and the before the trip he said he can’t go. But after going to 
the doctor we decided to go. It affects him a lot, but it doesn’t stop him doing what we want to do. 
So, it’s been there for a long time, but he had been able to cope with it.  
 
 
Interviewer: so how have you coped with it for such a long time? 
Patient: I’ve been on the exercise bike; I’ve been walking slowly and doing gentle exercise. So, I have 
been taking care of myself.  
Wife: he is taking care of himself, so he is controlling it by not straining himself too much.  
Interviewer: is it because you had advised on it when you were diagnosed? 
Patient: he is being seeing Dr. XXXXXX only for couple of years.  
(Rest of the conversation was deleted from the conversation because it was irrelevant to the topic) 
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Interviewer: When you met Dr. XXXXXX did you get a diagnosis on your breathlessness? 
Patient: I saw a young doctor 1st and she discovered my lungs were scared. Ten only I was diagnosed 
with IPF. I used to be a heavy smoker. 
 
 
Interviewer: so, when you were diagnosed how did you feel about it? 
Patient: it came as a little bit of a shock. It affected me but not in an excessive way.  
Wife: sometimes you get very breathless and I notice when that happens, he is very tired. (Rest of the 
conversation was removed from the transcript because it was irrelevant to the topic.  
 
 
Interviewer: if we were to offer you an exercise programme what would you like it to be? 
Patient: as long as it’s not strenuous I can do it. (Rest of the conversation was removed from the 
transcript because it was irrelevant to the topic) 
 
 
Interviewer: So, what kind of exercises do you think you could do? 
Patient: I can certainly go on the exercise bike, nothing hard but I find it useful for circulation on the 
legs.  
 
 
Interviewer: do you share everything about your disease with each other? 
Patient: we are pretty open about it and it been an excellent marriage. (Rest of the conversation was 
deleted from the transcript because it was irrelevant to the topic) 
 
 
Interviewer: when you 1st found about your condition did you get enough information about it? 
Patient: the impression that I got was that they haven’t reached to a stage in the repair process of the 
disease and this is what’s it’s all about. They are trying to get more information. 
 
Interviewer: have you got your own information about how might exercise help or not? 
Patient: well, I find that the stretching is good, and the exercise bicycle is wonderful. We also go for 
walks around the lake.  
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Interviewer: what is it about stretching that you find useful? 
Patient: my intercostal muscles were very stiff, so I wasn’t able to breathe properly. So, I stretch and 
eventually I get a comfort through that. And the more I did the better it became. (Rest of the 
conversation was deleted because it was irrelevant to the topic) 
 
 
Interviewer: you mentioned about stretching. If you were asked to create a rehabilitation 
programme to manage your IPF, what would that look like? 
Patient: starching is really good, and individual would be better because I can stop and start whenever 
I want, and it would help others too.  
 
Interviewer: finally, we have technology everywhere. Do you think technology could help you with 
exercise? 
Patient:  no, it’s not for us. 
Interviewer: Thank you for taking part in our study.  
END OF TRANSCRIPT 
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PATIENT INTERVIEW TRANSCRIPTION 
(patient 10)  
Age: 60 
Interview date: 25.08.2016 
Location: Swansea University Bay Campus 
Conducted by: Dr. Joan Hudson and Mr. Sameera Senanayake  
 
START OF THE TRANSCRIPT 
 
Interviewer: When you got your diagnosis what sort of information did you get? 
Patient: my background is in nickel and I have been exposed to obnoxious chemicals dust and so on. 
When I was 1st diagnosed I had a persisting cough like most people, and it didn’t clear for months. So, 
I went to see a consultant and they put me through a cat scan and that’s where they picked it up.  
 
Wife: but he had been having the cough two years before that. 
 
Interviewer: how did you feel when you 1st got your diagnosis? 
Patient:  Its ok. I didn’t know anything about it, and I’ve been living for 10 years.  
 
Wife: we found lot of information on the internet and it was a bit devastating because he is quite 
healthy. But we got on with life.  
 
Patient: lot of people don’t know what it is. They understand lung cancer but when it comes to IPF 
they are like what is that? (rest of the conversation was deleted because it was irrelevant to the topic.) 
Patient: also, I’ve been on nine drugs which I didn’t like at all.  
 
 
Interviewer: Tell me little bit about the psychological effect of your diagnosis? 
Patient: well, I wasn’t happy on 9 tablets a day. It also getting grips with this condition. You have your 
ups and downs. It’s a very debilitating condition. You have bursts of energy and bursts of you can’t do 
anything. Simple things like taking out the bins, moving the lawn, cutting the bush such is very 
frustrating being used to carry out these things. But you have to accept it and carry on. It’s very 
frustrating.  
 
Interviewer: But you accept it? 
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Patient: you have to.  I mean the fatigue you get when you are doing these things, I feel like a battery, 
your energy levels go down and you would have to stop. With 6 grandchildren we had a busy summer. 
During the holidays they were with us and I wasn’t able to involve with them as much as I liked.  
 
Wife: I think this new tablet he is on has increased his energy levels and psychological effect is good.  
 
Patient: but it’s been a little stressful taking care of the kids. (rest of the conversation was removed 
because it was irrelevant to the topic). 
Interviewer: did you find your stress made your condition worse? 
Patient: not really. I don’t like it when stress affects me.  
 
Wife: we get on with it. Stress id part of life isn’t it.  
 
Patient: 40 years in the chemical industry I’ve had disasters and stress but at the end you accept it and 
move on with life.  
 
Interviewer: it sounds like that how you have come to terms with IPF.  
Patient: you have to try to make the best of life. That’s the way the dice is rolled. I do get frustrated 
when its physical affects me, not being able to do things that I planned to do. You think about 
retirement and think it’s nice not to go to work but the health doesn’t keep up. You plan to do all these 
things that you wanted to do all these years. But here we are.  
 
Wife: we did them as much as we could. We travelled a lot, but the past three years not so much.  
 
Patient: I’ve also been on the rehabilitation programme at Morriston and its really good. You do half 
hour of exercise and the we had lectures on the condition, and it was really helpful.  
 
Wife: the social side of it is really good. You share ideas and share how things are and we pass ideas.  
 
Interviewer:  so, it gives you a support mechanism? 
Patient: yes, you get to see the different stages of the disease and lot of guys there use oxygen. I have 
oxygen but I only try to use it in an emergency.  
 
Interviewer: how did you find the exercise part of the programme? 
Patient: good. I’ve always exercised and I’m still a member of LC2. Next week we will start going back 
again. It benefits physically as well as mentally.  
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Wife: we have friends coming in as well. So, it really good.  
 
Interviewer: the mental and the physical benefits of your exercises, could you explain it a bit more? 
Patient: I have always exercised. When this condition came along, you start to worry about if exercise 
good or bad for you. I found after exercising I slept better, woke up better and it improved my 
flexibility. Mentally you are feeling better too, and it helps. And with more exercise and steroids I’m 
desperately trying to put some weight on and improve my condition.  
 
Interviewer: what kind of exercise do you do? 
Patient: I can go on the walking machine. I can do three kilometres at 6kmph in 30 minutes. I do row 
for 10 minutes. Then I do pull ups with weights and some machine exercises. At the end I do spend 
about one hour there.  
 
Wife: before the summer holidays there is a big improvement in his attitude. He is positive and I think 
it’s the new drugs se is taking. During the winter I was worrying that he would go for depression. But 
it had made a big difference. (rest of the conversation was deleted due to irrelevance to the subject).  
 
Interviewer: you said during the winter your mood was down. Do you think exercise helped you 
improve apart from drugs? 
Patient: Oh yes, definitely. We will get back to it after the summer holidays.  
 
Interviewer: going back on the exercise programme, you said you did a lot of walking. So, did you 
do the rest while seated? 
Patient: most of it was seated. And most of them were strength once.  
 
Interviewer: if you were to go on an advanced rehab programme, what should it look like to you? 
Patient: I think the course at Morriston is good. I could cope very well. It didn’t tax me that much.  
 
Wife: we have always done a lot of walking.  
 
Patient: I’m ok with flat but with angles it hard.  
 
Interviewer: staying active, is it hard to do? 
Patient: no. you just have to change yourself. We are going to start the gym again.  
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Interviewer: if you were asked to exercise at home as a part of a rehabilitation programme. Is it 
something that you would follow?  
Patient: They did it. I can’t say I picked it up. It easier for me to jump in the car and go to the gym. If 
you are in the house it very distracting.  
 
Interviewer: how important is it for you to have somebody with the knowledge to be there with you 
when you are exercising? 
Patient: not too important. I know what I’ve got, and I choose exercised that I can do and can get away 
with.  
 
Interviewer: do you think the individual session length of the exercise session at Morriston 
adequate? 
Patient: I think half an hour is enough for most people in it.  
 
Interviewer: Do you have anything else to add? 
Patient: not really, I think we have said it all.  
 
Interviewer: Thank you so much for both in taking part in the interview.  
 
END OF TRANSCRIPT 
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Appendix C: Data accompanying Chapter 5 
 
 
Figure C.1 Example plot of VO2 as a function of time for an individual patient (raw data). (Yellow dot 
indicates the Gas Exchange Threshold (GET) and green dot indicates VO2 max.) 
 
 
Figure C.2 Example plot of VO2 against VE, showing the calculation of OUES (slope of regression 
line). Y axis represent VO2 and x axis represent Log10 of minute ventilation (VE) 
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Table C.3: Physiological responses to incremental (maximal effort) exercise tests pre- and post-
rehabilitation for each individual who took part in the study.  
 
 VE (BPTS) VO2 
(ml·min-1) 
VO2  
(ml·kg-1·min-1) 
PEAK HR 
(bpm) 
PEAK 
WORK 
RATE (W) 
TIME TO 
PEAK WORK 
RATE (min)  
PATIENT 
ID 
Pre Post Pre Post Pre-
PR 
Post-
PR 
Pre Post Pre Post Pre Post 
P1 74.8 79.1 1659 1639 14.9 15.2 124 136 108 109 13.11 13.12 
P2 30.4 38 1040 898 10 8.4 73 75 29 59 11.16 6.12 
P3 92.3 80.8 1590 1538 18.7 17.1 142 125 100 86 12.34 13.12 
P4 49.1 47.4 1113 1079 13.1 12.8 138 135 55 62 12.07 12.59 
P5 64.7 59.7 1269 1538 14.6 13.5 94 88 81 65 12.22 13.58 
P6 64.9 43.1 1605 1119 16 12.5 147 127 99 72 15.05 10.55 
P7 86.8 90.5 1809 1912 18.3 19.3 141 111 158 128 13.03 14.07 
P8 60.5 35.2 1321 834 15.1 9.6 99 75 93 49 12.29 9.02 
P9 52.6 53.5 1057 916 14.3 12.8 101 56 94 35 9.2 7.38 
P10 75.3 70.5 1600 1467 28.4 26.2 159 100 148 97 16.39 16.35 
P11 43 58.6 1168 1382 12.5 15.4 127 72 135 96 10.51 14.48 
P12 34.7 48.2 1138 1256 14 18.2 126 65 132 83 12.27 11.14 
P13 22.4 30.7 849 1082  9.5  16.9 93 46 83 50 7.29 7.1 
P14 36 63.3 1073 1282 14.3  17.1 115 76 129 99 10.43 11.47 
P15 53 72.3 1194 1313 13.9 15.3 116 66 125 72 9.56 10.49 
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Table C.4: OUES for pre- and post- PR  states. (R2: Coefficient of determination.) 
 
PRE-PR POST-PR 
PATIENT ID OUES 
(ml·min-1·L-1) 
R2 OUES 
(ml·min-1·L-1) 
R2 
P1 1943.2 0.97 1754.1 0.97 
P2 1467.2 0.85 1121.2 0.84 
P3 1466.6 0.98 1399.2 0.96 
P4 1274.9 0.98 1245.8 0.98 
P5 1321.2 0.97 1750.6 0.98 
P6 1828.7 0.98 1889.4 0.96 
P7 1688.9 0.98 1929.6 0.98 
P8 1426.0 0.99 1185.1 0.98 
P9 1703.6 0.91 1684.9 0.93 
P10 1731.3 0.98 1664.8 0.98 
P11 1886.1 0.96 1570.6 0.97 
P12 1509.2 0.97 1348.7 0.97 
P13 1377.2 0.85 1423.4 0.90 
P14 1538.5 0.94 1292.0 0.98 
P15 1378.8 0.98 1374.7 0.98 
Mean 1569.4 0.95 1508.9 0.95 
SD 205.5 0.04 249.5 0.04 
SEM 53.1 0.01 64.4 0.01 
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Table C.5: Acceleration Capacity and Deceleration Capacity indices for each individual participant pre 
and post PR. (Δ Post-Pre = absolute change following PR, Δ (%) = relative change following PR).  
 
PATIENT ID ACCELERATION Capacity (ms) DECELERATION Capacity (ms) 
Pre-PR Post-PR Δ Post-
Pre 
Δ (%) Pre-PR Post-PR Δ Post-
Pre 
Δ (%) 
1 -18.1 -19.2 1.0 6.0 15.4 13.2 -2.2 -14.7 
2 -3.9 -5.1 1.2 30.1 5.1 4.6 -0.5 -11 
3 -3.9 -3.9 0 0 3.1 3.1 0 0 
4 -1.4 -3.4 2.0 144.6 1.4 3.3 1.9 138.5 
5 -2.2 -5.6 3.3 151.1 2.6 5.3 2.6 101.4 
6 -2.7 -1.2 -1.4 -52.8 2.1 1.3 -0.8 -38.3 
7 -1.1 -2.7 1.5 138.1 1.2 2.9 1.6 127.1 
8 -16.5 -15.8 -0.6 -4.2 17.2 18.2 0.9 5.8 
9 -1.8 -2.2 0.4 22.5 2.0 2.4 0.4 21.6 
10 -3.3 -2.9 -0.4 -12.4 3.7 2.4 -1.3 -34.8 
11 -1.2 -1.3 0.0 6.8 1.3 1.2 -0.1 -7.6 
12 -1.7 -2.4 0.6 36.6 1.7 1.7 0.0 3.7 
13 -2.2 -3.2 0.9 42.5 2.0 3.2 1.1 54.5 
14 -2.7 -2.5 -0.2 -7.1 2.3 2.6 0.3 15.4 
15 -5.7 -4.0 -1.6 -29.1 5.6 3.3 -2.2 -39.9 
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Appendix D: Data accompanying Chapter 6 
 
Figure D.1: Modelling of individual participants’ temporal V̇O2 data for (a) pre-PR and (b) post-PR 
conditions 
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(b) Post-PR 
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Figure D.2: Modelling of individual participants’ HR data for (a) pre-PR and (b) post-PR conditions 
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Appendix E: Example of an efficacy ‘staging’ system for pulmonary 
rehabilitation in IPF 
Figure E.1: Proposed staging system for pulmonary rehabilitation for IPF. Green, yellow 
and orange represent low, moderate and high disease severity  
Male  
Reference values (based on FVC %) Pre 
rehabilitation  
Post 
rehabilitation % change ˃80 80-55 ˂ 55 
Ve (BPTS) 
67 57 52       
VO2 (ml·kg-1·min-1) 
19 15 14       
Peak HR (BPM) 
117 115 101       
Peak WR (Watts) 
107 101 94       
Time to peak (min) 
14 11 9       
Oxygen saturation at peak VO2 
89 84 84       
six-minute walk test (m) 
319 286 222       
BMI (pre) BMI (Post) FVC% (Pre) FVC% (Post)     
            
            
            
Female  
Reference values (based on FCV %) Pre 
rehabilitation  
Post 
rehabilitation % change ˃80 80-55 ˂ 55 
six-minute walk test (m) 
384 358 310       
Oxygen saturation at peak VO2 
92 84 88       
Time to peak (min) 
15 12 10       
Peak WR (Watts) 
99 93 135       
Peak HR (BPM) 
147 132 127       
VO2 (ml·kg-1·min-1) 
16 14 12       
Ve (BPTS) 
65 42 43       
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Table E.1: Physiological parameters which were selected to be included in the staging system for every individual    
FVC % 
CATEGO
RY 
PATIEN
T ID 
SEX FVC 
% 
FEV1 
% 
VE (BPTS) (l) VO2  
(ml·kg-1·min-1) 
PEAK HR 
(BPM) 
PEAK WORK 
RATE (W) 
TIME TO PEAK 
WORK RATE 
(min) 
OXYGEN 
SATURATIO
N (%)  
SIX MINUTE 
WALK 
DISTANCE (m) 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre  Post Pre Post 
˃80 P06 M 131 130 64.7 59.7 14.6 13.5 94 88 81 65 12.22 13.6 93 85 181 300 
P09 M 82 85 60.5 35.2 15.1 9.6 99 75 93 49 12.29 9.02 89 92 300 322 
P11 M 107 93 75.3 70.5 28.4 26.2 159 100 148 97 16.39 16.4 85 85 475 440 
Mean 107 103 66.8 55.1 19.37 16.4 117 87.6 107 70.3 13.63 13 89 87.3 319 354 
P07 F 89 88 64.9 43.1 16 12.5 147 127 99 72 15.05 10.6 92 88 384 480 
 
    
                
55-80 P01 M 62 67 74.8 79.1 14.9 15.2 124 136 108 109 13.11 13.1 87 84 370 362 
P02 M 77 82 30.4 38 10 8.4 73 75 29 59 11.16 6.12 89 89 200 304 
P03 M 63 78 92.3 80.8 18.7 17.1 142 125 100 86 12.34 13.1 83 84 290 430 
P08 M 74 79 86.8 90.5 18.3 19.3 141 111 158 128 13.03 14.1 87 85 NA 427 
P14 M 59 55 22.4 30.7 9.5 16.9 93 46 83 50 7.29 7.1 77 82 NA NA 
P17 M 78 78 36 63.3 14.3 17.1 115 76 129 99 10.43 11.5 85 88 NA NA 
Mean 68.8 73.2 57.1 63.7 15.5 15.4 115 94.8 101 88.5 11.23 10.8 84.7 85.3 287 381 
P04 F 76 75 49.1 47.4 13.1 12.8 138 135 55 62 12.07 12.6 81 80 358 373 
P13 F 61 63 34.7 48.2 14 18.2 126 65 132 83 12.27 11.1 87 84 NA NA 
Mean 68.5 69 41.9 47.8 13.6 15.5 132 100 93.5 72.5 12.17 11.9 84 82 358 373 
 
    
                
˂55 P10 M 52 63 52.6 53.5 14.3 12.8 101 56 94 35 9.2 7.38 84 85 222 NA 
P12 F 53 60 43 58.6 12.5 15.4 127 72 135 96 10.51 14.5 88 92 310 304 
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Glossary of Terms 
TERM DEFINITION  
  
Fibrosis Thickening and scarring of connective tissue 
Extracellular Matrix Structure providing support to surrounding 
cells 
Interstitium Fluid filled space between tissues 
 
Minute Ventilation Amount of air a person breath in one minute 
Dyspnoea  Difficulty in breathing 
Cardiac Output Amount of blood pumped by the heart in one 
minute 
Stroke Volume Volume of blood pumped by the heart in one 
heart beat 
Sympathetic  Increasing the heart rate  
Parasympathetic  Reducing the heart rate  
Diurnal Variation Changes occurring during the parts of the day 
Metabolic Self-sustaining chemical reactions in organisms  
Biomarker Naturally occurring molecule or a gene 
Palliative Care Care for the terminally ill patient  
Aetiology Cause of a disease condition  
Epidemiology Incidence of a disease 
Hypoxaemia Low oxygen saturation in blood 
Pulmonary Oedema  Excess fluid in lungs 
Forced Expiratory Volume Volume of air a person can exhale during a 
forced breath 
Functional Residual Capacity Volume of air present in the lung after passive 
expiration  
Arterial Alveolar Gradient The difference between alveolar concentration 
of oxygen and arterial concentration of oxygen  
RR Interval  Interval between successive heart beats 
Ventilatory Anaerobic Threshold  Point during exercise at which ventilation starts 
to increase at a faster rate than inspiration  
Respiratory Exchange Ratio  Ratio between the amount of carbon dioxide 
produced and oxygen used  
Aerobic Threshold  Intensity at which lactate accumulates during 
exercise 
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